stop O
bleeding B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

clear O
( O
pathogenic O
) O
fire B-NEU
and O
invigorate O
blood B-DNP

-DOCSTART- O

To O
lessen O
contracture B-NEG
, O
regulate O
stomach B-NEU
function I-NEU
, O
and O
dispel O
contracture B-NEG
. O

-DOCSTART- O

frequent O
vomiting B-NEG

-DOCSTART- O

To O
dispel O
phlegm B-NEG
, O
to O
restore O
consciousness B-NEU
, O
and O
to O
reduce O
modulation B-NEU
and O
cause O
the O
subsidence B-NEU
of I-NEU
swelling I-NEU
. O

-DOCSTART- O

sore B-NEG

-DOCSTART- O

unblock O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

deficiency B-NEG
of I-NEG
the I-NEG
kidney I-NEG
; O

deficiency B-NEG
syndrome I-NEG
of I-NEG
the I-NEG
kidney I-NEG
the O
pathological B-NEG
changes I-NEG
due O
to O
deficiency B-NEG
of I-NEG
the I-NEG
kidney I-NEG
essence I-NEG
, O
usually O
characterized O
by O
dizziness B-NEG
, O
tinnitus B-NEG
, O
lumbago B-NEG
, O
nocturnal B-NEU
emission I-NEU
, O
impotence B-NEG
, O
lassitude B-NEG
, O
forgetfulness B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU

-DOCSTART- O

Bacterial B-NEG
infections I-NEG
of O
the O
eyes O
. O

-DOCSTART- O

moisten O
skin O

-DOCSTART- O

cosolidate O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

bruise B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
numbness O
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

To O
relieve O
rheumatic B-NEG
conditions I-NEG
, O
and O
to O
remove O
damp-heat B-NEG
. O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU
, O
Liver B-DNP

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Lipid O
profile O

-DOCSTART- O

To O
cool O
lung B-DNP
, O
release O
discomfort B-NEG
in O
pharynx O
, O
remove O
epidemic B-NEG
evils I-NEG
, O
and O
to O
relieve O
cough B-NEG
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
transform O
damp B-NEU
, O
disperse O
accumulation O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

cold B-NEG
and O
heat B-NEG
; O

cold B-NEG
syndrome I-NEG
and O
heat B-NEG
syndrome I-NEG
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-NEG
caused O
by O
excess O
of O
Eum O
, O
and O
heat B-NEG
caused O
by O
excess O
of O
Yang O
. O

chills B-NEG
and O
fever B-NEG

cold B-NEG
pathogene I-NEG
and O
heat B-NEG
pathogene I-NEG

-DOCSTART- O

move O
blood B-DNP

-DOCSTART- O

A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic B-DNP
species I-DNP
( O
As(III) B-DNP
) O
, O
dimethylarsinic B-DNP
acid I-DNP
( O
DMA B-DNP
) O
, O
monomethylarsonic B-DNP
acid I-DNP
( O
MMA B-DNP
) O
and O
arsenate B-DNP
As(V) I-DNP
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA B-DNP
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O

promote O
the O
intestine B-DNP

-DOCSTART- O

Stagnation O
of O
qi O
and O
blood B-NEU
marked O
by O
chest B-NEG
pain I-NEG
; O
dry B-NEG
cough I-NEG
with O
shortness B-NEG
of I-NEG
breath I-NEG
; O
insomnia B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
regulate O
menstruation B-NEU

-DOCSTART- O

Saengmaeksan O
inhibits O
inflammatory B-POS
mediators I-POS
by O
suppressing O
RIP-2 B-NEU
/ I-NEU
caspase-1 I-NEU
activation I-NEU
. O

-DOCSTART- O

gases B-NEG
retention I-NEG
in I-NEG
the I-NEG
lungs I-NEG

-DOCSTART- O

Treatment O
of O
cough B-NEG
, O
asthma B-NEG
and O
distending B-NEG
pain I-NEG
of O
the O
chest O
caused O
by O
cold B-NEG
phlegm I-NEG
, O
arthralgia B-NEG
accompanied I-NEG
by O
numbness B-NEG
due O
to O
obstruction O
of O
collaterals O
by O
phlegm B-NEG
, O
deep B-NEG
abscess I-NEG
. O

-DOCSTART- O

Rikkunshito O
, O
an O
herbal O
medicine O
, O
suppresses O
cisplatin-induced O
anorexia B-NEG
in O
rats O
via O
5-HT2 O
receptor O
antagonism O
. O

-DOCSTART- O

release O
muscles B-DNP

-DOCSTART- O

dribbling B-NEG
urination I-NEG
; O
dribbling B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

Recently O
, O
also O
used O
for O
biliary B-NEG
ascariasis I-NEG
, O
biliary B-NEG
infection I-NEG
and O
cholelithiasis B-NEG
with O
abdominal O
pain B-NEG
( O
adhesive O
ascarial O
and O
paralytic B-NEG
ileus I-NEG
) O
. O

-DOCSTART- O

attack O
and O
expel O

-DOCSTART- O

For O
the O
treatment O
of O
adult O
patients O
diagnosed O
with O
anaplastic B-NEG
astrocytoma I-NEG
whose O
disease O
has O
progressed O
after O
therapy O
with O
nitrosourea O
and O
procarbazine O
, O
as O
well O
as O
concomitantly O
with O
radiation O
therapy O
for O
treatment O
of O
newly O
diagnosed O
glioblastoma B-NEG
multiforme I-NEG
. O
Also O
used O
as O
maintenance O
therapy O
for O
glioblastoma B-NEG
multiforme I-NEG
. O

-DOCSTART- O

Keishibukuryogan O
ameliorates O
glucose B-NEG
intolerance I-NEG
and O
hyperlipidemia B-NEG
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG

-DOCSTART- O

diarrhea B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG

-DOCSTART- O

Epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-NEU
response I-NEU
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-DNP
cells I-DNP
by O
preventing O
mast B-NEU
cell I-NEU
degranulation I-NEU
to O
control O
the O
allergic B-NEU
response I-NEU
, O
2 O
prevents O
histamine B-DNP
binding O
to O
both O
the O
H1- O
and O
H O
2-receptors O
to O
stop O
itching B-NEG
and O
provide O
lasting B-POS
protection I-POS
, O
and O
3 O
prevents O
the O
release B-NEU
of I-NEU
proinflammatory I-NEU
chemical I-NEU
mediators I-NEU
from O
the O
blood O
vessel O
to O
halt O
progression O
of O
the O
allergic B-NEU
response I-NEU
. O

-DOCSTART- O

Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

Prazosin O
acts O
by O
inhibiting O
the O
postsynaptic B-DNP
alpha(1)-adrenoceptors I-DNP
on O
vascular O
smooth O
muscle O
. O

This O
inhibits O
the O
vasoconstrictor B-NEU
effect I-NEU
of O
circulating O
and O
locally O
released O
catecholamines O
, O
resulting O
in O
peripheral B-NEU
vasodilation I-NEU
. O

Oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O

the O
low B-NEG
back I-NEG
and I-NEG
knees I-NEG
being I-NEG
aching I-NEG
and O
limp(i B-NEG
. O
e O
. O
, O
weak B-NEG
) O

-DOCSTART- O

To O
induce O
subsidence O
of O
swelling B-NEG
and O
remove O
toxic B-NEG
substances O
, O
to O
cause O
purgation B-NEG
. O

-DOCSTART- O

jaundice B-NEG
a O
morbid B-NEG
condition I-NEG
clinically O
characterized O
by O
yellow-brown B-NEG
pigmentation I-NEG
of I-NEG
the I-NEG
skin I-NEG
and I-NEG
sclera I-NEG
and O
dark B-NEG
yellow I-NEG
colored I-NEG
urine I-NEG
, O
and O
classified O
into O
two O
types O
, O
Yang O
jaundice B-NEG
and O
Eum O
jaundice B-NEG
; O
one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

Vaccination O
of O
humans O
with O
CYT006-AngQb O
has O
been O
shown O
to O
induce O
angiotensin B-DNP
II I-DNP
specific O
antibodies O
that O
should O
inhibit O
binding O
of O
angiotensin B-DNP
II I-DNP
to O
its O
receptors O
and O
thus O
reduce O
the O
narrowing O
of O
blood B-DNP
vessels I-DNP
. O

-DOCSTART- O

tonify O
marrow B-DNP

-DOCSTART- O

Treatment O
of O
impotence O
and O
seminal B-NEU
emission I-NEU
, O
mass O
in O
the O
abdomen B-DNP
, O
scrofula B-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
external O
use O
for O
carbuncles B-NEG
and O
boils B-NEG
. O

-DOCSTART- O

Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Eye B-DNP
health I-DNP
, O
Eye B-DNP
health I-DNP
, O
Others O
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Strength O
and O
power O
, O
Intelligence B-POS
, O
Hemostatic B-POS
function I-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

This O
is O
a O
symptom O
with O
fullness B-NEU
and O
pain B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Bleeding B-NEG
due O
to O
blood B-NEU
heat I-NEU
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
knocks O
and O
falls O
, O
impediment O
pain B-NEG
in O
joints O
. O

-DOCSTART- O

Interferon O
alpha O
binds O
to O
type O
I O
interferon O
receptors O
which O
activate O
two O
Jak1 O
and O
Tyk2 O
and O
activate O
multiple O
dowmstream O
immunomodulatory B-NEU
and O
antiviral O
proteins O
. O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine O
monophosphate O
dehydrogenase O
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Telaprevir O
is O
an O
inhibitor O
of O
the O
HCV B-DNP
NS3/4A I-DNP
serine I-DNP
protease I-DNP
, O
necessary O
for O
the O
proteolytic O
cleavage O
of O
the O
HCV O
encoded O
polyprotein O
into O
mature O
forms O
of O
the O
NS4A O
, O
NS4B O
, O
NS5A O
and O
NS5B O
proteins O
and O
essential O
for O
viral O
replication O
. O

-DOCSTART- O

Genz-112638 O
, O
a O
novel O
ceramide O
analog O
given O
orally O
, O
is O
designed O
to O
inhibit O
the O
enzyme B-DNP
glucosylceramide I-DNP
synthase I-DNP
, O
which O
results O
in O
reduced O
production O
of O
glucocerebroside B-DNP
. O

This O
is O
the O
substance O
that O
builds O
up O
in O
the O
cells O
and O
tissues O
of O
people O
with O
Gaucher B-NEG
disease I-NEG
. O

In O
preclinical O
studies O
, O
the O
molecule O
has O
shown O
high O
potency O
and O
specificity O
. O

-DOCSTART- O

alleviate O
edema B-NEG

-DOCSTART- O

insubstantial O
wind B-NEG

-DOCSTART- O

Zuo O
Jin O
Wan O
( O
ZJW O
) O
, O
a O
typical O
traditional O
Chinese O
medicine O
( O
TCM O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-POS
activity I-POS
in O
recent O
studies O
. O

In O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
ZJW O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-NEG
cancer I-NEG
in O
vitro O
and O
in O
vivo O
. O

Our O
results O
showed O
that O
ZJW O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
, O
SGC7901/DDP O
, O
and O
Bel/Fu O
MDR O
cells O
. O

Moreover O
, O
combination O
of O
chemotherapy O
with O
ZJW O
could O
reverse O
the O
drug O
resistance O
of O
HCT116/L-OHP B-DNP
cells I-DNP
, O
increase O
the O
sensitivity O
of O
HCT116/L-OHP B-DNP
cells I-DNP
to O
L-OHP O
, O
DDP O
, O
5-Fu O
, O
and O
MMC O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-NEG
growth I-NEG
in O
the O
colorectal O
MDR O
cancer O
xenograft O
model O
. O

ICP-MS O
results O
showed O
that O
ZJW O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
cells O
in O
a O
dose-dependent O
manner O
. O

Furthermore O
, O
we O
showed O
that O
ZJW O
could O
reverse O
drug O
resistance O
of O
colorectal B-NEG
cancer I-NEG
cells O
by O
decreasing O
P-gp B-NEU
level I-NEU
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
MDR B-NEG
phenotype I-NEG
. O

Our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
ZJW O
plays O
an O
important O
role O
in O
reversing O
multidrug B-NEG
resistance I-NEG
of O
human O
colorectal B-NEG
cancer I-NEG
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer O
therapy O
. O

-DOCSTART- O

To O
remove O
phlegm B-NEG
, O
disperse O
the O
lumps O
, O
detoxify O
and O
relieve O
swelling B-NEG
. O

-DOCSTART- O

recurrent O
fever B-NEG
by O
the O
exhaustion B-NEG
after O
healing O
from O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
Parkinson's B-NEG
disease I-NEG
. O
Also O
used O
for O
the O
treatment O
of O
restless B-NEG
legs I-NEG
syndrome I-NEG
. O

-DOCSTART- O

a O
lumbago B-NEG
pain I-NEG
. O

Occur O
by O
invasion B-NEG
of I-NEG
wind-heat I-NEG
in O
kidney O
meridian O
. O

-DOCSTART- O

To O
stop O
pain B-NEG

-DOCSTART- O

major O
cold B-NEG
and O
heat B-NEU

-DOCSTART- O

dyspepsia B-NEG
; O
indigestion B-NEG

-DOCSTART- O

In O
addition O
, O
dalbavancin O
alters O
bacterial-cell-membrane O
permeability O
and O
RNA B-DNP
synthesis I-DNP
. O

-DOCSTART- O

1 O
For O
cases O
of O
malaria B-NEG
with O
splenomegaly B-NEG
, O
epicgastric B-NEG
fullness I-NEG
, O
whitish B-NEG
fur I-NEG
on I-NEG
the I-NEG
tongue I-NEG
, O
wiry B-NEG
pulse I-NEG
, O
which O
are O
attributive O
to O
dysfunction B-NEG
of I-NEG
spleen I-NEG
and O
stagnation O
of O
vital O
energy O
and O
blood O
, O
omit O
Glycyrrhizae O
and O
add O
Ramulus O
cinnamoni O
, O
carapax O
trionycis O
to O
ac O

-DOCSTART- O

absorption O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
motility O
, O
Others O

-DOCSTART- O

Wind-evil O
attacked O
meridian O
, O
facial B-NEG
paralysis I-NEG
, O
muscle B-NEG
numbness I-NEG
, O
pain B-NEG
of I-NEG
tendons I-NEG
and I-NEG
bone I-NEG
. O

-DOCSTART- O

Acetaminophen O
acts O
primarily O
in O
the O
CNS O
, O
by O
increasing O
the O
pain B-NEG
threshold O
by O
inhibiting O
both O
isoforms O
of O
cyclooxygenase O
, O
COX-1 O
, O
COX-2 O
, O
and O
COX-3 O
enzymes O
involved O
in O
prostaglandin B-DNP
( I-DNP
PG I-DNP
) I-DNP
synthesis I-DNP
. O

-DOCSTART- O

Weak B-NEG
and O
reduced O
yin O
blood B-DNP
after O
treatment O
, O
exterior O
evil O
, O
loss B-NEG
of I-NEG
blood I-NEG
, O
cold B-NEG
and O
period O
, O
headache B-NEG
, O
hot B-NEU
body I-NEU
, O
feeling O
slightly O
cold B-NEG
, O
no O
sweating B-NEG
. O

-DOCSTART- O

To O
kill O
worms B-NEG
. O

-DOCSTART- O

deficiency O
of O
Gi O
( O
vital O
energy O
) O
of O
the O
stomach O

-DOCSTART- O

clear O
heat B-NEU
and O
relieve O
toxicity B-NEG

-DOCSTART- O

1 O
Applicable O
to O
edema B-NEG
of I-NEG
wind I-NEG
type O
attributive O
to O
attack O
of O
dampness B-NEU
and O
heat B-NEU
, O
which O
is O
manifested O
as O
general O
edema O
beginning O
from O
the O
eyelids O
, O
dyuria B-NEG
, O
fever B-NEG
, O
chilliness B-NEG
, O
white B-NEG
and I-NEG
greasy I-NEG
fur I-NEG
on O
the O
tongue O
and O
slow B-NEG
pulse I-NEG
. O
2 O
Also O
applicable O
to O
urinar B-NEU

-DOCSTART- O

To O
replenish O
the O
kidney B-DNP
, O
to O
strengthen O
the O
bones B-DNP
, O
to O
promote O
the O
healing B-POS
of I-POS
fracture I-POS
, O
and O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

expel O
malign B-DNP
blood I-DNP

-DOCSTART- O

To O
benefit O
qi O
; O
To O
soothe O
stomach B-DNP
; O
To O
reduce O
lump B-NEG
; O
To O
stop O
vomiting B-NEG

-DOCSTART- O

To O
cause O
diuresis B-NEU
, O
to O
invigorate O
the O
spleen B-DNP
function I-DNP
, O
and O
to O
calm O
the O
mind B-NEU
. O

-DOCSTART- O

nourish O
essence-marrow B-NEU

-DOCSTART- O

1 O
Morellic B-NEU
acid I-NEU
, O
one O
of O
its O
components O
, O
inhibits O
Ehrljch-Ascites B-NEG
tumour I-NEG
and O
sarcoma180 B-NEG
. O

2 O
Inhibiting O
BEL-7402 B-DNP
species I-DNP
of O
hepatic B-NEG
cancer I-NEG
cells I-NEG
and O
HeLa B-DNP
cells I-DNP
in O
vitro O
. O

3 O
Increasing O
white B-DNP
blood I-DNP
cells I-DNP
and O
promoting O
its O
phagocytosis B-NEU
during O
the O
treatment O
of O
cancer B-NEG
in O
experimental O
animals O

-DOCSTART- O

Once O
bound O
, O
the O
receptor/ligand O
complex O
localizes O
to O
the O
nucleus O
and O
acts O
as O
a O
DNA O
binding O
transcription O
factor O
, O
regulating O
gene O
expression O
. O

-DOCSTART- O

promote O
liquid B-NEU

-DOCSTART- O

inner O
impairment B-NEG

-DOCSTART- O

Its O
component O
oleanolic O
acid O
can O
prevent O
and O
relieve O
cyclophosphamide-induced B-NEG
leukocytopenia I-NEG
in O
mice O
. O

Enhancing O
the O
anoxia B-NEU
tolerance I-NEU
of O
mice O
under O
atmospheric O
pressure O
. O

Increasing O
coronary B-NEU
flow I-NEU
in O
rabbits O
in O
vitro O
. O

Relaxing O
adrenaline-induced B-NEU
vasocontricyion I-NEU
in O
rabbits O
in O
vitro O
. O

Lowering O
the O
level O
of O
blood B-DNP
lipid I-DNP
. O

-DOCSTART- O

settle O
the O
pain B-NEG

-DOCSTART- O

Treatment O
of O
measles B-NEG
without O
adequate O
eruption B-NEG
, O
urticaria B-NEG
with O
itching B-NEG
, O
edema B-NEG
with O
oliguria B-NEG
. O

-DOCSTART- O

Clarithromycin O
is O
first O
metabolized O
to O
14-OH O
clarithromycin O
, O
which O
is O
active O
and O
works O
synergistically O
with O
its O
parent O
compound O
. O

-DOCSTART- O

Treatment O
of O
stagnation O
of O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
marked O
by O
distension O
and O
pain B-NEG
in O
the O
chest O
and O
hypochondriac B-NEG
regions O
, O
stuffiness B-NEG
feeling O
in O
the O
stomach O
, O
anorexia B-NEG
and O
vomiting B-NEG
. O

-DOCSTART- O

Acute B-NEG
Lymphoblastic I-NEG
Leukemia I-NEG

-DOCSTART- O

To O
promote O
diuresis B-NEU
, O
treat O
stranguria B-NEG
, O
remove O
urinary B-NEG
calculus I-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
contract O
uterus B-DNP
and O
stanch O
bleeding B-NEG
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

bloody O
stool B-NEG
; O
hematochezia B-NEG

-DOCSTART- O

strengthen O
tooth B-DNP

-DOCSTART- O

snake-bite B-NEG

-DOCSTART- O

AIM O
: O
Zhi O
Zhu O
Wan O
( O
ZZW O
) O
is O
a O
classical O
Chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-NEG
that O
attributed O
to O
Spleen B-NEG
- I-NEG
deficiency I-NEG
Syndrome I-NEG
. O

ZZW O
contains O
Atractylodes O
Rhizome O
and O
Fructus O
Citrus O
Immaturus O
, O
the O
later O
originates O
from O
both O
Citrus O
aurantium O
L. O
( O
BZZW O
) O
and O
Citrus O
sinensis O
Osbeck O
( O
RZZW O
) O
. O

The O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
ZZW O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

MEHTOD O
: O
After O
oral O
administration O
of O
ZZWs O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

Naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
RP-HPLC O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
WINNONLIN O
. O

RESULTS O
: O
After O
oral O
administration O
of O
BZZW O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

Ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
T(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
AUC O
( O
mg/Lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

However O
, O
in O
the O
case O
of O
RZZW O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
RZZW O
was O
different O
from O
that O
in O
BZZW O
. O

T(max O
) O
for O
hesperetin O
in O
RZZW O
is O
about O
8.515h O
, O
and O
its O
C(max O
) O
is O
much O
larger O
than O
that O
of O
BZZW O
. O

Moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
AUC O
value O
. O

CONCLUSION O
: O
The O
distinct O
therapeutic O
orientations O
of O
the O
Chinese O
medical O
formula O
ZZWs O
with O
different O
Fructus O
Citrus O
Immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O

Intraabdominal B-NEG
Infections I-NEG

-DOCSTART- O

excessive B-NEG
thought I-NEG
; O
anxiety B-NEG

-DOCSTART- O

erysipelas B-NEG
acute O
infection B-NEG
of O
the O
skin O
characterized O
by O
sudden O
onset O
of O
local O
bright O
red O
coloration O
and O
swelling B-NEG
with O
rapid O
spreading O
. O

-DOCSTART- O

smallpox B-NEG

-DOCSTART- O

calm O
five O
viscera B-DNP

-DOCSTART- O

Enteritis B-NEG
, O
dysentery B-NEG
, O
prolapse B-NEG
of O
rectum O
, O
emission B-NEG
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Ankylosing B-NEG
Spondylitis I-NEG

-DOCSTART- O

Some O
patients O
with O
major B-NEG
depressive I-NEG
disorder I-NEG
( O
MDD B-NEG
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-NEG
associated O
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-NEG
or I-NEG
weakness I-NEG
of I-NEG
the I-NEG
lower I-NEG
abdomen I-NEG
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-NEG
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O

This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard O
because O
of O
exhaustion B-NEG
syndrome I-NEG
. O

-DOCSTART- O

night B-NEG
sweat I-NEG
; O
night B-NEG
sweating I-NEG
spontaneous O
sweating B-NEU
during O
asleep O
and O
no O
sweating B-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-NEG
of O
vital O
essence O
and O
presence O
of O
internal O
heat O
. O

-DOCSTART- O

burn B-NEG

-DOCSTART- O

invigorate O
blood B-NEU
and O
relieve O
pain B-NEG

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
flooding B-NEG
, O
vaginal B-NEG
discharge I-NEG
, O
pharyngolaryngitis B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU

-DOCSTART- O

( O
1 O
) O
diarrhea B-NEG
( O
2 O
) O
diarrhea B-NEG
and O
urination B-NEG
( O
3 O
) O
diarrhea B-NEG
and O
dysentery B-NEG

-DOCSTART- O

promote O
water O
and O
purge O
/ O
relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

To O
expel O
wind B-NEG
from O
the O
body O
surface O
, O
clear O
away O
heat B-NEU
and O
promote O
bowel B-NEU
movement I-NEU
. O

-DOCSTART- O

Treatment O
of O
edema B-NEG
with O
oliguria B-NEG
, O
dizziness B-NEG
and O
palpitation B-NEG
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-DNP
marked O
by O
anorexia B-NEG
, O
loose O
stools B-NEG
or O
diarrhea B-NEG
, O
restlessness B-NEG
and O
insomnia B-NEG
. O

-DOCSTART- O

profuse O
bleeding B-NEG
after O
delivery B-NEU

-DOCSTART- O

weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG

-DOCSTART- O

This O
is O
a O
symptom O
with O
stuffiness B-NEG
and O
hot B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Eum O
deficiency B-NEG
of I-NEG
liver I-NEG
and I-NEG
kidney I-NEG
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver B-DNP
and O
kidney B-DNP

-DOCSTART- O

Zidovudine O
inhibits O
the O
activity O
of O
HIV-1 O
reverse O
transcriptase O
( O
RT O
) O
via O
DNA O
chain O
termination O
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

-DOCSTART- O

swollen O
check O
, O
mumps B-NEG
; O
epidemic B-NEG
parotitis I-NEG

-DOCSTART- O

Toxoplasmosis B-NEG

-DOCSTART- O

bald B-NEG
white I-NEG
scalp I-NEG
sore I-NEG
; O
tinea B-NEG
alba I-NEG
; O
white B-NEG
ringworm I-NEG

-DOCSTART- O

1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-DNP
and O
decrease O
the O
level O
of O
cGMP B-NEU
in I-NEU
plasma I-NEU
and O
in O
leukocytes O
. O
Protect O
the O
liver B-DNP
from O
damage O
. O
Hypotensive B-NEG
. O

-DOCSTART- O

Treatment O
of O
palpitation B-NEG
and O
insomnia B-NEG
, O
convulsion B-NEG
, O
epilepsy B-NEG
, O
nebula B-NEG
, O
skin B-NEG
ulcerations I-NEG
difficult O
to O
heal O
. O

-DOCSTART- O

To O
reduce O
masses B-NEG
by O
dissipating O
blood B-NEG
stasis I-NEG
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
stagnancy B-NEG
of O
food O
. O

-DOCSTART- O

Chronic B-NEG
Heart I-NEG
Failure I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
depression B-NEG
. O

-DOCSTART- O

Retention O
of O
moisture O
, O
dermatological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Liver B-DNP
, O
Liver B-DNP
health I-DNP

-DOCSTART- O

pain B-NEG
of O
back O
and O
vertebra O

-DOCSTART- O

Beginning O
stage O
of O
rash B-NEG
, O
fever B-NEG
, O
cough B-NEG
, O
alternating O
cold B-NEU
and I-NEU
hot I-NEU
feeling I-NEU

-DOCSTART- O

General O
Anesthetic O
Drug O
Adverse O
Reaction O

-DOCSTART- O

tenesmus B-NEG

-DOCSTART- O

Chunghyuldan O
( O
Daio-Orengedokuto O
in O
Japanese O
) O
( O
CHD O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-NEG
and O
antiischemic O
agent O
in O
Korea O
. O

To O
evaluate O
in O
vitro O
the O
efficacy O
of O
Chunghyuldans O
( O
CHDs O
) O
metabolized O
with O
and O
without O
human O
intestinal B-DNP
microflora I-DNP
against O
brain B-NEG
ischemia I-NEG
, O
we O
investigated O
its O
anti-inflammatory B-POS
effect I-POS
on O
LPB-induced O
RAW264.7 O
cells O
. O

Both O
metabolized O
CHD O
( O
MCHD O
) O
and O
CHD O
showed O
antioxidant B-NEU
activities I-NEU
in O
vitro O
, O
and O
inhibited O
nitric B-DNP
oxide I-DNP
( O
NO B-DNP
) O
and O
prostaglandin B-DNP
E2 I-DNP
( O
PGE2 B-DNP
) O
productions O
in O
lipopolysaccharide O
( O
LPS)-induced O
RAW264.7 O
cells O
. O

These O
also O
inhibited O
enzyme B-NEU
activities I-NEU
and O
protein B-NEU
expressions I-NEU
of O
inducible O
NO B-DNP
synthase I-DNP
and O
cyclooxygenase-2 B-DNP
in O
LPB-induced O
RAW264.7 O
cells O
. O

MCHD-inhibitory O
activity O
against O
NO B-NEU
and I-NEU
PGE2 I-NEU
productions I-NEU
in O
LPB-induced O
RAW264.7 O
cells O
was O
more O
potent O
than O
those O
of O
CHD O
. O

These O
results O
suggest O
that O
CHD O
may O
show O
potent O
anti-inflammatory B-POS
activity I-POS
in O
vivo O
and O
can O
improve O
brain B-NEG
ischemia I-NEG
. O

-DOCSTART- O

urticaria B-NEG

-DOCSTART- O

stop O
thirst B-NEU

-DOCSTART- O

Dermatological B-DNP
systems I-DNP
health I-DNP
, O
General O
skin B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

Hyperlipidemia B-NEG

-DOCSTART- O

linear O
lump B-NEG
of I-NEG
scrofula I-NEG

-DOCSTART- O

blood B-NEG
vomiting I-NEG
due O
to O
weakness B-NEG
and O
fatigue B-NEG

-DOCSTART- O

Swelling B-NEG
and O
pain B-NEG
due O
to O
blood B-NEG
stagnation I-NEG
caused O
by O
external B-NEG
injuries I-NEG
. O

-DOCSTART- O

disease O
due O
to O
wind-dampness B-NEG
; O
rheumatism B-NEG

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material O
. O
2 O
To O
clear O
liver-heat B-NEU
to O
treat O
eye B-NEG
disease I-NEG
. O
3 O
To O
clear O
dampness-heat B-NEU
. O

-DOCSTART- O

metrorrhagia B-NEG

-DOCSTART- O

Arrhythmia B-NEG

-DOCSTART- O

wind O
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease O
in O
association O
with O
other O
pathogenic O
agent O
. O
It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O

night B-NEG
sweat I-NEG
and O
nocturnal B-NEU
emission I-NEU

-DOCSTART- O

soften O
hard O
mass O

-DOCSTART- O

Oxamniquine O
may O
associate O
with O
an O
irreversible O
inhibition O
of O
the O
nucleic B-NEU
acid I-NEU
metabolism I-NEU
of I-NEU
the I-NEU
parasites I-NEU
. O

A O
hypothesis O
has O
been O
put O
forth O
that O
the O
drug O
is O
activated O
by O
a O
single O
step O
, O
in O
which O
a O
schistosome O
sulfotransferase O
enzyme O
converts O
oxamniquine O
into O
an O
ester O
( O
probably O
acetate O
, O
phosphate O
, O
or O
sulfate O
) O
. O

Subsequently O
, O
the O
ester O
spontaneously O
dissociates O
, O
the O
resulting O
electrophilic O
reactant O
is O
capable O
of O
alkylation O
of O
schistosome O
DNA O
. O

-DOCSTART- O

Dilating O
the O
coronary B-DNP
artery I-DNP
and O
blood B-DNP
vessels I-DNP
of O
hind O
legs O
in O
dogs O
. O

Lowering O
blood B-NEU
pressure I-NEU
transiently O
. O

Inhibiting O
the O
intestines B-DNP
in O
rabbits O
in O
vitro O
. O

Its O
component O
paeoniflorin O
inhibits O
the O
central B-DNP
nervous I-DNP
systems I-DNP
. O

-DOCSTART- O

prolapse B-NEG
of I-NEG
the I-NEG
rectum I-NEG

-DOCSTART- O

abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
parasitosis I-NEG
; O
abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
ascariasis I-NEG

-DOCSTART- O

Enfuvirtide O
binds O
to O
the O
first O
heptad-repeat O
( O
HR1 O
) O
in O
the O
gp41 O
subunit O
of O
the O
viral O
envelope O
glycoprotein O
and O
prevents O
the O
conformational B-NEU
changes I-NEU
required O
for O
the O
fusion O
of O
viral O
and O
cellular B-DNP
membranes I-DNP
. O

It O
works O
by O
disrupting O
the O
HIV-1 B-NEG
molecular I-NEG
machinery I-NEG
at O
the O
final O
stage O
of O
fusion O
with O
the O
target O
cell O
, O
preventing O
uninfected B-DNP
cells I-DNP
from O
becoming O
infected O
. O

Enfuvirtide O
is O
a O
biomimetic O
peptide O
that O
was O
rationally O
designed O
to O
mimic O
components O
of O
the O
HIV-1 O
fusion O
machinery O
and O
displace O
them O
, O
preventing O
normal O
fusion O
. O

-DOCSTART- O

Kallmann B-NEG
Syndrome I-NEG

-DOCSTART- O

dry O
cough B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

Used O
to O
provide O
skeletal B-POS
muscle I-POS
relaxation I-POS
as O
an O
adjunct O
to O
general B-NEU
anesthesia I-NEU
, O
for O
endotracheal O
intubation O
or O
to O
facilitate O
mechanical O
ventilation O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Eldery O
, O
Endocrine B-DNP
system I-DNP
, O
Intelligence B-POS
, O
Others O
, O
Memory B-DNP
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Hemostatic B-DNP
function I-DNP
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG

-DOCSTART- O

Swelling B-NEG
pain I-NEG
in O
throat O
, O
red B-NEG
eyes I-NEG
with O
gall O
, O
lung O
heat O
cough B-NEG
, O
mastitis B-NEG
, O
damp-heat B-NEG
jaundice I-NEG
, O
wind-damp B-NEG
impediment O
pain O
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

headache B-NEG

-DOCSTART- O

( O
1 O
) O
cold-type O
hernia B-NEG
; O
periumbilical B-NEG
colic I-NEG
due O
to O
invasion O
of O
cold B-NEG
( O
2 O
) O
testalgia B-NEG
due O
to O
pathogenic O
cold B-NEG

-DOCSTART- O

Analysis O
of O
the O
constituents O
in O
the O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
by O
UPLC/Q-TOF-MS/MS O
. O

-DOCSTART- O

1 O
To O
control O
the O
essence O
; O
2 O
To O
astringe O
the O
intestines B-DNP
and O
stop O
diarrhea B-NEG
; O
3 O
To O
decrease O
urination B-NEU

-DOCSTART- O

redness B-NEG

-DOCSTART- O

Juzentaihoto O
( O
JTT O
) O
is O
a O
well-known O
Japanese O
herbal O
medicine O
, O
which O
has O
been O
reported O
to O
modulate O
immune B-NEU
responses I-NEU
and O
enhance O
antitumor B-POS
immunity I-POS
in O
animal O
models O
. O

However O
, O
it O
is O
not O
clear O
whether O
JTT O
has O
similar O
effects O
on O
humans O
. O

In O
particular O
, O
there O
is O
little O
information O
on O
the O
effects O
of O
JTT O
in O
antigen-specific B-NEU
immunity I-NEU
in O
cancer B-NEG
patients O
. O

Here O
we O
conducted O
a O
randomized O
clinical O
study O
to O
investigate O
whether O
combined O
usage O
of O
JTT O
could O
affect O
antigen-specific B-NEU
immunity I-NEU
and O
clinical O
findings O
in O
advanced O
pancreatic B-NEG
cancer I-NEG
patients O
undergoing O
personalized O
peptide O
vaccination O
( O
PPV O
) O
, O
in O
which O
HLA-matched O
vaccine O
antigens O
were O
selected O
based O
on O
the O
preexisting O
host O
immunity O
. O

Fifty-seven O
patients O
were O
randomly O
assigned O
to O
receive O
PPV O
with O
(n O
= O
28 O
) O
or O
without O
(n O
= O
29 O
) O
JTT O
. O

Unexpectedly O
, O
JTT O
did O
not O
significantly O
affect O
cellular O
or O
humoral O
immune B-NEU
responses I-NEU
specific O
to O
the O
vaccine O
antigens O
, O
which O
were O
determined O
by O
antigen B-NEU
- I-NEU
specific I-NEU
interferon I-NEU
- I-NEU
y I-NEU
secretion I-NEU
in O
T B-DNP
cells I-DNP
and O
antigen B-DNP
- I-DNP
specific I-DNP
IgG I-DNP
titers I-DNP
in O
plasma O
, O
respectively O
. O

Nevertheless O
, O
JTT O
prevented O
deterioration O
of O
patients' O
conditions O
, O
such O
as O
anemia B-NEG
, O
lymphopenia B-NEG
, O
hypoalbuminemia B-NEG
, O
plasma B-DNP
IL-6 I-DNP
elevation O
, O
and O
reduction O
of O
performance O
status O
, O
which O
are O
frequently O
observed O
in O
advanced O
cancers B-NEG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
clinical O
study O
that O
examined O
the O
immunological O
and O
clinical O
effects O
of O
JTT O
in O
cancer O
patients O
undergoing O
immunotherapy O
in O
humans O
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Hemostatic B-DNP
function I-DNP
, O
Others O

-DOCSTART- O

The O
Chinese O
herb O
modified O
Yi O
Guan O
Jian O
( O
mYGJ O
) O
is O
an O
effective O
regimen O
that O
is O
usually O
used O
in O
outpatients O
with O
chronic B-NEG
liver I-NEG
diseases I-NEG
such O
as O
fibrosis B-NEG
and O
cirrhosis B-NEG
. O

However O
, O
the O
mechanism O
for O
the O
action O
of O
mYGJ O
on O
liver B-NEG
fibrosis I-NEG
is O
not O
yet O
clear O
. O

In O
this O
study O
, O
we O
found O
that O
mYGJ O
induced O
hepatic B-DNP
stellate I-DNP
cells I-DNP
( O
HSCs B-DNP
) O
apoptosis O
concomitant O
with O
the O
downregulation O
of O
Bcl-2 B-NEU
expression I-NEU
and O
slight O
elevation O
of O
Bax B-NEU
level I-NEU
. O

Moreover O
, O
the O
reactive B-DNP
oxygen I-DNP
species I-DNP
( O
ROS B-DNP
) O
were O
generated O
in O
the O
early O
stages O
of O
mYGJ-induced O
HSCs O
apoptosis O
to O
facilitate O
calcium O
and O
cytochrome O
c O
release O
from O
the O
mitochondria O
to O
cytosol O
. O

Subsequently O
, O
caspase B-DNP
9 I-DNP
and O
caspase B-DNP
3 I-DNP
were O
activated O
. O

Furthermore O
, O
the O
activation O
of O
ER O
stress-associated O
caspase B-DNP
12 I-DNP
in O
HSCs B-DNP
was O
also O
evaluated O
. O

Together O
, O
we O
report O
the O
first O
evidence-based O
study O
to O
demonstrate O
that O
mYGJ O
decoction O
induces O
HSCs B-DNP
apoptosis O
through O
ROS B-DNP
accumulation O
and O
the O
intrinsic O
apoptosis O
pathway O
. O

These O
findings O
provide O
rationale O
for O
further O
clinical O
investigation O
of O
traditional O
Chinese O
medicine O
recipes O
against O
liver B-NEG
fibrosis I-NEG
. O

-DOCSTART- O

Acute O
Gout B-NEG
Flare O

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O
emission B-NEU
; O
spermatorrhea B-NEU
; O
seminal B-NEU
emission I-NEU

-DOCSTART- O

This O
is O
a O
syndrome B-NEG
with I-NEG
numbness I-NEG
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

To O
dispel O
cold B-NEG
, O
eliminate O
damp B-NEG
and O
phlegm B-NEG
, O
and O
to O
arrest O
emesis B-NEG
or O
nausea B-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

all O
kinds O
of O
disease B-NEG
due O
to O
wind B-NEG

-DOCSTART- O

For O
the O
treatment O
of O
heparin-induced B-NEG
thrombocytopenia I-NEG

-DOCSTART- O

Migraine B-NEG

-DOCSTART- O

To O
quicken O
blood B-DNP
and O
free O
menstruation B-DNP
( O
raw O
) O
, O
transform O
stasis B-NEG
and O
stanch B-POS
bleeding I-POS
( O
scorch-fry O
) O
. O

-DOCSTART- O

pull O
up O
toxicity B-NEG
and O
regenerate O
flesh O

-DOCSTART- O

red-white O
dysentery B-NEG

-DOCSTART- O

Yang O
poison B-NEG
; O
extreme O
heat O
; O
symptoms O
due O
to O
extreme O
heat O

-DOCSTART- O

Multiple B-NEG
Myeloma I-NEG
and O
Plasma B-NEG
Cell I-NEG
Neoplasm I-NEG

-DOCSTART- O

pulmonary B-NEG
carbuncle I-NEG
; O
lung B-NEG
abscess I-NEG

-DOCSTART- O

To O
promote O
blood B-NEU
circulation I-NEU
, O
strengthen O
the O
muscles B-DNP
and O
tendon B-DNP
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Quality O
of O
life O
, O
Endocrine B-DNP
system I-DNP
, O
Motivation O
, O
Endurance B-NEU
, O
Memory B-POS
, O
Hemostatic B-DNP
function I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
Liver B-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Liver B-DNP
, O
Others O
, O
Respiratory B-DNP
systems I-DNP
, O
effort O
, O
Respiratory B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O

Labetuzumab O
is O
a O
humanized O
monoclonal O
antibody O
used O
to O
treat O
cancer O
. O

Retrieved O
from O
http://en.wikipedia.org/wiki/Labetuzumab O

-DOCSTART- O

Treatment O
of O
protracted O
diarrhea B-NEG
due O
to O
hypofunction B-NEG
of O
the O
spleen B-DNP
, O
seminal B-NEU
emission I-NEU
, O
leukorrhagia B-NEG
, O
palpitation B-NEG
, O
insomnia B-NEG
. O

-DOCSTART- O

Treatment O
of O
attack O
of O
damp-heat B-NEU
manifested O
by O
stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
, O
or O
causing O
acute O
dysentery B-NEG
of O
jaundice B-NEG
, O
high O
fever B-NEG
accompained O
by O
impairment O
of O
conciousness O
, O
fidgetness B-NEG
and O
insomnia B-NEG
due O
to O
exuberant O
fire O
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in O
the O
blood B-DNP
, O
inflammation B-NEG
of O
the O
eye O
, O
acid O
regurgitation O
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation B-NEG
, O
purulent B-NEG
discharge I-NEG
from O
the O
ear O
. O

-DOCSTART- O

stroke B-NEG
; O
sudden B-NEG
wind-stroke I-NEG
a O
sudden B-NEG
and I-NEG
severe I-NEG
attack I-NEG
, O
as O
of O
apoplexy B-NEG

-DOCSTART- O

Cholestyramine O
binds O
bile O
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O

stop O
tearing O

-DOCSTART- O

warm O
large O
intestine B-DNP

-DOCSTART- O

phlegmy B-NEG
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-NEG
of O
Gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-NEG
, O
usually O
causing B-NEG
mental I-NEG
disturbances O
such O
as O
hysteria B-NEG
, O
mania B-NEG
. O

-DOCSTART- O

dysenteric B-NEG
disorder I-NEG
; O
dysentery B-NEG

-DOCSTART- O

Post-operative B-NEG
Pain I-NEG

-DOCSTART- O

To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
by O
eliminating O
cold-phlegm B-NEG
, O
to O
reduce O
modulation O
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
the O
obstruction O
of O
collateral O
. O

-DOCSTART- O

Strength O
and O
power O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Liver B-DNP
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
absorption O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD O
, O
Liver B-DNP
health I-DNP
, O
Diet related O
cardiovascular B-NEG
disease I-NEG
, O
Inflammation B-NEG
, O
Other O
system O
health O
, O
Others O
, O
Neurological B-DNP
systems I-DNP
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Protective O
immunity B-NEU
, O
Hemostatic B-NEU
function I-NEU
, O
motility O

-DOCSTART- O

1 O
To O
clear O
the O
lungs B-DNP
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-DNP
and O
promote O
the O
production B-NEU
of I-NEU
body I-NEU
fluids I-NEU

-DOCSTART- O

Ritonavir O
inhibits O
the O
HIV B-NEG
viral O
proteinase O
enzyme O
which O
prevents O
cleavage O
of O
the O
gag-pol O
polyprotein O
, O
resulting O
in O
noninfectious O
, O
immature O
viral O
particles O
. O

-DOCSTART- O

epidemic B-NEG
smallpox I-NEG

-DOCSTART- O

The O
symptomatic O
relief O
of O
cough B-NEG
. O

-DOCSTART- O

Progestins O
diffuse O
freely O
into O
target O
cells O
and O
bind O
to O
the O
progesterone O
receptor O
. O

Once O
bound O
to O
the O
receptor O
, O
progestins O
slow O
the O
frequency O
of O
release O
of O
gonadotropin O
releasing O
hormone O
( O
GnRH O
) O
from O
the O
hypothalamus O
and O
blunt O
the O
pre-ovulatory O
LH O
surge O
. O

Ethinyl O
estradiol O
is O
a O
synthetic O
derivative O
of O
the O
natural O
estrogen O
estradiol O
. O

Estrogens O
increase O
the O
hepatic B-NEU
synthesis I-NEU
of I-NEU
sex I-NEU
hormone I-NEU
binding O
globulin O
, O
thyroid-binding O
globulin O
, O
and O
other O
serum B-DNP
proteins I-DNP
and O
suppress O
follicle-stimulating B-DNP
hormone I-DNP
from O
the O
anterior O
pituitary O
. O

-DOCSTART- O

dispel O
wind-damp B-NEG

-DOCSTART- O

harmonize O
blood B-NEU

-DOCSTART- O

The O
so O
called O
renin-angiotensin B-DNP
system I-DNP
( O
RAS B-DNP
) O
is O
an O
important O
regulator O
of O
blood B-NEU
pressure I-NEU
and O
has O
already O
been O
successfully O
targeted O
by O
three O
major O
classes O
of O
antihypertensive O
drugs O
: O
by O
ACE O
inhibitors O
, O
by O
ARBs O
and O
by O
renin O
inhibitors O
. O

-DOCSTART- O

( O
1 O
) O
hematochezia B-NEG
( O
2 O
) O
viginal B-NEG
bleeding I-NEG

-DOCSTART- O

dizziness B-NEG
and O
vertigo B-NEG

-DOCSTART- O

Roundworm B-NEG

-DOCSTART- O

edema B-NEG
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
and I-NEG
kidney I-NEG
. O

-DOCSTART- O

harmonize O
blood B-DNP
vessel I-DNP

-DOCSTART- O

Sermorelin O
binds O
to O
the O
growth O
hormone O
releasing O
hormone O
receptor O
and O
mimics O
native O
GRF O
in O
its O
ability O
to O
stimulate B-NEU
growth I-NEU
hormone I-NEU
secretion I-NEU
. O

-DOCSTART- O

pyogenic B-NEG
infections I-NEG
due O
to O
furuncle B-NEG

-DOCSTART- O

the O
four O
limbs O
are O
swollen B-NEG
and O
they O
feel O
painful O

-DOCSTART- O

We O
reported O
previously O
that O
cholesterol O
feeding O
induced O
an O
increase O
in O
hepatic B-NEU
secretion I-NEU
of O
VLDL B-DNP
and O
a O
decrease O
in O
that O
of O
LDL B-DNP
, O
especially O
LDL-apo B-DNP
B100 I-DNP
, O
using O
monkey O
liver O
perfusion O
. O

In O
the O
present O
study O
we O
conducted O
rat O
liver O
perfusion O
using O
the O
HMG O
Co O
A O
reductase O
inhibitor O
( O
CB-514 O
) O
and O
Kampo O
medicine O
( O
Daisaikoto O
) O
to O
elucidate O
the O
mechanism O
of O
the O
effect O
of O
dietary O
cholesterol O
on O
hepatic B-NEU
lipoprotein I-NEU
and O
apolipoprotein B-NEU
synthesis I-NEU
. O

Although O
the O
secretion B-NEU
of I-NEU
VLDL I-NEU
was O
increased O
by O
cholesterol O
feeding O
, O
that O
of O
LDL B-DNP
and O
especially O
of O
apo B-DNP
B100 I-DNP
of I-DNP
LDL I-DNP
were O
markedly O
decreased O
, O
and O
apo B-DNP
E I-DNP
of I-DNP
the I-DNP
LDL I-DNP
was O
increased O
as O
observed O
in O
the O
monkey O
liver O
perfusion O
experiments O
. O

The O
effect O
of O
CB-514 O
was O
clearly O
different O
from O
the O
effect O
of O
dietary O
cholesterol B-DNP
in O
spite O
of O
the O
suppression O
of O
hepatic O
cholesterogenesis O
which O
was O
comparable O
to O
that O
induced O
by O
cholesterol O
feeding O
, O
suggesting O
that O
the O
decrease O
in O
secretion B-NEU
of I-NEU
LDL-apo I-NEU
B100 I-NEU
induced O
by O
the O
dietary O
cholesterol O
is O
not O
due O
to O
suppressed O
cholesterogenesis O
. O

Daisaikoto O
, O
which O
was O
added O
to O
the O
diet O
together O
with O
cholesterol O
, O
diminished O
the O
effects O
of O
dietary O
cholesterol O
on O
the O
plasma B-NEU
and I-NEU
hepatic I-NEU
cholesterol I-NEU
levels I-NEU
. O

When O
the O
liver O
treated O
with O
Daisaikoto O
was O
perfused O
, O
the O
effect O
of O
dietary O
cholesterol O
on O
the O
production B-NEU
of I-NEU
lipoprotein I-NEU
and I-NEU
apolipoprotein I-NEU
was O
markedly O
diminished O
. O

This O
evidence O
indicates O
that O
the O
decrease O
in O
LDL-apo B-DNP
B100 I-DNP
and O
the O
increase O
in O
apo B-DNP
E I-DNP
were O
mediated O
by O
the O
hepatic B-NEU
cholesterol I-NEU
level I-NEU
. O

-DOCSTART- O

To O
kill O
roundworms B-NEG
; O

To O
kill O
worms B-NEG
; O

To O
move O
qi O
; O

To O
stop O
pain B-NEG

-DOCSTART- O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
water O
extract O
of O
Samultang O
( O
SMT O
) O
, O
a O
Chinese O
herb O
, O
on O
apoptotic O
cell B-NEU
death I-NEU
by O
H(2)O(2)-induced O
oxidative O
stress O
in O
SK-N-MC O
cells O
. O

A O
nuclear O
fragmentation O
was O
observed O
via O
fluorescence O
imaging O
12 O
h O
after O
exposure O
to O
30 O
microM O
H(2)O(2 O
) O
and O
DNA O
laddering O
was O
detected O
via O
agarose O
electrophoresis O
gel O
. O

In O
addition O
, O
increases O
in O
sub-G1 O
phase O
and O
cleavage O
of O
the O
PARP O
protein O
were O
observed O
. O

However O
, O
treatment O
with O
SMT O
for O
2 O
h O
prior O
to O
H(2)O(2 O
) O
exposure O
significantly O
reduced O
apoptotic O
cell B-NEU
death I-NEU
induced O
by O
incubation O
with O
30 O
microM O
H(2)O(2 O
) O
in O
SK-N-MC O
cells O
. O

Pre-incubation O
with O
water O
extract O
of O
SMT O
for O
2 O
h O
prevented O
the O
H(2)O(2)-induced O
decrease O
in O
mitochondrial O
transmembrane O
potential O
. O

SMT O
also O
attenuated O
the O
increase O
in O
caspase-3 B-NEU
activity I-NEU
and O
the O
breakdown O
of O
PARP B-DNP
protein I-DNP
caused O
by O
H(2)O(2)-induced O
oxidative O
stress O
. O

These O
results O
suggest O
that O
the O
water O
extract O
of O
SMT O
provides O
inhibition O
of O
apoptotic O
cell B-NEU
death I-NEU
against O
oxidative O
injury O
in O
SK-N-MC O
cells O
. O

-DOCSTART- O

Ovarian B-NEG
Hyperstimulation I-NEG
Syndrome I-NEG

-DOCSTART- O

phlegm B-NEG
syndrome I-NEG
induced O
by O
fright O

-DOCSTART- O

hypochondriac B-NEG
pain I-NEG

-DOCSTART- O

To O
provide O
some O
insights O
how O
herbal O
medicines O
affect O
deoxyribonucleic B-NEU
acid I-NEU
( I-NEU
DNA I-NEU
) I-NEU
synthesis I-NEU
in O
the O
uterus O
, O
the O
DNA B-NEU
polymerase I-NEU
activities I-NEU
( O
alpha O
and O
beta O
) O
in O
uterine O
samples O
taken O
from O
rats O
were O
measured O
. O

DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
with O
respect O
to O
DNA O
content O
revealed O
alpha O
cyclic O
change O
with O
the O
highest O
level O
on O
proestrus O
, O
while O
DNA B-NEU
polymerase I-NEU
beta I-NEU
activity I-NEU
showed O
no O
significant O
changes O
during O
the O
estrous O
cycle O
. O

The O
increased O
period O
of O
the O
activity O
coincided O
with O
that O
of O
17 B-DNP
beta-estradiol I-DNP
( O
E2 B-DNP
) O
but O
not O
progesterone B-DNP
( O
P4 B-DNP
) O
in O
the O
blood O
. O

Injection O
of O
10 O
IU O
pregnant O
mare O
serum O
gonadotropin O
( O
PMS O
) O
on O
day O
27 O
of O
age O
gradually O
increased O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
, O
while O
concomitant O
treatment O
with O
PMS O
and O
200 O
micrograms O
Tokishakuyakusan O
( O
TS O
) O
, O
Keishibukuryogan O
( O
KB O
) O
or O
Unkeito O
( O
UT O
) O
suppressed O
the O
enzyme B-NEU
activity I-NEU
, O
with O
a O
most O
remarkable O
effect O
of O
KB O
. O

These O
results O
suggest O
that O
TS O
, O
KB O
or O
UT O
suppresses O
in O
vivo O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
induced O
by O
PMS O
in O
the O
rat O
uterus O
. O

-DOCSTART- O

105AD7 O
vaccine O
is O
a O
human O
anti-idiotype O
which O
mimics O
the O
antigen B-DNP
791Tgp72 I-DNP
. O

The O
mechanism O
of O
action O
of O
the O
vaccine O
has O
recently O
been O
clarified O
. O

The O
anti-idiotype O
is O
rapidly O
internalized O
on O
antigen O
presenting O
cells O
by O
Fc O
mediated O
endocytosis O
as O
both O
Fab O
and O
Ab O
complexed O
to O
alum O
are O
processed O
1000 O
fold O
less O
efficiently O
than O
whole O
Ab O
. O

Sequencing O
of O
the O
Ab O
have O
revealed O
that O
the O
CDR-H3 B-DNP
is O
hypermutated O
and O
contains O
HLA B-DNP
A1 I-DNP
, I-DNP
A3 I-DNP
and I-DNP
A24 I-DNP
, O
and O
HLA-DR1 B-DNP
, I-DNP
3 I-DNP
and I-DNP
7 I-DNP
MHC I-DNP
binding O
motifs O
. O

105AD7 O
is O
an O
antibody-based O
vaccine O
that O
mimics O
a O
target O
( O
CD55 B-DNP
) O
which O
is O
over-expressed O
in O
numerous O
cancers B-NEG
including O
those O
of O
the O
prostate B-DNP
, O
colon B-DNP
and O
pancreas B-DNP
. O

-DOCSTART- O

To O
relieve O
cough B-NEG
and O
dyspnea B-NEG
, O
and O
eliminate O
retained O
phlegm B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Quality O
of O
life O
, O
Eye B-DNP
health I-DNP
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
General O
woman O
, O
General B-DNP
skin I-DNP
health I-DNP
, O
Others O
, O
Protective B-NEU
immunity I-NEU
, O
Intelligence B-POS
, O
Endurance B-NEU

-DOCSTART- O

This O
is O
a O
syndrome O
with O
felling O
of O
cold B-NEG
and O
a O
pain B-NEG
in O
the O
lower O
abdomen O
. O

-DOCSTART- O

general O
swelling B-NEG
and O
small O
amount O
urine B-DNP

-DOCSTART- O

bloodshot B-NEG
eyes I-NEG
; O
congestion B-NEG
of O
the O
eye O
; O
red B-NEG
eyes I-NEG
; O
redness B-NEG
of I-NEG
the I-NEG
eye I-NEG

-DOCSTART- O

relieve O
pain B-NEG

-DOCSTART- O

For O
appendicitis B-NEG
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
Radix O
et O
Rhizoma O
Rhei O
and O
Rhizoma O
Coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
Cinnabaris O
, O
applying O
on O
point O
Lanwei O
( O
Extra33 O
) O
. O

-DOCSTART- O

Repeated O
administration O
of O
Yokukansan O
inhibits O
DOI-induced O
head-twitch O
response O
and O
decreases O
expression O
of O
5-hydroxytryptamine B-DNP
( I-DNP
5-HT)2A I-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O

1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-NEG
wounds I-NEG
with O
hemorrhage B-NEG
( O
topical O
use O
) O
. O
2 O
Applicable O
to O
cases O
of O
angina B-NEG
pectoris I-NEG
which O
are O
attributive O
to O
retention O
of O
blood B-NEG
stasis I-NEG
. O
3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O

To O
replenish O
the O
liver B-DNP
and O
kidney B-DNP
, O
improve O
eyesight B-POS
and O
promote O
the O
growth B-POS
of I-POS
black I-POS
hair I-POS
. O

-DOCSTART- O

Gastric B-NEG
Varices I-NEG

-DOCSTART- O

To O
open O
orifices O
and O
arouse O
spirit O
, O
break O
phlegm B-NEG
and O
repel O
foulness B-NEG
, O
move O
qi O
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

Second-degree B-NEG
Burn I-NEG

-DOCSTART- O

For O
relieving O
exterior B-NEG
syndrome I-NEG

-DOCSTART- O

new O
and O
old O
cough B-NEG

-DOCSTART- O

a O
symptom O
of O
pruritis B-NEG
due O
to O
smallpox B-NEG

-DOCSTART- O

Qi O
vacuity O
, O
yin O
depletion O
and O
effulgent O
fire O
, O
cough B-NEG
and O
asthma B-NEG
with O
phlegm-blood B-NEG
, O
vacuity O
heat B-NEG
and O
vexation O
fatigue B-NEG
, O
diabetes B-NEG
mellitus I-NEG
due O
to O
internal O
heat B-NEG
, O
thirst B-NEU
with O
dry B-NEG
throat I-NEG
. O

-DOCSTART- O

all O
kinds O
of O
pain B-NEG
due O
to O
disorder O
of O
Gi O

-DOCSTART- O

Treatment O
of O
wind-heat B-NEU
type O
common O
cold B-NEG
, O
headache B-NEG
and O
dizziness B-NEG
, O
inflammation B-NEG
of O
the O
eye O
, O
blurred O
vision O
. O

-DOCSTART- O

Hypoglycemia B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Lipid O
profile O
, O
motility B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

disperse O
carbuncle B-NEG
swelling B-NEG

-DOCSTART- O

warm O
the O
stomach B-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Others O

-DOCSTART- O

To O
dissipate O
wind-cold B-NEG
, O
quicken O
network O
vessels B-DNP
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

As O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O

brighten O
the O
eyes O

-DOCSTART- O

To O
remove O
damp-heat B-NEU
, O
quench O
fire O
and O
counteract O
toxicity B-NEG
. O

-DOCSTART- O

red B-NEG
face I-NEG

-DOCSTART- O

The O
herbal O
medicine O
Tokishakuyakusan O
increases O
fetal O
blood B-NEU
glucose I-NEU
concentrations I-NEU
and O
growth B-NEU
hormone I-NEU
levels I-NEU
and O
improves O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
induced O
by O
N(omega)-nitro-L-arginine O
methyl O
ester O
. O

-DOCSTART- O

astringe O
and O
stop O
bleeding B-NEG

-DOCSTART- O

[Conservative O
treatment O
of O
benign O
prostatic O
hypertrophy O
- O
clinical O
effects O
of O
increased O
administration O
of O
Hachimijiogan O
and O
the O
relation O
between O
these O
effects O
and O
the O
Sho O
of O
Chinese O
medicine] O
. O

-DOCSTART- O

having O
a O
yellow B-NEG
or I-NEG
reddish I-NEG
urine I-NEG
due O
to O
blocking O
the O
circulation B-DNP
of O
bile O
by O
epidemic O
toxin O
, O
fail O
to O
control O
food O
, O
and O
damp-heat B-NEG
and O
cold-damp B-NEG
blocked O
in O
the O
middle O
heater O

-DOCSTART- O

Follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
FSH O
) O
. O

FSH O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
G-coupled O
transmembrane O
receptor O
. O

Binding O
of O
the O
FSH O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-DNP
and O
activation B-NEU
of I-NEU
the I-NEU
PI3K I-NEU
( O
Phosphatidylinositol-3-kinase O
) O
and O
Akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O

To O
tonify O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
prevent O
miscarrige B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
resolve O
stasis B-NEG

-DOCSTART- O

When O
administered O
, O
G17DT O
induces O
an O
immune B-NEU
response I-NEU
producing O
antibodies O
which O
bind O
with O
the O
peptide O
and O
also O
cross-react O
and O
neutralise O
gastrin B-DNP
17 I-DNP
thus O
inhibiting O
the O
growth B-NEU
of I-NEU
cancers I-NEU
and O
metastasis B-NEU
. O

In O
addition O
the O
product O
neutralizes O
glycine-extended O
gastrin O
17 O
which O
is O
also O
a O
stomach O
and O
pancreatic O
cancer O
growth O
factor O
. O

-DOCSTART- O

( O
1 O
) O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Hemostatic B-DNP
function I-DNP
, O
Overall O
CVD B-NEG
, O
Other O
system B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG

-DOCSTART- O

sore B-NEG
throat I-NEG
; O
swollen B-NEG
and I-NEG
pailful I-NEG
throat I-NEG

-DOCSTART- O

Dermatitis B-NEG
, I-NEG
Atopic I-NEG

-DOCSTART- O

mental B-NEG
confusion I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
urinary O
stone O
; O
dysuria B-NEG
caused O
by O
urinary O
stone O
; O
stranguria B-NEG
due O
to O
urolithiasis B-NEG
; O
stony B-NEG
dysuria I-NEG
; O
dysuria B-NEG
caused O
by O
calculi O

-DOCSTART- O

Gramicidin O
D O
binds O
and O
inserts O
itself O
into O
bacterial B-DNP
membranes I-DNP
and O
results O
in O
membrane B-NEG
disruption I-NEG
and O
permeabilization B-NEG
, O
which O
leads O
to O
cell B-NEU
death I-NEU
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-NEU
death I-NEU
. O

Neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30S O
ribosome O
of O
susceptible O
organisms O
. O

Binding O
interferes O
with O
mRNA B-NEU
binding I-NEU
and O
acceptor O
tRNA O
sites O
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-DNP
peptides I-DNP
. O

-DOCSTART- O

hematemesis B-NEG
; O
blood B-NEG
vomiting I-NEG
; O
spitting B-NEG
blood I-NEG
; O
blood B-NEG
vomiting I-NEG

-DOCSTART- O

1 O
Inhibiting O
experimental O
arthritis B-NEG
in O
mice O
and O
decreasing O
capillary B-NEU
permeability I-NEU
. O

2 O
. O
Anti-allergric B-NEU
. O

3 O
. O
Inducing O
transient O
hypotensive B-NEG
effect I-NEG
. O

-DOCSTART- O

furuncle B-NEG
; O
boil B-NEG

-DOCSTART- O

The O
bactericidal O
action O
of O
lomefloxacin O
results O
from O
interference O
with O
the O
activity B-NEG
of I-NEG
the I-NEG
bacterial I-NEG
enzymes I-NEG
DNA I-NEG
gyrase I-NEG
and O
topoisomerase B-DNP
IV I-DNP
, O
which O
are O
needed O
for O
the O
transcription O
and O
replication O
of O
bacterial O
DNA O
, O
as O
a O
result O
of O
inhibition O
of O
DNA B-NEU
replication I-NEU
and I-NEU
transcription I-NEU
. O

Furosemide O
blocks O
the O
Na-K-Cl B-DNP
cotransporter I-DNP
( O
NKCC B-DNP
) O
in O
the O
luminal O
membrane O
of O
the O
thick O
ascending O
limb O
of O
the O
loop O
of O
Henle O
in O
the O
kidney O
, O
by O
binding O
to O
the O
Cl-binding O
site O
located O
in O
the O
cotransporter's O
transmembrane O
domain O
, O
thereby O
inhibiting O
reabsorption B-NEU
of I-NEU
sodium I-NEU
, O
chloride B-DNP
, O
potassium B-DNP
ions I-DNP
and O
water O
. O

This O
agent O
reduces O
plasma B-DNP
and O
extracellular B-NEU
fluid I-NEU
volume I-NEU
resulting O
in O
decreased O
blood B-NEU
pressure I-NEU
and O
cardiac B-NEU
output I-NEU
. O

-DOCSTART- O

A O
traditional O
Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
is O
a O
well-known O
Kampo O
formula O
, O
and O
has O
been O
found O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
not O
only O
local O
mucosal O
immune B-DNP
system I-DNP
in O
upper O
respiratory O
tract O
, O
but O
also O
systemic O
immune B-DNP
system I-DNP
through O
upper O
respiratory O
mucosal O
immune O
system O
. O

Although O
this O
immunopharmacological O
effect O
has O
been O
proposed O
to O
express O
by O
modulation O
of O
intestinal O
immune B-DNP
system I-DNP
including O
Peyer's O
patches O
and O
intestinal O
epithelial B-DNP
cells I-DNP
, O
active O
ingredients O
are O
not O
known O
. O

TJ-41 O
directly O
affected O
the O
production O
of O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferative O
growth B-DNP
factors I-DNP
from O
murine O
Peyer's O
patch O
immunocompetent O
cells O
in O
vitro O
. O

Among O
low O
molecular O
, O
intermediate O
size O
and O
macromolecular O
weight O
fractions O
prepared O
from O
TJ-41 O
, O
only O
fraction O
containing O
macromolecular O
weight O
ingredients O
showed O
Peyer's O
patch O
- O
mediated O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferation O
enhancing O
activity O
. O

Anion-exchange O
chromatography O
and O
gel O
filtration O
gave O
17 O
subfractions O
comprising O
polysaccharides O
and O
lignins O
from O
the O
macromolecular O
weight O
fraction O
of O
TJ-41 O
, O
and O
some O
of O
the O
subfractions O
showed O
significant O
enhancing O
activities O
having O
different O
degrees O
. O

Some O
of O
the O
subfractions O
also O
expressed O
stimulating O
activity O
on O
G-CSF B-DNP
- O
production O
from O
colonic O
epithelial O
cells O
, O
and O
statistically O
significant O
positive O
correlation O
was O
observed O
among O
enhancing O
activities O
of O
the O
subfractions O
against O
Peyer's O
patch O
immunocompetent B-DNP
cells I-DNP
and O
epithelial B-DNP
cells I-DNP
. O

Among O
the O
fractions O
from O
TJ-41 O
oral O
administration O
of O
macromolecular O
weight O
ingredient O
fraction O
to O
mice O
succeeded O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
systemic O
immune B-DNP
system I-DNP
through O
upper O
respiratory O
mucosal O
immune O
system O
, O
but O
all O
the O
separated O
fractions O
failed O
to O
enhance O
the O
in O
vivo O
antibody B-NEU
response I-NEU
in O
upper O
respiratory O
tract O
. O

-DOCSTART- O

Treatment O
of O
rheumatic B-NEG
or I-NEG
rheumatoid I-NEG
arthrits I-NEG
with O
muscular B-NEG
contracture I-NEG
and O
severe O
joint B-NEG
pain I-NEG
, O
fever B-NEG
recurring O
daily O
in O
the O
afternoon O
, O
fever B-NEG
in I-NEG
infants I-NEG
with O
malnutrition B-NEG
. O

-DOCSTART- O

Strength B-POS
and O
power B-POS
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

To O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
. O

-DOCSTART- O

Infant B-NEG
, I-NEG
Newborn I-NEG
, I-NEG
Diseases I-NEG

-DOCSTART- O

epigastric O
twisting O
pain B-NEG
. O

-DOCSTART- O

To O
dispel O
wind-damp B-NEG
, O
quicken O
blood B-DNP
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

prolapse B-NEG
of I-NEG
uterus I-NEG

-DOCSTART- O

invigorate O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

Treatment O
of O
consumptive B-NEG
diseases I-NEG
, O
impotence B-NEG
, O
cold B-NEG
sperm I-NEG
, O
lassitude B-NEG
in O
the O
loins O
and O
legs O
due O
to O
deficiency O
of O
the O
kidney-yang O
, O
etc O
. O

-DOCSTART- O

Exposure B-NEG
to I-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG

-DOCSTART- O

Hypertension B-NEG
. O

-DOCSTART- O

Injury B-NEG
of I-NEG
Bladder I-NEG

-DOCSTART- O

To O
remove O
heat B-NEU
and O
counteract O
toxicity B-NEG
, O
to O
expel O
intestinal B-NEG
worms I-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

diabetes B-NEG
; O
wasting(emaciation B-NEG
) O
and O
thirsting B-NEG
syndrome I-NEG

-DOCSTART- O

retention O
of O
undigested O
food O
; O
dyspepsia O

-DOCSTART- O

This O
is O
kinds O
of O
consciousness B-NEG
disorder I-NEG
with O
a O
light O
stupor O
. O
It O
is O
sleeping O
at O
nights O
and O
days O
, O
and O
responding O
with O
opening O
an O
eye O
. O
It O
is O
cause O
by O
palsy B-NEG
. O

-DOCSTART- O

Spontaneous O
external O
bleeding B-NEG
, O
hematochezia B-NEG
, O
headache B-NEG
, O
dizziness B-NEG
and O
dim B-NEG
vision I-NEG
, O
red B-NEG
eyes I-NEG
, O
night B-NEG
blindness I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
fecal B-NEG
stoppage I-NEG
, O
hemorrhoids B-NEG
. O

-DOCSTART- O

Chloramphenicol O
reversibly O
binds O
to O
the O
L16 O
protein O
of O
the O
50S O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-NEU
synthesis I-NEU
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase O
I, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular O
DNA O
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-DNP
molecules I-DNP
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human O
mucosa O
. O

-DOCSTART- O

SP-01A O
is O
an O
HIV B-NEG
oral O
entry O
inhibitor O
drug O
. O
In O
order O
for O
viruses B-NEG
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses O
. O
Just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-DNP
cells I-DNP
, O
or O
new O
blood B-DNP
cells I-DNP
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O
Viruses O
hide O
their O
own O
DNA O
in O
the O
DNA O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses O
as O
well O
. O
HIV B-NEG
mostly O
infects O
cells O
in O
the O
immune B-NEU
system I-NEU
. O

-DOCSTART- O

Treatment O
of O
sore B-NEG
throat I-NEG
and O
hoarseness B-NEG
of I-NEG
voice I-NEG
, O
cough B-NEG
with O
yellow O
sticky O
sputum B-NEG
, O
dysuria B-NEG
, O
external O
use O
for O
pemphigus B-NEG
and O
eczema B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
motility B-NEU
, O
Evacuation B-NEU
, O
Protective O
immunity B-NEU

-DOCSTART- O

nfantile O
malnutrition B-NEG
with O
diarrhea B-NEG

-DOCSTART- O

deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-DNP

-DOCSTART- O

To O
clear O
heat B-NEG
and O
resolve O
toxin O
, O
disinhibit O
water O
and O
disperse O
edema B-NEG
. O

-DOCSTART- O

For O
tonifying O
blood B-DNP

-DOCSTART- O

T'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG
; O

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG
in O
T'aeyang B-NEG
meridian I-NEG

-DOCSTART- O

Esophageal B-NEG
Bleeding I-NEG

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Lipid B-NEU
profile I-NEU

-DOCSTART- O

This O
is O
bleeding B-NEG
due O
to O
an O
external B-NEG
wound I-NEG
. O

-DOCSTART- O

freckles B-NEG
on O
face O

-DOCSTART- O

For O
dispelling O
wind-dampness B-NEG
and O
dispersing O
coldness B-NEG
. O

-DOCSTART- O

Schizophrenia B-NEG

-DOCSTART- O

nourish O
the O
liver B-DNP
and O
kidney B-DNP

-DOCSTART- O

night B-NEG
blindness I-NEG
. O
Visual B-NEG
disorder I-NEG
at O
night O
. O

-DOCSTART- O

insulin O
sensitivity O
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
and O
cause O
diuresis B-NEG
. O

-DOCSTART- O

Acute B-NEG
Myelogenous I-NEG
Leukemia I-NEG

-DOCSTART- O

Rheumatism B-NEG
numbness I-NEG
, O
damp-heat B-NEG
itchy I-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
menstruant O
morbidity O
. O

-DOCSTART- O

Treatment O
of O
cough B-NEG
in O
colds O
with O
retention O
of O
phlegm B-NEG
marked O
by O
dyspnea B-NEG
, O
profuse O
expectoration B-NEG
and O
feeling O
of O
stuffiness B-NEG
in O
the O
chest O
, O
external O
use O
for O
pyogenic B-NEG
infections I-NEG
of O
the O
skin O
. O

-DOCSTART- O

ceruminal B-NEG
impaction I-NEG

-DOCSTART- O

difficult B-NEG
delivery I-NEG
; O

dystocia B-NEG

-DOCSTART- O

Other O
system O
health O
, O
Others O

-DOCSTART- O

Pregnancy B-NEU
Outcome O

-DOCSTART- O

Treatment O
of O
protracted O
diarrhea B-NEG
due O
to O
hypofunction B-NEG
of O
the O
spleen O
, O
seminal B-NEU
emission I-NEU
, O
leukorrhagia B-NEG
, O
palpitation B-NEG
, O
insomnia B-NEG
. O

-DOCSTART- O

To O
remove O
heat O
and O
damp O
, O
to O
counteract O
toxicity B-NEG
, O
and O
to O
cause O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

Symptoms O
associated O
with O
stagnation B-NEG
of I-NEG
liver I-NEG
qi I-NEG
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood B-DNP

-DOCSTART- O

1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O

To O
invigorate O
blood B-DNP
and O
remove O
stagnation B-NEG
. O

-DOCSTART- O

Exerting O
prolong O
hypotensive B-NEU
effect I-NEU
in O
anesthetized O
animals. O
. O

-DOCSTART- O

Deficiency O
of O
yin O
of O
the O
liver B-DNP
and O
the O
kidney B-DNP
marked O
by O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
, O
dizziness B-NEG
and O
blurred B-NEG
vision I-NEG
. O

-DOCSTART- O

Lung O
cancer O

-DOCSTART- O

Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis O
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins O
and O
leukotrienes O
by O
inhibiting O
the O
release O
of O
their O
common O
precursor B-DNP
arachidonic I-DNP
acid I-DNP
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic B-DNP
transcription I-DNP
factors I-DNP
, O
causing O
the O
increase O
in O
expression B-NEU
of I-NEU
specific I-NEU
target I-NEU
genes I-NEU
. O

-DOCSTART- O

hemiplegia B-NEG

-DOCSTART- O

Possessing O
broad-spectrum O
antibacterial B-POS
and I-POS
antiprotozoal I-POS
effects I-POS
. O

-DOCSTART- O

restrain O
acid O

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Overall O
CVD B-NEG

-DOCSTART- O

12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-NEG
component I-NEG
. O

-DOCSTART- O

Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 B-DNP
receptors I-DNP
. O

Naproxen O
inhibits O
the O
activity B-DNP
of I-DNP
the I-DNP
enzymes I-DNP
cyclo-oxygenase I-DNP
I I-DNP
and I-DNP
II I-DNP
, O
resulting O
in O
a O
decreased O
formation B-DNP
of I-DNP
precursors I-DNP
of I-DNP
prostaglandins I-DNP
and I-DNP
thromboxanes I-DNP
. O

-DOCSTART- O

affection O
due O
to O
wind-cold B-NEG
; O
common O
cold B-NEG
caused O
by O
wind B-NEG
and O
cold B-NEG

-DOCSTART- O

Treament O
of O
edema B-NEG
or O
retained B-NEU
fluid I-NEU
with O
abdominal B-NEG
distension I-NEG
, O
oliguria B-NEG
and O
constipation B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
external O
use O
for O
ringworm B-NEG
and O
verrucous B-NEG
vegetations I-NEG
. O

-DOCSTART- O

To O
eliminate O
phlegm B-NEG
, O
resuscitate O
, O
tranquilize O
, O
suppress O
wind B-NEG
and O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

relieve O
throat B-DNP

-DOCSTART- O

move O
drug O
effect O

-DOCSTART- O

To O
promote O
blood B-DNP
circulation I-DNP
, O
remove O
blood B-NEG
stasis I-NEG
, O
restore O
consciousness B-NEU
, O
remove O
obstruction B-NEG
in O
the O
channels O
, O
suppress O
the O
hyperfunction O
of O
liver-yang O
and O
stop O
endogenous B-NEG
wind I-NEG
to O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

rigidity B-NEG
of O
the O
limbs O
; O

contracture B-NEG
; O

subjective B-NEU
sensation I-NEU
of O
contraction O

-DOCSTART- O

Uncomplicated B-NEG
Falciparum I-NEG
Malaria I-NEG

-DOCSTART- O

Gumiganghwaltang O
( O
GMGHT O
) O
is O
an O
Oriental O
herbal O
prescription O
, O
which O
has O
been O
commonly O
used O
to O
treat O
a O
cold O
and O
inflammatory B-NEG
diseases I-NEG
in O
Korea O
. O

However O
, O
the O
mechanism O
of O
GMGHT O
is O
not O
clear O
. O

In O
this O
study O
, O
we O
investigated O
the O
anti-inflammatory B-POS
mechanism O
of O
GMGHT O
in O
mouse O
peritoneal O
macrophages O
. O

GMGHT O
exerted O
an O
anti-inflammatory B-POS
action O
through O
inhibiting O
lipopolysaccaride O
( O
LPS)-induced O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
interleukin O
( O
IL)-6 O
production O
in O
mouse O
peritoneal O
macrophages O
. O

The O
maximal O
inhibition O
rate O
of O
TNF-alpha O
, O
and O
IL-6 O
production O
by O
GMGHT O
(1 O
mg/ml O
) O
was O
52.31+/-2.8% O
and O
56.31+/-3.1% O
, O
respectively O
. O

In O
the O
inflammatory B-NEG
process I-NEG
, O
cyclooxygenase O
2 O
( O
COX-2 O
) O
and O
inducible O
nitric B-DNP
oxide I-DNP
synthase I-DNP
( O
iNOS B-DNP
) O
increased O
in O
peritoneal O
macrophages O
. O

GMGHT O
decreased O
the O
protein O
level O
of O
COX-2 B-DNP
and O
iNOS B-DNP
in O
LPB-stimulated O
mouse O
peritoneal O
macrophages O
. O

In O
addition O
, O
GMGHT O
inhibited O
nuclear B-NEU
factor-kappaB I-NEU
activation I-NEU
and O
IkappaB-alpha B-DNP
degradation O
. O

Our O
study O
suggests O
that O
an O
important O
molecular O
mechanism O
by O
GMKHT O
reduce O
inflammation B-NEG
, O
which O
might O
explain O
its O
beneficial O
effect O
in O
the O
regulation O
of O
inflammatory B-NEU
reactions I-NEU
. O

-DOCSTART- O

To O
tonify O
the O
spleen B-DNP
, O
to O
relieve O
diarrhea B-NEG
, O
to O
replenish O
the O
kidney B-DNP
, O
to O
arrest O
seminal B-NEU
emission I-NEU
, O
and O
to O
nourish O
the O
heart B-DNP
, O
to O
induce O
tranquillization B-POS
. O

-DOCSTART- O

papule B-NEG

-DOCSTART- O

night B-NEG
sweat I-NEG
; O
night B-NEG
sweating I-NEG
spontaneous B-NEG
sweating I-NEG
during O
asleep O
and O
no O
sweating B-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-NEG
of O
vital O
essence O
and O
presence O
of O
internal O
heat B-NEU
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Overall O
CVD B-NEG

-DOCSTART- O

de O
Novo O
Kidney B-DNP
Transplantation O

-DOCSTART- O

bloody B-NEG
stool I-NEG
; O
hematochezia B-NEG

-DOCSTART- O

Anemia B-NEG

-DOCSTART- O

Reproductive B-DNP
systems I-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Menopausal B-NEG
woman I-NEG
, O
Endocrine B-DNP
system I-DNP
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Metabolism B-NEU
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Woman O
, O
Quality O
of O
life O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Liver B-DNP
, O
Others O
, O
Kids O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Liver B-DNP
health I-DNP
, O
Strength B-POS
and O
power B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Intelligence B-POS
, O
Overall O
CVD B-NEG
, O
General O
woman O
, O
Body B-NEU
weight I-NEU
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

reinforce O
bone B-NEG
fracture I-NEG

-DOCSTART- O

Heat B-NEG
sensation I-NEG
in O
the O
chest O
, O
palms O
and O
soles O

-DOCSTART- O

Juvenile B-NEG
Idiopathic I-NEG
Arthritis I-NEG

-DOCSTART- O

infertility B-NEG

-DOCSTART- O

To O
clear O
heat B-NEU
and O
dry B-NEU
damp I-NEU
, O
check O
dysentery B-NEG
. O

-DOCSTART- O

Purging B-NEG

-DOCSTART- O

Neoplasms B-NEG
, I-NEG
Breast I-NEG

-DOCSTART- O

Anesthesia B-DNP
With O
Use O
of O
LMA O
( O
Laryngeal O
Mask O
Airway O
) O

-DOCSTART- O

pain B-NEG
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O

Ramipril O
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
used O
to O
treat O
high B-NEG
blood I-NEG
pressure I-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

Irbesartan O
, O
by O
blocking O
the O
binding O
of O
angiotensin O
II O
to O
the O
AT1 O
receptor O
, O
promotes O
vasodilation B-NEU
and O
decreases O
the O
effects B-NEU
of I-NEU
aldosterone I-NEU
. O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Mental B-NEU
state I-NEU
and I-NEU
performance I-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Memory B-POS

-DOCSTART- O

a O
symptom B-NEG
of I-NEG
perspiration I-NEG
. O

-DOCSTART- O

support O
five O
viscera B-DNP

-DOCSTART- O

Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O

Pseudoephedrine O
relaxes O
bronchial B-DNP
smooth I-DNP
muscle I-DNP
by O
stimulating O
beta2-adrenergic O
receptors O
. O
Hydrocodone O
exerts O
its O
analgesic O
activity O
by O
binding O
to O
the O
mu-receptors O
in O
the O
central B-DNP
nervous I-DNP
system I-DNP
( O
CNS B-DNP
) O
, O
thereby O
mimicking O
the O
effects O
of O
endogenous O
opioids O
. O

-DOCSTART- O

Treatment O
of O
lung B-NEG
abscess I-NEG
with O
purulent B-NEG
expectoration I-NEG
, O
heat B-NEG
in O
the O
lung O
with O
cough B-NEG
and O
dyspnea B-NEG
, O
acute B-NEG
dysentery I-NEG
, O
acute B-NEG
urinary I-NEG
infection I-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
. O

-DOCSTART- O

1 O
For O
cases O
of O
apoplexy O
with O
sudden O
onset O
of O
face B-NEG
distortion,dysphasia,numbness I-NEG
of O
the O
limbs,or O
even O
hemiplegia,rigidty B-NEG
of O
the O
extremities,white O
and O
greasy O
fur O
on O
the O
tongue,floating O
and O
smooth O
pulse,which O
are O
attributive O
to O
attack O
of O
wind-phlegm B-NEG
to O
the O

-DOCSTART- O

affection O
due O
to O
wind-cold B-NEG
; O
common B-NEG
cold I-NEG
caused O
by O
wind B-NEG
and O
cold B-NEG

-DOCSTART- O

insulin B-NEG
sensitivity I-NEG
and O
diabetes B-NEG
risk O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
absorption B-NEU
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-POS
, O
Hypersensitivity B-NEG
, O
motility B-POS

-DOCSTART- O

epistaxis B-NEG
; O
nosebleed B-NEG

-DOCSTART- O

diabetics B-NEG
; O
emaciation-thirst B-NEG

-DOCSTART- O

To O
strengthen O
the O
body O
resistance O
to O
consolidate O
the O
constitution O
, O
replenish O
qi O
, O
invigorate O
the O
spleen B-DNP
and O
tonify O
the O
spleen B-DNP
and O
tonify O
the O
kidney B-DNP
to O
relieve O
mental B-NEU
strain I-NEU
. O

-DOCSTART- O

For O
dispelling O
wind-dampness B-NEG
and O
dispersing O
coldness B-NEG

-DOCSTART- O

Strengthen O
the O
heart B-DNP
and O
replenish O
qi O
, O
activating O
yang O
and O
blood B-DNP
circulation I-DNP
, O
promoting O
the O
restoration B-POS
of I-POS
consciousness I-POS
with O
drugs O
of O
fragnant O
flavour O
, O
relieving O
pain B-NEG
. O

-DOCSTART- O

break O
blood B-DNP

-DOCSTART- O

HER2-overexpressing O
breast B-NEG
cancer I-NEG

-DOCSTART- O

Type O
2 O
Diabetes B-NEG
Mellitus I-NEG
. O

-DOCSTART- O

tinea B-NEG
favosa I-NEG
; O
mouth-corner B-NEG
ulcer I-NEG

-DOCSTART- O

To O
arrest O
seminal B-NEU
emission I-NEU
, O
to O
restrain O
urination B-NEU
, O
and O
to O
check O
diarrhea B-NEG
. O
cturnal B-NEU
emission I-NEU
, O
spermatorrhea B-NEG
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
excessive O
leukorrhea B-NEG
, O
protracted O
diarrhea B-NEG
, O
chronic B-NEG
dysentery I-NEG
. O

-DOCSTART- O

For O
nutritional O
supplementation O
, O
also O
for O
treating O
dietary B-NEG
shortage I-NEG
or O
imbalance B-NEG
. O

-DOCSTART- O

Treatment O
of O
headache B-NEG
and O
dizziness B-NEG
, O
costal O
and O
abdomina O
pain B-NEG
, O
spasmodic O
pain B-NEG
of O
the O
limbs O
, O
anemia B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
spontaneous O
sweating B-NEU
and O
night B-NEU
sweating I-NEU
. O

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG

-DOCSTART- O

To O
invigorate O
the O
function O
of O
the O
kidney B-DNP
, O
to O
alleviate O
asthma B-NEG
, O
and O
to O
relieve O
diarrhea B-NEG
. O

-DOCSTART- O

Angina B-NEG
pectoris I-NEG
, O
cerebral B-NEG
atherosclerosis I-NEG
, O
diffusive O
intravascular B-NEG
clotting I-NEG
, O
thrombophlebitis B-NEG
, O
hepatitis B-NEG
, O
acute B-NEG
surgical I-NEG
infection I-NEG
, O
mastitis B-NEG
, O
erysipelas B-NEG
, O
otitis B-NEG
media I-NEG
, O
tonsillitis B-NEG
, O
bone B-NEG
marrow I-NEG
infection I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
dysmenorrhea O
, O
amenorrhea B-NEG
, O
postpartum B-NEG
stasis I-NEG
stagnation I-NEG
abdominal I-NEG
pain I-NEG
, O
pain B-NEG
in O
heart O
and O
abdomen O
, O
concretion B-NEG
conglomeration I-NEG
accumulation I-NEG
and O
gathering O
, O
heat B-NEU
impediment O
swelling B-NEG
and O
pain B-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
heat B-NEU
entering O
construction-blood B-NEG
, O
vexation B-NEG
and O
agitation B-NEG
, O
insomnia B-NEG
and O
vexation B-NEG
, O
swelling B-NEG
toxin O
of O
welling O
abscess B-NEG
and O
sore B-NEG
, O
zoster B-NEG
, O
neurodermatitis B-NEG
, O
psoriasis B-NEG
. O

-DOCSTART- O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O
Although O
it O
does O
not O
display O
selectivity O
for O
specific O
muscarinic O
receptors O
, O
on O
topical O
application O
it O
acts O
mainly O
on O
M3 O
muscarinic O
receptors O
located O
in O
the O
airways B-DNP
to O
produce O
smooth B-POS
muscle I-POS
relaxation I-POS
, O
thus O
producing O
a O
bronchodilatory B-POS
effect I-POS
. O

-DOCSTART- O

Intravenous O
Anesthetic O
Interaction O
Unrecognized B-NEG
Condition I-NEG

-DOCSTART- O

Dimethindene O
can O
also O
be O
used O
as O
an O
adjuvant O
in O
eczema B-NEG
and O
other O
pruriginous B-NEG
dermatoses I-NEG
of O
allergic O
origin O
. O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
adverse O
effects O
( O
chemotherapy O
) O
and O
bone B-DNP
marrow I-DNP
transplant O
. O

-DOCSTART- O

For O
ascariasis B-NEG
and O
taeniasis B-NEG
. O
For O
constipation B-NEG
due O
to O
dryness O
of O
intestine O
. O

-DOCSTART- O

soothe O
diaphragm B-DNP

-DOCSTART- O

To O
nourish O
blood B-DNP
, O
stanch B-NEG
bleeding I-NEG
, O
calm O
liver B-DNP
, O
moisten O
dryness O
. O

-DOCSTART- O

Heart B-NEG
Failure I-NEG
. O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

relieve O
cough B-NEG

-DOCSTART- O

affection O
by O
cold B-NEG
1 O
common O
cold B-NEG
2 O
influenza B-NEG

-DOCSTART- O

dyspnea B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

fever B-NEG
with O
overstrain B-NEG

-DOCSTART- O

Its O
aqueous O
infusion O
inhibits O
the O
growth O
of O
skin O
fungi O
such O
as O
Trichophyton O
violaceum O
. O

-DOCSTART- O

Acute B-NEG
Mania I-NEG

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
abdominal B-NEG
fullness I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body O
weight O
regulation O
, O
Woman O
, O
Reproductive B-DNP
systems I-DNP
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
Intelligence O
, O
Dermatological B-DNP
systems I-DNP
health O
, O
Eldery O
, O
Overall O
CVD O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
menopausal B-DNP
woman I-DNP
, O
Others O
, O
Hemostatic B-DNP
function I-DNP
, O
Mental B-DNP
state I-DNP
and O
performance O
, O
Man O

-DOCSTART- O

abdominal O
pain B-NEG

-DOCSTART- O

Treatment O
of O
mass B-NEG
in O
the O
abdomen O
, O
goitre B-NEG
with O
pain B-NEG
, O
epigastric B-NEG
pain I-NEG
and O
distension B-NEG
due O
to O
indigestion B-NEG
. O

-DOCSTART- O

Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-NEG
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-NEU
cell I-NEU
phagocytosis I-NEU
. O

Anti-inflammation B-POS
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Others O
, O
Man O

-DOCSTART- O

Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEU
effect I-NEU
on O
experimental O
animals O
. O

-DOCSTART- O

To O
warm O
the O
spleen B-DNP
, O
stop O
vomiting B-NEG
, O
clear O
away O
summer-heat B-NEG
and O
eliminate O
dampness B-NEG
. O

-DOCSTART- O

destroy O
intestinal B-NEG
parasites I-NEG

-DOCSTART- O

blood B-NEG
stagnation I-NEG
caused O
by O
falling O
or O
strike O

-DOCSTART- O

Used O
in O
the O
treatment O
of O
relapsing O
forms O
of O
multiple B-NEG
sclerosis I-NEG
( O
MS B-NEG
) O
. O

-DOCSTART- O

Unresectable O
Metastasis O
Originating O
in O
Colonic B-NEG
Cancer I-NEG
. O

-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
invigorate O
the O
network B-NEU
vessels O

-DOCSTART- O

constipation B-DNP
and O
dry B-NEG
stool I-NEG

-DOCSTART- O

For O
tonifying O
weakness B-NEG

-DOCSTART- O

distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Man O

-DOCSTART- O

Clarithromycin O
also O
inhibits O
the O
hepatic O
microsomal O
CYP3A4 O
isoenzyme O
and O
P-glycoprotein O
, O
an O
energy-dependent O
drug O
efflux O
pump O
. O

-DOCSTART- O

constrain O
the O
lung B-DNP

-DOCSTART- O

warm O
the O
menses B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

clear O
heat B-NEU
and O
cool O
blood B-NEU

-DOCSTART- O

wind-heat B-NEG
; O

wind B-NEG
and O
heat B-NEG
; O

wind-heat B-NEG
pathogene I-NEG
wind B-NEG
and O
heat B-NEG
blended O
as O
a O
pathogenic B-NEG
factor I-NEG
. O

-DOCSTART- O

Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-NEG
. O

-DOCSTART- O

Treatment O
of O
bdominal O
pain B-NEG
and O
constipation B-NEG
due O
to O
cold B-NEG
or O
retention O
of O
food O
in O
the O
intestines O
. O

-DOCSTART- O

Treatment O
of O
stagnation O
of O
undigested O
meat O
with O
epigastric B-NEG
distension I-NEG
, O
diarrhea B-NEG
and O
abdominal B-NEG
pain I-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
epigastric B-NEG
pain I-NEG
or O
abdominal B-NEG
colic I-NEG
, O
after O
childbirth O
, O
heraial O
pain B-NEG
, O
hyperlipemia B-NEG
. O

-DOCSTART- O

Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O

Damp-heat B-NEG
diarrhea I-NEG
, O
vaginal B-NEG
discharge I-NEG
, O
hemorrhoids B-NEG
, O
pain B-NEG
from O
swollen O
welling O
abscess B-NEG
, O
scrofula B-NEG
. O

-DOCSTART- O

impetigo B-NEG
; O
pyoderma B-NEG

-DOCSTART- O

Breast B-NEG
Pain I-NEG

-DOCSTART- O

Palonosetron O
is O
a O
selective O
serotonin O
5-HT O
3 O
receptor O
antagonist O
. O

The O
antiemetic O
activity O
of O
the O
drug O
is O
brought O
about O
through O
the O
inhibition O
of O
5-HT B-DNP
3 I-DNP
receptors I-DNP
present O
both O
centrally O
( O
medullary O
chemoreceptor O
zone O
) O
and O
peripherally O
( O
GI O
tract O
) O
. O

This O
inhibition O
of O
5-HT B-DNP
3 I-DNP
receptors I-DNP
in O
turn O
inhibits O
the O
visceral B-NEG
afferent I-NEG
stimulation I-NEG
of I-NEG
the I-NEG
vomiting I-NEG
center I-NEG
, O
likely O
indirectly O
at O
the O
level O
of O
the O
area O
postrema O
, O
as O
well O
as O
through O
direct O
inhibition O
of O
serotonin B-DNP
activity I-DNP
within O
the O
area O
postrema O
and O
the O
chemoreceptor O
trigger O
zone O
. O

Alternative O
mechanisms O
appear O
to O
be O
primarily O
responsible O
for O
delayed O
nausea B-NEG
and O
vomiting B-NEG
induced O
by O
emetogenic O
chemotherapy O
, O
since O
similar O
temporal O
relationships O
between O
between O
serotonin O
and O
emesis O
beyond O
the O
first O
day O
after O
a O
dose O
have O
not O
been O
established O
, O
and O
5-HT O
3 O
receptor O
antagonists O
generally O
have O
not O
appeared O
to O
be O
effective O
alone O
in O
preventing O
or O
ameliorating O
delayed O
effects O
. O

It O
has O
been O
hypothesized O
that O
palonosetron's O
potency O
and O
long O
plasma O
half-life O
may O
contribute O
to O
its O
observed O
efficacy O
in O
preventing O
delayed O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
moderately O
emetogenic O
cancer O
chemotherapy O
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Mood O
, O
Quality O
of O
life O
, O
Inflammation O
, O
Other B-DNP
system I-DNP
health I-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

tidal O
fever B-NEG
in O
the O
afternoon O

-DOCSTART- O

For O
cases O
of O
collapse O
due O
to O
massive O
hemorrhage B-NEG
manifested O
as O
cold B-NEG
limbs I-NEG
, O
oily B-NEG
sweat I-NEG
, O
pale B-NEG
complexion I-NEG
, O
spiritlessness B-NEG
, O
small B-NEG
and I-NEG
indistinct I-NEG
pulse I-NEG
, O
use O
high O
grade O
of O
Radix O
Ginseng O
( O
such O
as O
Ginseng O
Korea O
or O
Ginseng O
Jilin O
) O
instead O
of O
Codonopsis O
Pilosulae O
. O

-DOCSTART- O

release O
the O
exterior O
and O
dispel O
wind B-NEG

-DOCSTART- O

Used O
in O
the O
treatment O
of O
Kaposi's B-NEG
sarcoma I-NEG
and O
cancer B-NEG
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

Abraxane® O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-NEG
breast I-NEG
cancer I-NEG
and O
locally O
advanced B-NEG
or I-NEG
metastatic I-NEG
non-small I-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
fullness B-NEG
and O
pain B-NEG
in I-NEG
the I-NEG
chest I-NEG
and I-NEG
abdomen I-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEG
from O
the O
lung O
and O
relieve O
sore B-NEG
throat I-NEG
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm B-NEG

-DOCSTART- O

Macular B-NEG
Edema I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
hepatitis B-NEG
( O
viral O
, O
B O
) O
. O

-DOCSTART- O

anal B-NEG
fistula I-NEG
hemorrhoids B-NEG
complicated O
by O
anal B-NEG
fistula I-NEG
. O

-DOCSTART- O

For O
acute O
and O
long-term O
management O
of O
signs O
and O
symptoms O
of O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
, O
as O
well O
as O
for O
the O
management O
of O
pain B-NEG
. O

-DOCSTART- O

The O
large O
hydrophilic O
molecule O
is O
able O
to O
form O
hydrogen O
bond O
interactions O
with O
the O
terminal O
D-alanyl-D-alanine O
moieties O
of O
the O
NAM/NAG-peptides O
, O
which O
is O
normally O
a O
five-point O
interaction O
. O

-DOCSTART- O

1 O
An O
active O
component O
arcitiin O
is O
a O
vasodilator O
and O
hypotensive O
. O
2 O
. O
Over O
dosage O
of O
arctiin O
may O
lead O
to O
convulsion B-NEG
and O
respiratory B-NEG
failure I-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP

-DOCSTART- O

swelling B-NEG
of O
carbuncle B-NEG
is O
lumped O
at O
the O
neck O

-DOCSTART- O

flatulence B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O

-DOCSTART- O

suffering B-NEG
from O
diarrhea B-NEG
and O
having O
a O
stomachache B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG
, O
Pediatric O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver B-DNP
, O
Others O

-DOCSTART- O

blood B-NEG
vacuity I-NEG
, O
septicemia B-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
aching B-NEG
in O
lumbus O
and O
legs O
. O

-DOCSTART- O

Treatment O
of O
deficient O
yin O
of O
the O
liver O
and O
kidneys O
and O
hyperactivity O
of O
liver O
yang O
manifested O
as O
distension O
and O
pain B-NEG
in O
the O
head O
and O
eyes O
, O
dizziness B-NEG
and O
vertigo B-NEG
. O

Red O
ochre O
( O
Daizheshi O
) O
is O
used O
with O
Dragon's O
bone O
( O
Longgu O
) O
, O
Oyster O
shell O
( O
Muli O
) O
, O
White O
peony O
root O
( O
Bais O

-DOCSTART- O

Blood B-NEG
stasis I-NEG
in O
the O
hypochondriac O
region O
due O
to O
traumatic B-NEG
injury I-NEG
characterised O
by O
hypochondriac B-NEG
pain I-NEG
. O

Traumatic B-NEG
swelling I-NEG
pain I-NEG
, O
intercostal B-NEG
neuralgia I-NEG
, O
costal B-NEG
chrondritis I-NEG
marked O
by O
accumulation O
of O
blood B-NEG
stasis I-NEG
can O
be O
treated O
by O
the O
modified O
recipe O
. O

-DOCSTART- O

To O
tonify O
Qi O
and O
strengthen O
the O
spleen B-DNP
. O

To O
consolidate O
the O
Chong B-DNP
channel I-DNP
and O
control O
the O
blood B-DNP
. O

-DOCSTART- O

amenorrhea B-NEG
; O
menstrual B-NEG
block I-NEG
absence I-NEG
or O
suppression B-NEG
of I-NEG
menstruation I-NEG
. O

-DOCSTART- O

To O
promote O
contraction B-NEU
and O
stem B-NEU
desertion I-NEU
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
dryness B-NEG
of I-NEG
the I-NEG
lung I-NEG

-DOCSTART- O

Thioridazine O
blocks O
postsynaptic O
mesolimbic O
dopaminergic O
D1 O
and O
D2 O
receptors O
in O
the O
brain B-DNP
; O
blocks O
alpha-adrenergic O
effect O
, O
depresses O
the O
release O
of O
hypothalamic B-DNP
and I-DNP
hypophyseal I-DNP
hormones I-DNP
and O
is O
believed O
to O
depress O
the O
reticular B-DNP
activating I-DNP
system I-DNP
thus O
affecting O
basal B-DNP
metabolism I-DNP
, O
body B-NEU
temperature I-NEU
, O
wakefulness B-NEG
, O
vasomotor B-NEU
tone I-NEU
, O
and O
emesis B-NEG
. O

-DOCSTART- O

reinforce O
blood B-DNP

-DOCSTART- O

distribution O
) O
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU

-DOCSTART- O

To O
warm O
and O
replenish O
qi O
and O
blood B-NEU
. O

-DOCSTART- O

repel O
all O
malign O
sore B-NEG

-DOCSTART- O

Kidney B-NEG
Failure I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

Treatment O
of O
deficiency B-NEG
of I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
lassitude B-NEG
, O
palpitation B-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

Fructus O
Crataegi O
( O
charred O
) O
: O
Has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation O
of O
undigested O
meat O
and O
diarrhea B-NEG
with O
inadequate O
discharge O
from O
the O
bowels B-DNP
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

To O
boost O
essence O
, O
brighten O
eyes B-DNP
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
lung B-DNP
subcutaneous I-DNP
nodes I-DNP

-DOCSTART- O

1 O
Its O
decoction O
enhances O
th O
intestinal B-NEG
contraction I-NEG
and O
tensity B-NEG
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O
2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-NEG
180 I-NEG
in O
mice O
. O

-DOCSTART- O

An O
inhibition O
of O
DNA B-DNP
polymerase I-DNP
. O

-DOCSTART- O

tinea B-NEG

-DOCSTART- O

Dexamethasone O
is O
a O
glucocorticoid O
agonist O
. O

-DOCSTART- O

For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-NEG
colorectal I-NEG
carcinoma I-NEG
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O

The O
powder O
of O
Croton O
seed O
( O
Badou O
) O
is O
blown O
into O
the O
throat B-DNP
to O
cause O
vomiting B-NEG
. O

-DOCSTART- O

stop O
thirst B-NEG

-DOCSTART- O

Hemophilia B-NEG
A I-NEG

-DOCSTART- O

To O
eliminate O
mass O
, O
reduce O
fullness B-NEG
, O
strengthen O
spleen B-DNP
and O
regulate O
stomach B-DNP
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Lipid O
profile O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

nfantile B-NEG
convulsive I-NEG
seizure I-NEG
due O
to O
fright O

-DOCSTART- O

Indicated O
as O
symptomatic O
treatment O
of O
allergic B-NEG
reactions I-NEG
: O
urticaria B-NEG
, O
allergies B-NEG
of O
the O
upper O
respiratory O
tract O
such O
as O
hey B-NEG
fever I-NEG
and O
perennial B-NEG
rhinitis I-NEG
, O
food O
and O
drug O
allergies B-NEG
; O
pruritus B-NEG
of O
various O
origins O
, O
except O
pruritus B-NEG
due O
to O
cholestasis B-NEG
; O
insect B-NEG
bites I-NEG
. O

-DOCSTART- O

Rikkunshito O
improves O
globus B-NEG
sensation I-NEG
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal O
reflux O
. O

-DOCSTART- O

Fever B-NEG
, O
Sweats B-NEU
, O
and O
Hot B-NEG
Flashes I-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
cool O
blood B-DNP
; O

To O
benefit O
qi O
and O
contain O
blood B-DNP
; O

To O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

restlessness B-NEG
and O
thirst B-NEU
; O
polydipsia B-NEG

-DOCSTART- O

Myelodysplastic B-NEG
Syndromes I-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
palpitation B-NEG
and O
severe O
palpitation B-NEG
. O

-DOCSTART- O

Hyperactivity B-NEG
of O
the O
liver-yang O
, O
hypertension B-NEG
, O
dizziness B-NEG
, O
vertigo B-NEG
, O
insomnia B-NEG
, O
amnesia B-NEG
. O

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Hemostatic B-NEU
function I-NEU

-DOCSTART- O

Knocks B-NEG
and O
falls B-NEG
, O
stasis B-NEG
swelling I-NEG
pain I-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

dissipate O
stasis B-NEG

-DOCSTART- O

Vaginal B-NEG
Diseases I-NEG

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Strength B-POS
and O
power B-POS
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

a O
disease O
that O
menstruation B-NEU
is O
not O
even O
due O
to O
coldness B-NEG

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
, O
invigorate O
yang O
, O
replenish O
the O
vital B-POS
essence I-POS
and O
reinforce O
the O
marrow B-DNP

-DOCSTART- O

To O
transform O
dampness O
and O
promote O
water B-NEU
metabolism I-NEU
. O

-DOCSTART- O

Hepatocellular B-NEG
Carcinoma I-NEG

-DOCSTART- O

Anemia B-NEG
in I-NEG
Chronic I-NEG
Renal I-NEG
Disease I-NEG

-DOCSTART- O

fever B-NEG

-DOCSTART- O

old O
ulceration B-NEG

-DOCSTART- O

Breast B-NEG
Cancer I-NEG

-DOCSTART- O

Diabetic B-NEG
Neuropathy I-NEG
, O
Painful O

-DOCSTART- O

To O
replenish O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
by O
removing O
heat B-NEU
from I-NEU
blood I-NEU
. O

-DOCSTART- O

Hydrochlorothiazide O
allows O
the O
blood B-DNP
vessels I-DNP
to O
relax O
and O
causes O
kidneys B-DNP
to O
remove O
more O
salt B-DNP
and I-DNP
water I-DNP
from I-DNP
the I-DNP
blood I-DNP
in O
order O
to O
reduce O
blood B-DNP
volume I-DNP
. O

Valsartan O
is O
in O
a O
group O
of O
drugs O
called O
angiotensin O
II O
receptor O
antagonists O
. O

Valsartan O
keeps O
blood B-DNP
vessels I-DNP
from O
narrowing O
, O
which O
lowers O
blood B-NEU
pressure I-NEU
and O
improves O
blood B-NEU
flow I-NEU
. O

-DOCSTART- O

eliminate O
vexation B-NEG
and O
thirst B-NEU

-DOCSTART- O

muscular B-NEG
twitching I-NEG
and O
cramp B-NEG
; O

twitching B-NEG
of I-NEG
muscles I-NEG

-DOCSTART- O

invigorate O
the O
network O
vessels O

-DOCSTART- O

dizziness B-NEG
; O
vertigo B-NEG

-DOCSTART- O

IMC-A12 O
is O
a O
fully O
human O
monoclonal O
antibody O
that O
specifically O
targets O
the O
type O
1 O
human O
insulin-like O
growth O
factor O
receptor O
( O
IGF-IR O
) O
. O

Tumors B-NEG
have O
receptors O
for O
the O
insulin-like O
growth O
factor-1 O
( O
IGF-I O
) O
, O
and O
it O
is O
thought O
that O
the O
presence O
of O
these O
receptors O
cause O
tumors B-NEG
to O
grow O
. O

IMC-A12 O
attaches O
to O
the O
receptors O
and O
may O
inhibit O
the O
growth B-NEG
of I-NEG
cancer I-NEG
cells I-NEG
. O

-DOCSTART- O

Emergence B-NEG
Agitation I-NEG

-DOCSTART- O

pain B-NEG
in O
the O
supraorbital O
bone O

-DOCSTART- O

To O
remove O
blood B-NEG
stasis I-NEG
, O
promote O
the O
subsidence O
of O
swelling B-NEG
, O
relieve O
pain B-NEG
and O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

moisten B-NEU
face I-NEU

-DOCSTART- O

deafness B-NEG

-DOCSTART- O

Specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
N-acetylmuramic B-DNP
acid I-DNP
( O
NAM)- O
and O
N-acetylglucosamine B-DNP
( I-DNP
NAG)-peptide I-DNP
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
Gram-positive O
cell O
walls O
. O

-DOCSTART- O

Major B-NEG
Depressive I-NEG
Disorder I-NEG

-DOCSTART- O

Purging B-NEG
by O
moisterizing O

-DOCSTART- O

cool O
blood B-DNP
and O
stop O
bleeding B-NEG

-DOCSTART- O

diarrhea B-NEG

dysentery B-NEG

-DOCSTART- O

To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O

Imipenem O
acts O
as O
an O
antimicrobial O
through O
the O
inhibition O
of O
cell B-DNP
wall I-DNP
synthesis I-DNP
which O
leads O
to O
rapid O
cell B-DNP
lysis I-DNP
and O
death O
without O
filament B-DNP
formation I-DNP
. O
Cilastatin O
helps O
imipenem O
work O
more O
effectively O
by O
preventing O
the O
breakdown O
of O
the O
antibiotic O
in O
the O
kidneys B-DNP
. O

-DOCSTART- O

Food B-NEG
accumulation I-NEG
, O
stomachache B-NEG
, O
abdomin B-NEG
al I-NEG
pain I-NEG
. O

-DOCSTART- O

ischuria B-NEG
; O
dysuria B-NEG
; O
retention B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

bloody B-NEG
dysentery I-NEG

-DOCSTART- O

wind B-NEG
stroke I-NEG
1 O
apoplexy B-NEG
2 O
invasion O
of O
wind B-NEG
pathogen I-NEG
3 O
wind-stroke B-NEG
syndrome I-NEG
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-NEG
wind I-NEG
, O
manifested O
by O
fever B-NEG
, O
headache B-NEG
, O
perspiration B-NEG
, O
slow B-NEG
and I-NEG
floating I-NEG
pulse I-NEG
. O

-DOCSTART- O

Cisplatin O
binds O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA O
, O
inducing O
intrastrand O
and O
interstrand O
DNA O
cross-links O
, O
as O
well O
as O
DNA-protein O
cross-links O
. O

-DOCSTART- O

Treatment O
of O
: O
1 O
Hemorrhages B-NEG
due O
to O
external B-NEG
injuries I-NEG
. O
Dragon's O
blood B-DNP
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O

cosolidate O
the O
kidney B-DNP

-DOCSTART- O

dyspnea B-NEG
with O
coughing B-NEG

-DOCSTART- O

Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-DNP
artery I-DNP
significantly O
. O

-DOCSTART- O

Treatment O
of O
arthralgia B-NEG
with O
weakness B-NEG
of O
the O
loins O
and O
knees O
, O
excessive B-NEG
menstrual I-NEG
flow I-NEG
, O
chronic B-NEG
phthisical I-NEG
cough I-NEG
. O

-DOCSTART- O

black B-POS
hair I-POS

-DOCSTART- O

Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA O
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
initiating O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

ThioTEPA O
is O
used O
a O
as O
conditioning O
treatment O
prior O
to O
allogeneic O
or O
autologous O
haematopoietic O
progenitor O
cell O
transplantation O
( O
HPCT O
) O
in O
haematological B-NEG
diseases I-NEG
in O
adult O
and O
paediatric O
patients O
. O

Also O
, O
when O
high O
dose O
chemotherapy O
with O
HPCT O
support O
it O
is O
appropriate O
for O
the O
treatment O
of O
solid B-NEG
tumours I-NEG
in O
adult O
and O
paediatric O
patients O
. O

-DOCSTART- O

Glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
G O
protein-coupled O
receptor O
located O
in O
the O
plasma B-DNP
membrane I-DNP
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-DNP
calcium I-DNP
. O

Adenylate O
cyclase O
manufactures O
cAMP O
( O
cyclic O
AMP O
) O
, O
which O
activates O
protein B-DNP
kinase I-DNP
A I-DNP
( O
cAMP-dependent B-DNP
protein I-DNP
kinase I-DNP
) O
. O

This O
enzyme O
, O
in O
turn O
, O
activates O
phosphorylase B-DNP
kinase I-DNP
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen O
phosphorylase O
, O
converting O
into O
the O
active O
form O
called O
phosphorylase O
A O

Phosphorylase O
A O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

This O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood B-DNP
. O

Glucagon O
receptors O
are O
found O
in O
the O
liver B-DNP
, O
kidney B-DNP
, O
brain B-DNP
and O
pancreatic B-DNP
islet I-DNP
cells I-DNP
. O

The O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-NEU
excretion I-NEU

-DOCSTART- O

Linezolid O
selectively O
inhibits O
bacterial B-NEU
protein I-NEU
synthesis I-NEU
through O
binding O
to O
sites O
on O
the O
bacterial O
ribosome O
and O
prevents O
the O
formation B-NEU
of I-NEU
a I-NEU
functional I-NEU
70B-initiation I-NEU
complex I-NEU
. O

Isoniazid O
appears O
to O
block O
the O
synthesis B-NEU
of I-NEU
mycolic I-NEU
acids I-NEU
, O
major O
components O
of O
the O
mycobacterial O
cell O
wall O
. O

This O
agent O
is O
only O
active O
against O
actively O
growing O
mycobacteria O
because O
, O
as O
a O
pro-drug O
, O
it O
requires O
activation O
in O
susceptible O
mycobacterial O
species O
. O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent B-DNP
RNA I-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression B-DNP
of I-DNP
RNA I-DNP
synthesis I-DNP
and O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

To O
remove O
heat O
from O
the O
lung B-DNP
, O
and O
to O
relieve O
cough B-NEG
and O
dyspnea B-NEG
. O

-DOCSTART- O

Treatment O
of O
thrist B-NEG
in O
febrile O
disease O
, O
dry B-NEG
cough I-NEG
due O
to O
heat B-NEG
in O
the O
lung O
, O
diabetes B-NEG
caused O
by O
internal O
heat O
, O
sores B-NEG
and O
abscess B-NEG
. O

-DOCSTART- O

Ocular B-NEG
Hypertension I-NEG

-DOCSTART- O

Liver B-NEG
Disease I-NEG

-DOCSTART- O

flaccidity B-NEG
and O
limping B-NEG

-DOCSTART- O

To O
remove O
blood B-NEG
stasis I-NEG
and O
promote O
the O
blood B-NEU
flow I-NEU
, O
to O
stimulate O
menstrual B-NEG
discharge I-NEG
, O
and O
to O
induce O
labour O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

Valproic O
Acid O
acts O
by O
increasing O
gamma-aminobutyric O
acid O
levels O
in O
the O
brain O
or O
by O
altering O
the O
properties O
of O
voltage O
dependent O
sodium O
channels O
. O

Lamotrigine O
inhibits O
voltage-sensitive O
sodium O
channels O
and/or O
calcium O
channels O
, O
thereby O
stabilizing O
neuronal B-DNP
membranes I-DNP
and O
consequently O
modulating O
presynaptic O
transmitter O
release O
of O
excitatory O
amino O
acids O
. O

-DOCSTART- O

cough B-NEG

-DOCSTART- O

relaxing O
apoplexy B-NEG

-DOCSTART- O

To O
pacify O
the O
liver B-DNP
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-NEG
; O

To O
stop O
bleeding B-NEG

-DOCSTART- O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine O
kinases O
( O
TK O
) O
, O
thereby O
inhibiting O
ATP B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation B-NEU
of I-NEU
growth I-NEU
receptors I-NEU
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-NEG
of O
MTIC O
is O
due O
primarily O
to O
methylation B-NEU
of I-NEU
DNA I-NEU
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition O
of O
DNA B-NEU
replication I-NEU
. O

-DOCSTART- O

Obesity B-NEG

-DOCSTART- O

diarrhea B-NEG
due O
to O
damp-heat B-NEG

-DOCSTART- O

Pulmonary B-NEG
Arterial I-NEG
Hypertension I-NEG

-DOCSTART- O

Doxapram O
produces O
respiratory O
stimulation O
mediated O
through O
the O
peripheral O
carotid O
chemoreceptors O
. O

It O
is O
thought O
to O
stimulate O
the O
carotid B-DNP
body I-DNP
by O
inhibiting O
certain B-DNP
potassium I-DNP
channels I-DNP
. O

-DOCSTART- O

Wind-cold-damp B-NEG
impediment I-NEG
, O
paralysis B-NEG
, O
painful O
wound B-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
tetanus B-NEG
. O

-DOCSTART- O

Kidney B-DNP
Transplant O

-DOCSTART- O

have O
no O
menstruation B-DNP
due O
to O
static O
blood B-NEU
. O

-DOCSTART- O

Endometriosis B-NEG

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material I-NEG
, O
deprive O
dampness B-NEU
and O
kill O
parasites B-NEG
. O

For O
sorethroat B-NEG
, O
dysentery B-NEG
, O
trichomonas B-NEG
enteritis I-NEG
, O
toothache B-NEG
, O
stomachache B-NEG
and O
leucorrhagia B-NEU
, O
external O
use O
for O
tinea B-NEG
and O
eczema B-NEG
. O

2 O
To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
. O

3 O
Anticarcinogenic B-POS
. O
For O
malignant B-NEG
hydatidiform I-NEG
mole I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
and O
leukemia B-NEG
. O

-DOCSTART- O

fracture B-NEG

-DOCSTART- O

stop O
tearing B-NEG

-DOCSTART- O

clear O
heat B-NEU
and O
moisten O
the O
lung B-DNP

-DOCSTART- O

nine O
kinds O
of O
illness B-NEG
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O

Enduring O
cough B-NEG
and O
asthma B-NEG
, O
bronchitis B-NEG
, O
lumbago B-NEG
and O
limp O
leg B-DNP
, O
frequent O
urination B-NEU
, O
enuresis B-NEG
, O
impotence B-NEG
, O
emission B-NEU
, O
intestinal B-NEG
dry I-NEG
and O
constipation B-NEG
, O
stone B-NEG
strangury I-NEG
, O
sores B-NEG
and O
scrofula B-NEG
. O

-DOCSTART- O

Atrophy B-NEG

-DOCSTART- O

Intelligence B-POS
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
, O
Protective O
immunity B-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG

-DOCSTART- O

skin B-NEG
disease I-NEG
on O
palms O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG
and O
tenesmus B-NEG

-DOCSTART- O

Traumatic B-NEG
brain I-NEG
injury I-NEG

-DOCSTART- O

stop O
sweating B-NEU

-DOCSTART- O

For O
the O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
B O
in O
adult O
and O
adolescent O
patients O
6 O
years O
of O
age O
with O
evidence O
of O
viral O
replication O
and O
either O
evidence O
of O
persistent O
elevations O
in O
serum O
aminotransferases O
( O
ALT O
or O
AST O
) O
or O
histologically B-NEG
active I-NEG
disease I-NEG
. O

-DOCSTART- O

Ipilimumab O
is O
a O
fully O
human O
IgG1 O
antibody O
that O
binds O
to O
CTLA-4 O
( O
cytotoxic O
T O
lymphocyte-associated O
antigen O
4 O
) O
, O
a O
molecule O
on O
T-cells O
that O
is O
indicated O
for O
unresectable B-NEG
or I-NEG
metastatic I-NEG
melanoma I-NEG
. O

The O
absence O
or O
presence O
of O
CTLA-4 O
can O
augment O
or O
suppress O
the O
immune B-DNP
system's I-DNP
T-cell O
response O
in O
fighting O
disease B-NEG
. O

Ipilimumab O
is O
designed O
to O
block O
the O
activity O
of O
CTLA-4 O
, O
thereby O
sustaining O
an O
active B-DNP
immune I-DNP
response I-DNP
in O
its O
attack O
on O
cancer B-NEG
cells I-NEG
. O

The O
proposed O
mechanism O
of O
action O
is O
indirect O
, O
and O
may O
be O
through O
T-cell O
- O
mediated O
anti-tumor B-DNP
immune I-DNP
responses I-DNP
. O

-DOCSTART- O

Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase O
II O
activity O
by O
stabilizing O
the O
DNA-topoisomerase O
II O
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase O
II O
catalyzes O
. O

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Rhubarb O
( O
Dahuang O
) O
and O
Dried O
ginger O
( O
Ganjiang O
) O
in O
the O
formula O
Sanwu O
Beiji O
Wan O
. O

-DOCSTART- O

To O
supplement O
blood B-DNP
, O
quicken B-NEU
blood I-NEU
, O
strengthen O
lumbus B-DNP
and O
knees B-DNP
. O

-DOCSTART- O

invigorate O
blood B-DNP

-DOCSTART- O

Binds O
to O
the O
nicotinic O
acetycholine O
receptors O
( O
by O
virtue O
of O
its O
similarity O
to O
acetylcholine O
) O
in O
the O
motor O
endplate O
and O
blocks O
access O
to O
the O
receptors O
. O

-DOCSTART- O

unconsciousness B-NEG

-DOCSTART- O

Encainide O
is O
a O
sodium O
channel O
blocker O
, O
binding O
to O
voltage B-DNP
gated I-DNP
sodium I-DNP
channels I-DNP
. O

It O
stabilizes O
the O
neuronal B-DNP
membrane I-DNP
by O
inhibiting O
the O
ionic B-NEU
fluxes I-NEU
required O
for O
the O
initiation O
and O
conduction O
of O
impulses O
. O

Ventricular O
excitability O
is O
depressed O
and O
the O
stimulation O
threshold O
of O
the O
ventricle O
is O
increased O
during O
diastole O
. O

-DOCSTART- O

Edema B-NEG
due O
to O
deficiency B-NEG
in I-NEG
the I-NEG
kidney I-NEG
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-NEG
and O
cough B-NEG
. O

-DOCSTART- O

To O
benefit O
vital B-POS
energy I-POS
to O
control O
blood B-DNP
. O

-DOCSTART- O

Cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
cold B-NEG
mounting O
with O
abdominal O
pain B-NEG
, O
menstrual B-NEG
disorder I-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Inflammation B-NEG
, O
Others O

-DOCSTART- O

illness B-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP

-DOCSTART- O

promote O
the O
large O
intestine B-DNP

-DOCSTART- O

Treament O
of O
vertigo B-NEG
, O
tinnitus B-NEG
, O
weakness B-NEG
in I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
premature B-NEG
whitening I-NEG
of I-NEG
hair I-NEG
and O
impaired B-NEG
eyesight I-NEG
due O
to O
deficiency O
of O
yin O
of O
the O
liver O
and O
kidney O
. O

-DOCSTART- O

Liver B-NEG
cancer I-NEG

-DOCSTART- O

Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-NEU
of I-NEU
serotonin I-NEU
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-NEU
of I-NEU
serotonin I-NEU
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O

swelling B-NEG
of I-NEG
carbuncle I-NEG
caused O
by O
heat B-NEG
toxin I-NEG

-DOCSTART- O

Unspecified B-NEG
Adult I-NEG
Solid I-NEG
Tumor I-NEG
, I-NEG
Protocol I-NEG
Specific I-NEG

-DOCSTART- O

Woman O
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

The O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
FdUMP O
) O
and O
the O
folate O
cofactor O
, O
N50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
TS O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

This O
results O
in O
the O
inhibition O
of O
the O
formation B-NEU
of I-NEU
thymidylate I-NEU
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
DNA B-NEU
and I-NEU
RNA I-NEU
synthesis I-NEU
and O
cell O
death O
. O

Fluorouracil O
can O
also O
be O
incorporated O
into O
RNA O
in O
place O
of O
uridine O
triphosphate O
( O
UTP O
) O
, O
producing O
a O
fraudulent B-DNP
RNA I-DNP
and O
interfering O
with O
RNA B-NEU
processing I-NEU
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
vomiting B-NEG
because O
of O
Cold-Damp B-NEG
. O

-DOCSTART- O

To O
enrich O
yin O
and O
supplement O
kidney B-DNP
, O
clear O
lung B-DNP
and O
moisten O
dryness B-NEU
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
quicken O
blood B-DNP
and O
regulate O
menstruation B-NEU
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Wind-damp B-NEG
bone O
pain B-NEG
, O
knocks O
and O
falls O
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
, O
child O
gan O
accumulation O
. O

-DOCSTART- O

Spasticity B-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-NEG
and O
convulsions B-NEG
. O

-DOCSTART- O

A O
symptom O
that O
a O
person O
has O
tightness B-NEG
in I-NEG
the I-NEG
chest I-NEG
and O
does O
not O
feel O
hungry O
. O

-DOCSTART- O

For O
palliative O
, O
not O
definitive O
, O
therapy O
to O
temporarily O
maintain O
the O
patency B-NEG
of I-NEG
the I-NEG
ductus I-NEG
arteriosus I-NEG
until O
corrective O
or O
palliative O
surgery O
can O
be O
performed O
in O
neonates O
who O
have O
congenital B-NEG
heart I-NEG
defects I-NEG
and O
who O
depend O
upon O
the O
patent O
ductus O
for O
survival O
. O
Also O
for O
the O
treatment O
of O
erectile B-NEG
dysfunction I-NEG
due O
to O
neurogenic O
, O
vasculogenic O
, O
psychogenic O
, O
or O
mixed O
etiology O
. O

-DOCSTART- O

To O
warm O
the O
spleen B-DNP
and O
stomach B-DNP
, O
to O
regulate O
the O
adverse O
flow O
of O
the O
stomach O
qi O
, O
and O
to O
restore O
the O
kidney O
yang O
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
resolve O
toxin B-NEG
, O
disinhibit O
urine B-NEU
, O
relieve O
cough B-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

Treatment O
of O
edema B-NEG
, O
oliguria B-NEG
, O
arthritis B-NEG
with O
contracture B-NEG
of O
joints O
, O
diarrhea B-NEG
due O
to O
diminished O
function O
of O
the O
spleen B-DNP
, O
lung B-NEG
abscess I-NEG
, O
appendicitis B-NEG
, O
verruca B-NEG
plana I-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
pricking O
pain B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Psoriatic B-NEG
Arthritis I-NEG

-DOCSTART- O

Despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced O
lymphedema B-NEG
. O

Saireito O
( O
SRT O
) O
is O
a O
traditional O
Japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-NEG
and O
inflammation B-NEG
in O
conditions O
such O
as O
nephritic O
disease B-NEG
. O

This O
study O
investigated O
the O
effect O
of O
SRT O
on O
lymphedema B-NEG
caused O
by O
radiotherapy O
. O

Four O
patients O
were O
treated O
with O
SRT O
at O
a O
dose O
of O
9 O
g/day O
. O

The O
severity O
of O
lymphedema O
was O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4 O
and O
Numerical O
Rating O
Scale O
before O
and O
after O
SRT O
treatment O
. O

After O
the O
treatment O
with O
SRT O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-NEG
. O

One O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
SRT O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

One O
case O
decided O
to O
stop O
taking O
SRT O
3 O
days O
after O
initiation O
because O
cough B-NEG
and O
fever B-NEG
appeared O
. O

In O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor O
control O
rates O
. O

Prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O

moisten O
the O
liver B-DNP

-DOCSTART- O

general O
weakness B-NEG
and O
weight B-NEU
loss I-NEU

-DOCSTART- O

Purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O

It O
may O
also O
bind O
to O
bacterial O
potassium O
transporters O
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O

A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O

Other B-DNP
system I-DNP
health I-DNP
, O
Others O

-DOCSTART- O

a O
symptom O
of O
having O
muscular B-NEG
flaccidity I-NEG
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-NEG
of I-NEG
nourishment I-NEG
in O
organs O
due O
to O
deficiency B-NEG
of I-NEG
blood I-NEG

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
with O
chest B-NEG
congested I-NEG

-DOCSTART- O

dysentery B-NEG

-DOCSTART- O

Nausea B-NEG

-DOCSTART- O

cough B-NEG
due O
to O
lung B-NEG
exhaustion I-NEG
syndrome I-NEG

-DOCSTART- O

sores B-NEG
; O
boil B-NEG
suppurative I-NEG
infection I-NEG
on O
the O
body O
surface O
. O
including O
carbuncle B-NEG
, O
furuncle B-NEG
, O
deep-rooted O
carbuncle B-NEG
, O
multiple O
abscess B-NEG
, O
scrofula B-NEG
, O
ulcer B-NEG
. O

-DOCSTART- O

fetal O
irritability B-NEG
; O

threatened B-NEG
abortion I-NEG
; O

excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-NEG
in O
the O
lower O
abdomen O
. O

-DOCSTART- O

Cardiac B-NEG
Output I-NEG
, I-NEG
Low I-NEG

-DOCSTART- O

aversion O
to O
cold B-NEG
; O
severe O
chillness B-NEG
; O
creeping B-NEG
chills I-NEG

-DOCSTART- O

Cardiac B-NEG
carbuncle I-NEG
has O
half O
conscious O
, O
stuffiness B-NEG
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O

In O
the O
process O
of O
binding O
, O
the O
receptor O
is O
actually O
activated O
- O
causing O
a O
process O
known O
as O
depolarization B-DNP
. O

-DOCSTART- O

invigorate O
waist O
and O
limbs O

-DOCSTART- O

To O
lower O
blood B-NEU
pressure I-NEU
, O
supplement O
liver B-DNP
and O
kidney B-DNP
, O
strengthen O
sinews B-DNP
and O
bones B-DNP
, O
quiet O
fetus O
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
, O
resolve O
phlegm B-NEG
and O
promote O
blood B-NEU
circulation I-NEU
to O
remove O
obstruction B-NEG
in O
the O
channels O
. O

-DOCSTART- O

To O
regulate O
the O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

pain B-NEG
with O
1 O
hernia B-NEG
2 O
diseases B-NEG
of I-NEG
genitalia I-NEG
3 O
. O
severe O
pain B-NEG
in O
the O
lower O
abdomen O

-DOCSTART- O

eliminate O
vacuity B-NEG
and I-NEG
clod I-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG

-DOCSTART- O

Infection B-NEG

-DOCSTART- O

Heartburn B-NEG

-DOCSTART- O

Type B-NEG
1 I-NEG
Diabetes I-NEG
Mellitus I-NEG

-DOCSTART- O

Chronic B-NEG
Viral I-NEG
Hepatitis I-NEG
B I-NEG
Without I-NEG
Delta-agent I-NEG

-DOCSTART- O

wind-cold B-NEG
; O

wind-cold B-NEG
pathogen I-NEG
wind B-NEG
and O
cold B-NEG
blended O
as O
a O
pathogenic O
facto O

-DOCSTART- O

loss B-NEG
of I-NEG
appetite I-NEG

-DOCSTART- O

edema B-NEG

-DOCSTART- O

For O
the O
treatment O
and O
management O
of O
congestive B-NEG
cardiac I-NEG
insufficiency I-NEG
, O
arrhythmias B-NEG
and O
heart B-NEG
failure I-NEG
. O

-DOCSTART- O

Aortic B-NEG
Valve I-NEG
Stenosis I-NEG

-DOCSTART- O

facial B-NEG
hemiparalysis I-NEG
due O
to O
wind B-NEG
stroke I-NEG

-DOCSTART- O

Treatment O
of O
weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
lung I-NEG
manifested O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
, O
palpitation B-NEG
, O
anorexia B-NEG
, O
loose B-NEG
stools I-NEG
, O
diabetes B-NEG
caused O
by O
internal O
heat B-NEU
. O

-DOCSTART- O

High-Grade O
Lymphoma B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Intelligence O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Strength O
and O
power O
, O
Neurological B-DNP
systems I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

blurred B-NEG
vision I-NEG

-DOCSTART- O

Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-NEG
sensation I-NEG
and O
numbness B-NEG
after O
stroke B-NEG
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke O
patients O
. O

-DOCSTART- O

to O
have O
skin B-NEG
rashes I-NEG
due O
to O
epidemic B-NEG
febrile I-NEG

-DOCSTART- O

Applicable O
to O
cases O
of O
watery B-NEG
diarrhea I-NEG
with O
increased O
gurgling O
sounds O
, O
abdominal B-NEG
pain I-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
, O
vexation B-NEG
, O
thirst B-NEU
, O
yellow B-NEU
and I-NEU
greasy I-NEU
fur I-NEU
, O
soft O
and O
floating O
, O
smooth B-NEU
pulse I-NEU
, O
which O
are O
attributive O
to O
dampness-heat B-NEG
of O
intestines O
and O
stomach O
( O
predominantly O
da O

-DOCSTART- O

food B-NEG
damage I-NEG
; O
injury B-NEG
due O
to O
improper O
diet O
; O
eating B-NEG
food I-NEG
much I-NEG
injury B-NEG
of O
spleen O
and O
stomach O

-DOCSTART- O

a O
disease O
with O
dry O
cough B-NEG
with O
little O
amount O
of O
phlegm B-NEG

-DOCSTART- O

Bacterial B-NEG
infections I-NEG
of O
the O
ear O

-DOCSTART- O

Hepatoma B-NEG

-DOCSTART- O

Seasonal B-NEG
Allergic I-NEG
Rhinitis I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
benefit O
vital O
Qi O
, O
invigorate O
the O
spleen B-DNP
and O
nourish O
the O
stomach B-DNP
. O

For O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
peptic B-NEG
ulcer I-NEG
and O
chronic B-NEG
gastritis I-NEG
. O

Recently O
, O
also O
used O
for O
the O
cancers B-NEG
of I-NEG
erophagus I-NEG
, I-NEG
stomach I-NEG
and I-NEG
intestines I-NEG
. O

-DOCSTART- O

deficiency B-NEG
of O
the O
heart O
; O
deficiency B-NEG
syndrome O
of O
the O
heart O
including O
deficiency B-NEG
of O
blood O
and O
Eum O
, O
and O
insufficiency O
of O
Gi O
and O
Yang O
of O
the O
heart O

-DOCSTART- O

Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute O
hepatitis B-NEG
with O
jaundice B-NEG
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-POS
and I-POS
HSV-2 I-POS
activities I-POS
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-NEG
and O
HSV-2 B-NEG
infections O
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-NEG
than O
against O
HSV-1 B-NEG
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-NEG
infection O
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-NEG
infection O
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-NEG
infectivity O
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection O
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections O
by O
HSV-1 B-NEG
and O
HSV-2 B-NEG
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-NEG
infectivity O
. O

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
and O
promote O
virility B-DNP
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

Traumatic B-NEG
injury I-NEG
with O
ecchymosis B-NEG
, O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

Pharyngitis B-NEG
, O
excessive O
sputum B-NEG
blocking O
the O
windpipe O
, O
rapid B-NEG
breathing I-NEG
and O
even O
suffocation B-NEG
. O

-DOCSTART- O

Omeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

By O
acting O
specifically O
on O
the O
proton O
pump O
, O
omeprazole O
blocks O
the O
final O
step O
in O
acid O
production O
, O
thus O
reducing O
gastric B-NEU
acidity I-NEU
. O

-DOCSTART- O

disliking O
wind B-NEG
syndrome I-NEG
due O
to O
external O
and O
internal O
injury B-NEG
. O

-DOCSTART- O

polydipsia B-NEG
due O
to O
high O
fever B-NEG

-DOCSTART- O

precipitation O
of O
blood O
during O
pregnancy B-NEU

-DOCSTART- O

Water O
extract O
of O
Samultang O
reduces O
apoptotic O
cell B-NEU
death I-NEU
by O
h(2)o(2)-induced O
oxidative O
injury O
in O
sk-N-mc O
cells O
. O

-DOCSTART- O

Prednisolone O
can O
inhibit O
leukocyte B-NEG
infiltration I-NEG
at O
the O
site O
of O
inflammation B-NEG
, O
interfere O
with O
mediators O
of O
inflammatory B-NEG
response I-NEG
, O
and O
suppress O
humoral B-NEU
immune I-NEU
responses I-NEU
. O

-DOCSTART- O

Gabapentin O
interacts O
with O
cortical B-DNP
neurons I-DNP
at O
auxillary O
subunits O
of O
voltage-sensitive O
calcium O
channels O
and O
increases O
the O
synaptic B-NEU
concentration I-NEU
of I-NEU
GABA I-NEU
, O
enhances O
GABA B-NEU
responses I-NEU
at O
non-synaptic O
sites O
in O
neuronal O
tissues O
, O
and O
reduces O
the O
release O
of O
mono-amine B-DNP
neurotransmitters I-DNP
. O

Duloxetine O
selectively O
prevents O
the O
reuptake B-NEU
of I-NEU
5-HT I-NEU
and I-NEU
NE I-NEU
via O
transporter O
complexes O
on O
the O
pre-synaptic O
membrane O
, O
thereby O
increasing O
the O
level O
of O
these O
neurotransmitters B-DNP
within O
the O
synaptic O
cleft O
. O

-DOCSTART- O

There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular O
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm O
maturation O
and O
binding O
of O
sperm O
to O
the O
oviduct O
epithelium O
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene O
duplication O
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-NEU
pressure I-NEU
regulation I-NEU
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic B-NEU
stem I-NEU
cell I-NEU
differentiation I-NEU
and I-NEU
proliferation I-NEU
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Enalaprilat O
, O
the O
principle O
active O
metabolite O
of O
enalapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic B-NEU
proteolysis I-NEU
of I-NEU
ATI I-NEU
to O
ATII O
. O

Decreasing O
ATII B-NEU
levels I-NEU
in O
the O
body O
decreases O
blood B-NEU
pressure I-NEU
by O
inhibiting O
the O
pressor B-NEU
effects I-NEU
of I-NEU
ATII I-NEU
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Enalapril O
also O
causes O
an O
increase O
in O
plasma B-NEU
renin I-NEU
activity I-NEU
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin O
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

Enalaprilat's O
affinity O
for O
ACE O
is O
approximately O
200,000 O
times O
greater O
than O
that O
of O
ATI O
and O
300-1000 O
times O
greater O
than O
that O
enalapril O
. O

-DOCSTART- O

Amenorrhea B-NEG
, O
concretion B-NEG
and O
conglomeration B-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
abdominal B-NEG
pain I-NEG
, O
asthma B-NEG
( O
raw O
) O
, O
blood B-NEG
ejection I-NEG
, O
hematuria B-NEG
, O
hematochezia B-NEG
, O
prolapse B-NEG
of O
rectum O
( O
scorch-fry O
) O
. O

-DOCSTART- O

Hydroflumethiazide O
is O
a O
thiazide O
diuretic O
that O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
( O
SLC12A3 B-DNP
) O
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
5% O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

Normally O
, O
the O
sodium-chloride B-DNP
symporter I-DNP
transports O
sodium O
and O
chloride O
from O
the O
lumen O
into O
the O
epithelial O
cell O
lining O
the O
distal O
convoluted O
tubule O
. O

The O
energy O
for O
this O
is O
provided O
by O
a O
sodium B-NEU
gradient I-NEU
established O
by O
sodium-potassium O
ATPases O
on O
the O
basolateral O
membrane O
. O

Once O
sodium O
has O
entered O
the O
cell O
, O
it O
is O
transported O
out O
into O
the O
basolateral O
interstitium O
via O
the O
sodium-potassium O
ATPase O
, O
causing O
an O
increase O
in O
the O
osmolarity O
of O
the O
interstitium O
, O
thereby O
establishing O
an O
osmotic B-NEU
gradient I-NEU
for O
water B-NEU
reabsorption I-NEU
. O

By O
blocking O
the O
sodium-chloride B-DNP
symporter I-DNP
, O
Hydroflumethiazide O
effectively O
reduces O
the O
osmotic B-NEU
gradient I-NEU
and O
water B-NEU
reabsorption I-NEU
throughout O
the O
nephron O
. O

-DOCSTART- O

Carotid B-NEG
Artery I-NEG
Stenosis I-NEG

-DOCSTART- O

Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene O
expression O
that O
lead O
to O
cell O
differentiation O
, O
decreased O
cell O
proliferation O
, O
and O
inhibition O
of O
tumorigenesis B-NEG
. O

-DOCSTART- O

Mouth B-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
hemorrhoids B-NEG
, O
scrotal B-NEG
eczema I-NEG
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
a O
pain B-NEG
under O
the O
side O
. O

-DOCSTART- O

difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
the O
network O
vessels B-NEU

-DOCSTART- O

Used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O

Hepatitis B-NEG
B I-NEG

-DOCSTART- O

To O
stop O
bleeding B-NEG
and O
promote O
the O
healing O
of O
wounds B-NEG
. O

-DOCSTART- O

exogenous B-NEG
febrile I-NEG
disease I-NEG
of O
four O
seasons O

-DOCSTART- O

lack O
of O
Gi O
; O

asthenic B-NEG
breathing I-NEG
a O
morbid B-NEG
condition I-NEG
chiefly O
manifested O
as O
disinclination B-NEG
ta1k O
, O
low O
voice O
, O
listlessness B-NEG
and O
asthenia B-NEG
, O
lack B-NEG
of I-NEG
strength I-NEG
in O
speaking O
, O
weak O
pulse B-DNP

-DOCSTART- O

The O
exact O
mechanism O
of O
action O
of O
ingenol O
mebutate O
in O
actinic O
keratosis O
is O
unknown O
. O

It O
is O
presumed O
to O
involve O
primary O
necrosis B-NEG
then O
neutrophil-mediated B-NEG
inflammation I-NEG
and O
antibody-dependent B-NEG
cell I-NEG
death I-NEG
of O
residual O
disease B-NEG
cells I-NEG
. O

Additionally O
in O
early O
studies O
, O
PEP005 O
was O
shown O
to O
be O
an O
effective O
activator O
of O
PKC-delta O
and O
PKC-delta O
translocation O
into O
nucleus O
and O
membranes O
. O

PEP005 O
also O
downregulates O
the O
expression B-DNP
and I-DNP
activity I-DNP
of I-DNP
PKC-alpha I-DNP
. O

PEP005 O
induced O
modulation O
of O
PKCs O
leads O
to O
Ras O
/ O
Raf O
/ O
MAPK O
and O
p38 O
activation O
and O
AKT O
/ O
PKB O
inhibition O
. O

-DOCSTART- O

stabilize O
pain B-NEG

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Medicated O
leaven O
( O
Shenqu O
) O
, O
Arisaema O
tuber O
with O
bile O
( O
Dannanxing O
) O
and O
Cinnabar O
( O
Zhusha O
) O
in O
the O
formula O
Baochi O
San O
. O

-DOCSTART- O

For O
induction O
and O
maintenance O
in O
the O
treatment O
of O
cytomegalovirus B-NEG
( O
CMV B-NEG
) O
retinitis B-NEG
in O
immunocompromised O
patients O
, O
including O
patients O
with O
acquired B-NEG
immunodeficiency I-NEG
syndrome I-NEG
( O
AIDS B-NEG
) O
. O

Also O
used O
in O
the O
treatment O
of O
severe O
cytomegalovirus B-NEG
( O
CMV B-NEG
) O
disease B-NEG
, O
including O
CMV B-NEG
pneumonia I-NEG
, O
CMV B-NEG
gastrointestinal I-NEG
disease I-NEG
, O
and O
disseminated O
CMV B-NEG
infections I-NEG
, O
in O
immunocompromised O
patients O
. O

-DOCSTART- O

Respiratory B-NEG
Distress I-NEG

-DOCSTART- O

white B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

Colorectal B-NEG
Cancer I-NEG

-DOCSTART- O

Its O
chief O
component O
is O
berberine O
. O

-DOCSTART- O

1 O
To O
remove O
blood B-NEG
stasis I-NEG
and O
alleviate O
pain B-NEG
. O
For O
stomachache B-NEG
, O
headache B-NEG
, O
toothache B-NEG
, O
trauma B-NEG
and O
rheumatism B-NEG
. O
2 O
To O
clear O
heat B-NEU
and O
toxic O
material O
. O
For O
sorethroat B-NEG
, O
aphthae B-NEG
, O
carbuncle B-NEG
, O
burn B-NEG
, O
snake B-NEG
bite I-NEG
, O
dysentery B-NEG
and O
diarrhea B-NEG
. O
3 O
To O
relax O
the O
muscles B-POS
. O
As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-NEG
and O
surgical O
operation O
. O

-DOCSTART- O

Behavioral O
and O
psychological B-NEG
symptoms I-NEG
of I-NEG
dementia I-NEG
( O
BPSD B-NEG
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-NEG
disease I-NEG
( O
AD B-NEG
) O
and O
other O
forms O
of O
senile B-NEG
dementia I-NEG
. O

BPSD B-NEG
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-NEG
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-NEG
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-NEG
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-NEG
of I-NEG
the I-NEG
serotonin I-NEG
( I-NEG
5-HT I-NEG
) I-NEG
system I-NEG
such O
as O
5-HT2A B-DNP
receptors I-DNP
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-NEG
of O
AD B-NEG
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A B-DNP
receptors I-DNP
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced O
head-twitch O
response O
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A B-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch O
response O
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced O
head-twitch O
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A B-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-DNP
system I-DNP
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O

Sore B-NEG
Throat I-NEG
Due O
to O
a O
Common O
Cold O

-DOCSTART- O

Treatment O
of O
loss B-NEG
of I-NEG
consciousness I-NEG
in O
stroke B-NEG
and O
epilepsy B-NEG
, O
sore B-NEG
throat I-NEG
, O
dyspnea B-NEG
and O
cough B-NEG
with O
phlegm B-NEG
difficult O
to O
spit O
out O
, O
constipation B-NEG
, O
external O
use O
for O
subcutaneous B-NEG
pyogenic I-NEG
infections I-NEG
. O

-DOCSTART- O

retention B-NEG
or I-NEG
stagnancy I-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

For O
promoting O
diuresis B-NEU
and O
desolving O
inflammation B-NEG
. O

-DOCSTART- O

blood B-NEG
vomiting I-NEG

-DOCSTART- O

burn O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
infectious B-NEG
and O
parasitic B-NEG
disease I-NEG
( O
unspecified O
) O
and O
pediatric O
indications O
. O

-DOCSTART- O

Hyperuricemia B-NEG

-DOCSTART- O

seven O
injuries B-NEG
; O
seven O
kinds O
of O
impairments B-NEG

-DOCSTART- O

To O
expel O
wind B-NEG
and O
heat B-NEU
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels B-NEG
. O

-DOCSTART- O

disperse O
cold B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Digestant O
. O

-DOCSTART- O

vertigo B-NEG
due O
to O
wind-phlegm B-NEG

-DOCSTART- O

metrorrhagia B-NEG
and O
metrostaxis B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG

-DOCSTART- O

Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O

disperse O
wind B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Blockade O
of O
dopaminergic O
D2 O
receptors O
in O
the O
limbic B-DNP
system I-DNP
alleviates O
positive O
symptoms O
of O
schizophrenia B-NEG
such O
as O
hallucinations B-NEG
, O
delusions B-NEG
, O
and O
erratic B-NEG
behavior I-NEG
and O
speech O
. O
Blockade O
of O
serotonergic O
5-HT O
2 O
receptors O
in O
the O
mesocortical B-DNP
tract I-DNP
, O
causes O
an O
excess O
of O
dopamine O
and O
an O
increase O
in O
dopamine O
transmission O
, O
resulting O
in O
an O
increase O
in O
dopamine O
transmission O
and O
an O
elimination O
of O
core O
negative O
symptoms O
. O
Dopamine O
receptors O
in O
the O
nigrostriatal O
pathway O
are O
not O
affected O
by O
risperidone O
and O
extrapyramidal O
effects O
are O
avoided O
. O
Like O
other O
5-HT O
2 O
antagonists O
, O
risperidone O
also O
binds O
at O
alpha(1)-adrenergic O
receptors O
and O
, O
to O
a O
lesser O
extent O
, O
at O
histamine O
H1 O
and O
alpha(2)-adrenergic O
receptors O
. O

-DOCSTART- O

asthma B-NEG

-DOCSTART- O

It O
means O
not O
shiny O
hair O

-DOCSTART- O

epigastric B-NEG
fullness I-NEG
; O
stuffiness B-NEG
in O
the O
gastric O
region O

-DOCSTART- O

HGB-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-NEU
and O
has O
anti-tumor B-POS
activity I-POS
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGB-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody O
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-NEG
human I-NEG
tumors I-NEG
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-NEG
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis O
( O
programmed O
cell O
death O
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O

relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

Dihydroergotamine O
is O
a O
5-HT1D O
receptor O
agonists O
used O
for O
migraine O
, O
activation O
of O
5-HT1D O
receptors O
located O
on O
intracranial O
blood B-DNP
vessels I-DNP
, O
leads O
to O
vasoconstriction B-DNP
; O
activation O
of O
5-HT1D O
receptors O
on O
sensory O
nerve O
endings O
of O
the O
trigeminal O
system O
results O
in O
the O
inhibition O
of O
pro-inflammatory O
neuropeptide O
release O
. O

-DOCSTART- O

For O
bacterial B-NEG
infections I-NEG
of O
eyes O

-DOCSTART- O

For O
the O
treatment O
of O
moderate O
and O
severe O
hypertension B-NEG
, O
either O
alone O
or O
as O
an O
adjunct O
, O
and O
for O
the O
treatment O
of O
renal B-NEG
hypertension I-NEG
. O

-DOCSTART- O

For O
the O
symptomatic B-POS
relief I-POS
of O
pain B-NEG
, O
burning B-NEG
, O
urgency B-NEG
, O
frequency O
, O
and O
other O
discomforts B-NEG
arising O
from O
irritation B-NEG
of O
the O
lower O
urinary O
tract O
mucosa O
caused O
by O
infection B-NEG
, O
trauma B-NEG
, O
surgery O
, O
endoscopic O
procedures O
, O
or O
the O
passage O
of O
sounds O
or O
catheters O
. O

-DOCSTART- O

warm O
the O
lung B-DNP

-DOCSTART- O

To O
eliminate O
blood B-NEG
stasis I-NEG
with O
strong O
effect O
, O
promote O
the O
flow O
of O
qi O
, O
remove O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Postreperfusion B-NEG
Syndrome I-NEG

-DOCSTART- O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine O
monophosphate O
dehydrogenase O
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Sofosbuvir O
is O
a O
nucleotide O
analogue O
inhibitor O
of O
the O
hepatitis O
C O
virus O
polymerase O
which O
is O
a O
RNA-dependent O
RNA O
polymerase O
critical O
for O
the O
viral O
cycle O
. O

Alfa O
interferons O
bind O
to O
specific O
cell-surface O
receptors O
, O
resulting O
in O
the O
transcription O
and O
translation O
of O
genes O
whose O
protein O
products O
mediate O
antiviral O
, O
antiproliferative O
, O
anticancer O
, O
and O
immune-modulating O
effects O
. O

-DOCSTART- O

abdominal B-NEG
mass I-NEG

-DOCSTART- O

general O
edema B-NEG
with O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

Cancer B-NEG

-DOCSTART- O

vomiting B-NEG
due O
to O
heat B-NEU
in I-NEU
the I-NEU
stomach I-NEU

-DOCSTART- O

1 O
Inhibiting O
sarcoma180 O
and O
cervix O
carcinoma14 O
in O
mice O
and O
L16 O
cells O
isolated O
from O
human O
liver B-NEG
cancer I-NEG
. O
2 O
. O
Promoting O
the O
adrenocortical B-DNP
function I-DNP
in O
mice O
. O
3 O
. O
Promoting O
metabolism B-NEU
and O
reticuloendothelial B-DNP
function I-DNP
. O

-DOCSTART- O

1 O
Analgeic B-NEG
. O
2 O
Sedative B-NEG
. O
3 O
Antispasmodic B-NEG

-DOCSTART- O

This O
is O
a O
syndrome B-NEG
with I-NEG
bloat I-NEG
and I-NEG
fullness I-NEG
in O
abdominal O
region O
. O

-DOCSTART- O

Solid O
Tumors B-NEG

-DOCSTART- O

In O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
Asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
LIDAR O
system O
, O
at O
the O
Gosan O
super O
site O
( O
33 O
degrees O
17'N O
, O
126 O
degrees O
10'E O
) O
in O
Jeju O
Island O
, O
Korea O
, O
during O
the O
ACI-Asia O
intensive O
observation O
period O
, O
11 O
42798 O
May O
2001 O
. O

An O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
Hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
Chinese O
desert O
regions O
during O
the O
period O
of O
Asian O
dust O
storm O
events O
. O

Vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
Asian O
dust O
storm O
event O
days O
, O
22 O
March O
and O
13 O
and O
26 O
April O
2001 O
, O
have O
been O
analyzed O
. O

The O
LIDAR-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O

Quality O
of O
life O

-DOCSTART- O

TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin B-DNP
, O
a O
potent O
mediator O
of O
blood B-NEU
vessel I-NEU
constriction I-NEU
and O
growth O
of O
smooth O
muscle O
in O
vascular B-DNP
walls I-DNP
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-NEG
arterial I-NEG
hypertension I-NEG
. O
TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O

dispel O
wind B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Blood B-NEU
pressure I-NEU
, O
Lipid O
profile O
, O
Overall O
CVD B-NEG
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Others O
, O
Hemostatic B-DNP
function I-DNP
, O
Protective O
immunity B-NEU

-DOCSTART- O

Treatment O
of O
attack O
of O
damp-heat B-NEG
manifested O
by O
stuffiness B-NEG
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
, O
or O
causing O
acute B-NEG
dysentery I-NEG
of O
jaundice B-NEG
, O
high O
fever B-NEG
accompained O
by O
impairment B-NEG
of O
conciousness B-DNP
, O
fidgetness O
and O
insomnia B-NEG
due O
to O
exuberant O
fire O
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in O
the O
blood O
, O
inflammation B-NEG
of O
the O
eye O
, O
acid B-NEG
regurgitation I-NEG
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation O
, O
purulent B-POS
discharge I-POS
from O
the O
ear O
. O
Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O
Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness O
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEG
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

Purging B-POS
by O
aggression O

-DOCSTART- O

This O
is O
running O
a O
fever B-NEG
due O
to O
epidemic B-NEG
. O

-DOCSTART- O

Prednisone O
enters O
the O
nucleus O
where O
it O
binds O
to O
and O
activates O
specific O
nuclear O
receptors O
, O
resulting O
in O
an O
altered O
gene B-DNP
expression I-DNP
and O
inhibition O
of O
proinflammatory B-NEU
cytokine I-NEU
production I-NEU
. O

-DOCSTART- O

reinforce O
the O
kidney B-DNP

-DOCSTART- O

somnolence B-NEG

-DOCSTART- O

blood B-NEG
wind I-NEG
of O
female O

-DOCSTART- O

Different O
poisoning B-NEG
, O

-DOCSTART- O

pain B-NEG
in O
ear O

-DOCSTART- O

Septic B-NEG
Shock I-NEG

-DOCSTART- O

frost B-NEG
bite I-NEG
; O
chilblain B-NEG
; O
frostbite B-NEG

-DOCSTART- O

disperse O
accumulation B-NEU
and O
kill O
worm B-NEG

-DOCSTART- O

Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme O
acetylcholinesterase O
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-NEG
disease I-NEG
. O

-DOCSTART- O

venomous O
snake-bite B-NEG

-DOCSTART- O

( O
1 O
) O
cold-type O
hernia B-NEG
; O
periumbilical O
colic B-NEG
due O
to O
invasion O
of O
cold B-NEG
( O
2 O
) O
testalgia B-NEG
due O
to O
pathogenic O
cold B-NEG

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O

emission B-NEU
; O

spermatorrhea B-NEG
; O

seminal B-NEU
emission I-NEU

-DOCSTART- O

convulsion B-NEG
; O

epilepsy B-NEG

-DOCSTART- O

Rivanicline O
is O
a O
( O
E)-metanicotine O
hemigalactarate O
. O
It O
effectively O
inhibits O
TNF- O
and O
LPB-induced O
IL-8 B-DNP
production O
in O
different O
cell O
types O
. O

-DOCSTART- O

reinforce O
the O
spleen B-DNP

-DOCSTART- O

affection B-NEG
due O
to O
wind-heat B-NEG
; O
common O
cold B-NEG
of O
the O
wind-heat B-NEG
type O
; O
flu B-NEG
caused O
by O
wind B-NEG
and O
heat B-NEU

-DOCSTART- O

Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-NEG
, O
insomnia B-NEG
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-NEG
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor B-DNP
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor B-DNP
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors B-DNP
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor B-DNP
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor B-DNP
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O

To O
astringe O
intestines B-DNP
and O
check O
diarrhea B-NEG
, O
resolve O
toxin B-NEG
, O
relieve O
itch B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
bacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

Counteracting O
the O
arrhythmias B-NEG
induced O
pituitrin O
in O
rabbits. O
. O

-DOCSTART- O

Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-NEG
coli I-NEG
. O

-DOCSTART- O

Carcinoma B-NEG
of I-NEG
mammary I-NEG
glands I-NEG
, O
nasopharyngeal B-NEG
carcinoma I-NEG
, O
carcinoma B-NEG
of I-NEG
salivary I-NEG
gland I-NEG
, O
scrofula B-NEG
, O
swelling B-NEG
of I-NEG
skin I-NEG
, O
pain B-NEG
wind I-NEG
. O

-DOCSTART- O

Penbutolol O
is O
indicated O
in O
the O
treatment O
of O
mild O
to O
moderate O
arterial B-NEG
hypertension I-NEG
. O

It O
may O
be O
used O
alone O
or O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
especially O
thiazide-type O
diuretics O
. O

Penbutolol O
is O
contraindicated O
in O
patients O
with O
cardiogenic B-NEG
shock I-NEG
, O
sinus B-NEG
bradycardia I-NEG
, O
second B-NEG
and I-NEG
third I-NEG
degree I-NEG
atrioventricular I-NEG
conduction I-NEG
block I-NEG
, O
bronchial B-NEG
asthma I-NEG
, O
and O
those O
with O
known O
hypersensitivity B-NEG
. O

-DOCSTART- O

critical B-NEG
symptom I-NEG
complex I-NEG
with O
complicated O
, O
changable O
and O
serious O
conditions O
; O

disease B-NEG
due O
to O
the O
poisonous B-NEG

-DOCSTART- O

Tetracycline O
passively O
diffuses O
through O
porin B-DNP
channels I-DNP
in O
the O
bacterial O
membrane O
and O
reversibly O
binds O
to O
the O
30S O
ribosomal O
subunit O
, O
preventing O
binding O
of O
tRNA O
to O
the O
mRNA-ribosome O
complex O
, O
and O
thus O
interfering O
with O
protein B-NEU
synthesis I-NEU
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-NEG
nucleic I-NEG
acid I-NEG
synthesis I-NEG
and O
resulting O
in O
bacterial B-NEU
cell I-NEU
death I-NEU
. O

Esomeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

-DOCSTART- O

To O
resolve O
exterior O
, O
eliminate O
damp B-NEU
, O
relieve O
cough B-NEG
and O
calm O
asthma B-NEG
. O

-DOCSTART- O

Treatment O
of O
stroke B-NEG
with O
gurgling O
in O
the O
throat O
, O
deviation O
of O
the O
eye B-DNP
and O
the O
mouth B-DNP
, O
and O
impairment B-NEG
of O
speech O
, O
upward O
invasion O
of O
phlegm B-NEG
causing O
headache B-NEG
accompanied O
with O
dizziness B-NEG
, O
heaviness B-NEG
of O
the O
body O
, O
restlessness B-NEG
, O
fidgetness B-NEG
, O
nausea B-NEG
and O
cold B-NEG
extremities O
, O
or O
migraine B-NEG
, O
sore B-NEG
throat I-NEG
, O
tetanus B-NEG
, O
external O
use O
for O
scrofula B-NEG
, O
venomous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
C I-NEG
, O
Chronic O

-DOCSTART- O

Treatment O
of O
amenorrhea B-NEG
with O
mass B-NEG
in I-NEG
the I-NEG
abdomen I-NEG
, O
swelling B-NEG
of I-NEG
breast I-NEG
after O
childbirth O
, O
rubella B-NEG
red O
in O
colour O
, O
itching B-NEG
, O
acne B-NEG
. O

-DOCSTART- O

hematuria B-NEG
with O
pain B-NEG
; O
stranguria B-NEG
with O
hematuria B-NEG
; O
painful O
urination B-NEG
with I-NEG
blood I-NEG

-DOCSTART- O

abdominal B-NEG
mass I-NEG
; O
accumulation O

-DOCSTART- O

epiphora B-NEG
; O
lacrimation B-NEG

-DOCSTART- O

having O
painful O
and O
benumbed O
joint B-DNP

-DOCSTART- O

To O
relax O
the O
bowels B-DNP
( O
sthenia-syndrome B-NEG
with O
constipation B-NEG
due O
to O
accumulation O
of O
cold B-NEG
, O
dysentery B-NEG
of I-NEG
cold I-NEG
type O
) O
. O

-DOCSTART- O

Statin O
Therapy O

-DOCSTART- O

Hyperkalemia B-NEG

-DOCSTART- O

weakness B-NEG
of I-NEG
the I-NEG
waist I-NEG

-DOCSTART- O

To O
strengthen O
spleen B-DNP
and O
benefit O
dampness B-NEU
; O

To O
kill O
worms B-NEG
and O
stop O
diarrhea B-NEG

-DOCSTART- O

illness B-NEG
that O
occurs O
on O
teeth O

-DOCSTART- O

dryness B-NEU
of O
mouth O

-DOCSTART- O

Other O
Nutritional B-NEG
Deficiencies I-NEG

-DOCSTART- O

Ascites O
. O
Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Apricot O
seed O
( O
Xingren O
) O
. O

-DOCSTART- O

a O
symptom O
of O
fingers O
being O
cold B-NEG
although O
the O
temperature O
is O
not O

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
externally O
. O

-DOCSTART- O

Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-NEU
activities I-NEU
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-NEU
activity I-NEU
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-NEU
activity I-NEU
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity B-NEG
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-NEU
activity I-NEU
by O
Shosaikoto O
. O

-DOCSTART- O

Therapeutic O
effect O
of O
Kakkonto O
in O
a O
mouse O
model O
of O
food O
allergy B-NEG
with O
gastrointestinal O
symptoms O
. O

-DOCSTART- O

Schizophrenia B-NEG
Prodrome I-NEG

-DOCSTART- O

hemiplegia B-NEG
; O

paralysis B-NEG

-DOCSTART- O

accumulation O
of O
pathogenic B-NEG
factors I-NEG
in I-NEG
the I-NEG
chest I-NEG
; O
accumulation O
of O
pathogens B-NEG
in I-NEG
the I-NEG
chest I-NEG
; O
knotted B-NEG
chest I-NEG
a O
syndrome O
due O
to O
accumulation O
of O
pathogenic B-NEG
heat I-NEG
or I-NEG
cold I-NEG
with O
stagnancy B-NEG
of I-NEG
fluid I-NEG
or O
phlegm B-NEG
or O
blood B-DNP
in O
the O
chest O
. O

-DOCSTART- O

To O
activate O
blood B-NEU
circulation I-NEU
, O
eliminate O
stasis B-NEG
, O
promote O
the O
subsidence B-POS
of I-POS
swelling I-POS
and O
alleviate O
pain B-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
a O
pain B-NEG
, O
bloat B-NEU
, O
and O
fullness B-NEU
in O
abdominal O
region O
. O

-DOCSTART- O

tonify O
the O
kidney B-DNP

-DOCSTART- O

hoarseness B-NEG
due O
to O
singing O

-DOCSTART- O

To O
kill O
worms O
. O

-DOCSTART- O

Pralnacasan O
inhibits O
interleukin-1beta B-DNP
converting I-DNP
enzyme I-DNP
( O
ICE O
) O
, O
an O
enzyme O
that O
regulates O
the O
production O
of O
IL-1 B-DNP
and O
IFN B-DNP
gamma I-DNP
- O
intercellular O
mediators O
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation O
. O
Inhibiting O
ICE O
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
and O
osteoarthritis B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
kill O
worms O
and O
relieve O
itch O
, O
resolve B-NEG
toxin I-NEG
and O
close O
sores B-NEG
. O

-DOCSTART- O

This O
means O
urolithiasis B-NEG
made O
of O
coagulation B-NEG
of I-NEG
phlegm I-NEG
. O

-DOCSTART- O

A O
symptom O
that O
Gi O
gets O
together O
and O
blood B-DNP
does O
not O
circulate O
well O
. O

An O
affected O
part O
has O
abdominal B-NEG
distension I-NEG
or O
a O
sore B-NEG
. O

If O
it O
keeps O
long O
, O
it O
becomes O
blood B-NEG
stagnation I-NEG
, O
and O
causes O
a O
hard B-NEG
swelling I-NEG
and O
a O
serious O
pain B-NEG
on O
the O
part O
. O

-DOCSTART- O

To O
replenish O
yin O
of O
the O
lung B-DNP
and O
stomach B-DNP
, O
remove O
heat B-NEU
from I-NEU
the I-NEU
lung I-NEU
, O
and O
promote O
fluid B-NEU
secretion I-NEU
. O

-DOCSTART- O

Familial B-NEG
Adenomatous I-NEG
Polyposis I-NEG

-DOCSTART- O

( O
1 O
) O
/ O
/ O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Treatment O
of O
scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
lower O
abdominal B-NEG
pain I-NEG
and O
cold B-NEG
sensation I-NEG
, O
distending B-NEG
pain I-NEG
in I-NEG
the I-NEG
epigastrium I-NEG
with O
anorexia B-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
, O
hydrocele B-NEG
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
abdominal B-NEG
pain I-NEG
caused O
by O
cold B-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
that O
children O
wet O
their O
pants O
regardless O
of O
time O
. O

-DOCSTART- O

Protective B-NEU
immunity I-NEU
, O
Others O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
health I-DNP
and O
immunity B-NEU
, O
Metabolism B-NEU

-DOCSTART- O

Binding O
of O
dalbavancin O
to O
the O
D-Ala-D-Ala O
prevents O
the O
incorporation O
of O
the O
NAM/NAG-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O

promote O
sweating B-NEU

-DOCSTART- O

Stagnation O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
marked O
by O
distending O
pain B-NEG
in O
the O
epigastrium O
, O
feeling O
of O
stuffiness B-NEG
and O
fullness B-NEU
in O
the O
chest O
, O
anorexia B-NEG
, O
belching B-NEG
and O
acid B-NEG
regurgitation I-NEG
. O

-DOCSTART- O

sudden O
turmoil B-NEG
; O

cholera B-NEG
disease I-NEG
; O

acute B-NEG
gastroenteritis I-NEG
; O

acute B-NEG
vomiting I-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases B-NEG
including O
cholera B-NEG
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

To O
relieve O
exterior B-NEG
syndrome I-NEG
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Blood B-NEU
pressure I-NEU

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
soothe O
sinews B-DNP
and O
quicken O
network B-DNP
vessels I-DNP
. O

-DOCSTART- O

To O
cause O
catharsis O
and O
purge O
away O
heat B-NEU
, O
to O
reduce O
heat B-NEU
in O
blood B-DNP
and O
counteract O
toxicity B-NEG
, O
and O
to O
eliminate O
blood B-DNP
stasis I-DNP
and O
stimulate O
menstrual B-DNP
discharge I-DNP
. O

-DOCSTART- O

Its O
alcoholic O
extract O
inhibits O
the O
heart B-DNP
and O
lowers O
blood B-NEU
pressure I-NEU
in O
anesthetized O
cats O
. O

-DOCSTART- O

1 O
Its O
purgative O
effect O
is O
as O
three O
times O
as O
castor O
oil O
. O
2 O
. O
Its O
fresh O
preparation O
may O
inhibit O
the O
progress O
of O
acute B-NEG
lymphatic I-NEG
leukemia I-NEG
, O
acute B-NEG
and I-NEG
chronic I-NEG
granulocytic I-NEG
leukemia I-NEG
and O
acute B-NEG
monocytic I-NEG
leukemia I-NEG
. O

-DOCSTART- O

alleviate O
edema B-NEG
and O
relieve O
toxicity B-NEG

-DOCSTART- O

hoarseness B-NEG

-DOCSTART- O

Svere O
nodular B-NEG
acne I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
heat B-NEU
; O
heat-type O
stranguria B-NEG

-DOCSTART- O

For O
activating O
blood B-DNP
and O
modulating O
period O

-DOCSTART- O

Hemodialysis B-NEG

-DOCSTART- O

Obesity B-NEG
and O
Obesity-related O
Medical O
Conditions O

-DOCSTART- O

irritability B-NEG
and O
restlessness B-NEG
; O

dysphoria B-NEG

-DOCSTART- O

Follicular B-NEG
Lymphoma I-NEG

-DOCSTART- O

constipation B-NEG

-DOCSTART- O

To O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O

Loratadine O
is O
a O
second-generation O
H1 O
histamine B-DNP
antagonist O
drug O
and O
appears O
to O
suppress O
the O
release O
of O
histamine B-DNP
and O
leukotrienes O
from O
mast O
cells O
, O
and O
the O
release O
of O
leukotrienes O
from O
human O
lung B-DNP
fragments O
. O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver O
. O

-DOCSTART- O

Wind-cold B-NEG
common B-NEG
cold I-NEG
, O
headache O
, O
cough B-NEG
and O
asthma B-NEG
, O
deep-source O
nasal B-NEG
congestion I-NEG
, O
cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
wind-cold-damp B-NEG
impediment I-NEG
, O
cold-damp B-NEG
vaginal B-NEG
discharge I-NEG
, O
dysmenorrhea B-NEG
, O
toxin B-NEG
swelling I-NEG
of O
sores B-NEG
, O
wind B-NEG
papule I-NEG
itching I-NEG
. O

-DOCSTART- O

tonify O
the O
bladder B-DNP

-DOCSTART- O

inflammation B-NEG
of O
the O
throat O
; O
sore B-NEG
throat I-NEG
; O
hoarse B-NEG
voice I-NEG
; O
aphonia B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
ooze O
from O
a O
sore B-NEG
. O

-DOCSTART- O

OBJECTIVE O
: O
The O
purpose O
of O
this O
clinical O
trial O
was O
to O
assess O
the O
efficacy O
of O
Goshuyuto O
, O
a O
typical O
Kampo O
formula O
, O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
Because O
the O
treatment O
target O
of O
a O
Kampo O
formula O
is O
decided O
on O
a O
basis O
different O
to O
that O
of O
Western O
medicine O
, O
we O
first O
selected O
patients O
belonging O
to O
a O
subgroup O
that O
responded O
to O
goshuyuto O
before O
conducting O
the O
usual O
randomized O
controlled O
trial O
. O

During O
stage O
1, O
the O
subjects O
were O
instructed O
to O
orally O
consume O
goshuyuto O
for O
4 O
weeks O
. O

Only O
those O
subjects O
judged O
as O
responders O
advanced O
to O
stage O
2, O
during O
which O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
conducted O
. O

The O
subjects O
consumed O
the O
same O
dose O
of O
goshuyuto O
or O
placebo O
for O
12 O
weeks O
. O

RESULTS O
: O
Of O
the O
91 O
subjects O
enrolled O
in O
stage O
1, O
60 O
were O
judged O
as O
responders O
. O

Of O
these O
, O
53 O
advanced O
to O
stage O
2; O
28 O
were O
assigned O
to O
the O
goshuyuto O
group O
and O
25 O
to O
the O
placebo O
group O
. O

The O
decrease O
in O
the O
number O
of O
days O
on O
which O
headache B-NEG
episodes O
occurred O
was O
greater O
in O
the O
goshuyuto O
group O
than O
in O
the O
placebo O
group O
( O
2.6 O
+/- O
3.7 O
vs O
. O
0.3 O
+/- O
4 O
days O
, O
p O
= O
0.034 O
) O
; O
no O
difference O
was O
observed O
with O
regard O
to O
the O
reduction O
in O
the O
frequency O
of O
consuming O
reliever O
medications O
( O
2.2 O
+/- O
4 O
vs O
. O
1.4 O
+/- O
8.2 O
, O
p O
= O
0.672 O
) O
. O

Improvement O
in O
the O
associated O
symptoms O
was O
observed O
in O
more O
than O
0.5 O
of O
the O
subjects O
in O
the O
goshuyuto O
group O
. O

CONCLUSION O
: O
Goshuyuto O
is O
useful O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

Responder-limited O
design O
is O
a O
candidate O
for O
evaluating O
Kampo O
medicine O
. O

-DOCSTART- O

cough B-NEG
due O
to O
pulmonary B-NEG
flaccidity I-NEG

-DOCSTART- O

Paclitaxel O
interferes O
with O
the O
normal O
function B-NEU
of I-NEU
microtubule I-NEU
growth I-NEU
. O

Whereas O
drugs O
like O
colchicine O
cause O
the O
depolymerization B-NEU
of I-NEU
microtubules I-NEU
in O
vivo O
, O
paclitaxel O
arrests O
their O
function O
by O
having O
the O
opposite O
effect O
; O

it O
hyper-stabilizes O
their O
structure O
. O

This O
destroys O
the O
cell's O
ability O
to O
use O
its O
cytoskeleton O
in O
a O
flexible O
manner O
. O

Specifically O
, O
paclitaxel O
binds O
to O
the O
; O

subunit O
of O
tubulin O
. O

Tubulin O
is O
the O
building O
block O
of O
mictotubules O
, O
and O
the O
binding O
of O
paclitaxel O
locks O
these O
building O
blocks O
in O
place O
. O

The O
resulting O
microtubule O
/ O
paclitaxel O
complex O
does O
not O
have O
the O
ability O
to O
disassemble O
. O

This O
adversely O
affects O
cell O
function O
because O
the O
shortening O
and O
lengthening O
of O
microtubules O
( O
termed O
dynamic O
instability O
) O
is O
necessary O
for O
their O
function O
as O
a O
transportation O
highway O
for O
the O
cell O
. O

Chromosomes O
, O
for O
example O
, O
rely O
upon O
this O
property O
of O
microtubules O
during O
mitosis O
. O

Further O
research O
has O
indicated O
that O
paclitaxel O
induces O
programmed O
cell B-POS
death I-POS
( I-POS
apoptosis I-POS
) I-POS
in I-POS
cancer I-POS
cells I-POS
by O
binding O
to O
an O
apoptosis B-NEU
stopping O
protein O
called O
Bcl-2 O
( O
B-cell O
leukemia O
2 O
) O
and O
thus O
arresting O
its O
function O
. O

-DOCSTART- O

Quality O
of O
life O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
, O
Protective B-NEU
immunity I-NEU
, O
Inflammation B-NEG

-DOCSTART- O

The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic O
bile O
acids O
in O
the O
gastrointestinal O
tract O
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O

Advanced B-NEG
Breast I-NEG
Cancer I-NEG

-DOCSTART- O

Pregnancy B-NEG
in I-NEG
Diabetics I-NEG

-DOCSTART- O

miasma B-NEG
1 O
pestilential B-NEG
pathogene B-NEG
2 O
malaria O

-DOCSTART- O

To O
dispel O
wind-heat B-NEG
, O
to O
promote O
eruption B-NEG
, O
and O
to O
cause O
diuresis B-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Digestion O
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Body B-NEU
fat I-NEU
deposition I-NEU
( O
total O
amount O

-DOCSTART- O

To O
cool O
blood B-DNP
and O
stanch B-POS
bleeding I-POS
, O
quicken O
blood B-DNP
and O
transform O
stasis O
. O

-DOCSTART- O

affection O
by O
summer O
heat O
; O
exposure O
to O
summer O
heat O

-DOCSTART- O

A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-NEG
pain I-NEG
and O
general O
fatigue B-NEG
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-NEG
pain I-NEG
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain O
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-NEG
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced O
pneumonitis B-NEG
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic O
pneumonitis B-NEG
. O

-DOCSTART- O

Cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
vomiting B-NEG
nausea B-NEG
, O
diarrhea B-NEG
, O
cold B-NEG
mounting O
, O
dysmenorrhea B-NEG
, O
urethral B-NEG
stone I-NEG
, O
swelling B-NEG
pain I-NEG
of O
sore O
and O
boil O
. O

-DOCSTART- O

Simvastatin O
competitively O
inhibits O
HMG-CoA O
reductase O
, O
lowers O
plasma B-NEU
cholesterol I-NEU
and O
lipoprotein B-NEU
levels I-NEU
, O
and O
modulates O
immune B-NEU
responses I-NEU
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting B-DNP
cells I-DNP
such O
as O
human B-DNP
vascular I-DNP
endothelial I-DNP
cells I-DNP
. O
Sitagliptin O
is O
a O
highly O
selective O
DPP-4 O
inhibitor O
, O
and O
increases O
insulin B-NEU
release I-NEU
and O
decreases O
glucagon B-NEU
levels I-NEU
in O
the O
circulation O
in O
a O
glucose-dependent O
manner O
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
remove O
toxic B-NEG
materials I-NEG
; O
To O
tonify O
kidney B-DNP
and O
revitalize O
blood B-DNP

-DOCSTART- O

( O
1 O
) O
pain B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O
( O
2 O
) O
upper B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD B-NEG
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
General O
skin B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

1 O
Application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-NEG
, O
chilliness B-NEG
, O
fever B-NEG
, O
bitter B-NEG
mouth I-NEG
, O
constipation B-NEG
, O
oliguria B-NEG
, O
red B-NEG
tongue I-NEG
with O
white O
fur O
and O
rapid B-NEU
pulse I-NEU
. O
2 O
Also O
indicated O
for O
cases O
of O
urticaria B-NEG
and O
e O

-DOCSTART- O

arrest O
cough B-NEG
and O
relieve O
asthms B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
after O
phlegm B-NEG
due O
to O
Wind O
sidesae O
blocked O
Gi O
. O

-DOCSTART- O

Protective B-NEU
immunity I-NEU
, O
Urinary B-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

Postpartum O
bleeding B-NEG
, O
migraine B-NEG
. O

-DOCSTART- O

Proellex O
selectively O
blocks B-DNP
the I-DNP
progesterone I-DNP
receptor I-DNP
thus O
avoiding O
the O
adverse O
effects O
of O
GnRH O
agonists O
associated O
with O
the O
induction O
of O
a O
low O
estrogen B-DNP
, O
menopausal-like B-DNP
state O
in O
women O
. O

-DOCSTART- O

lingual B-NEG
pustule I-NEG
; O
boil B-NEG
of O
the O
tongue O

-DOCSTART- O

Sirolimus O
inhibits O
T O
lymphocyte O
activation O
and O
proliferation O
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine O
( O
Interleukin O
IL-2 O
, O
IL-4 O
, O
and O
IL-15 O
) O
stimulation O
by O
a O
mechanism O
that O
is O
distinct O
from O
that O
of O
other O
immunosuppressants O
. O

-DOCSTART- O

BACKGROUND O
: O
The O
diagnosis O
of O
encephalitis B-NEG
is O
usually O
presumptive O
based O
on O
MRI O
, O
cerebrospinal O
fluid O
analysis O
, O
or O
both O
. O

A O
definitive O
diagnosis O
based O
on O
histopathology O
, O
however O
, O
is O
required O
for O
optimizing O
treatment O
strategies O
. O

OBJECTIVE O
: O
To O
investigate O
the O
diagnostic O
yield O
and O
adverse O
effects O
of O
minimally O
invasive O
brain O
biopsies O
in O
dogs O
with O
encephalitis B-NEG
. O

ANIMALS O
: O
Seventeen O
dogs O
with O
suspected O
encephalitis B-NEG
, O
based O
on O
MR O
imaging O
and O
cerebrospinal O
fluid O
analysis O
. O

METHODS O
: O
Retrospective O
study O
. O

Minimally O
invasive O
, O
free-hand O
brain O
biopsy O
specimens O
were O
taken O
from O
forebrain O
lesions O
through O
a O
4-mm O
burr O
hole O
using O
a O
Sedan O
side-cutting O
needle O
. O

Routine O
histopathological O
examination O
was O
performed O
. O

The O
adverse O
effects O
were O
assessed O
by O
MRI O
evaluations O
after O
biopsy O
procedure O
( O
1217 O
) O
and O
by O
sequential O
neurological O
examinations O
. O

RESULTS O
: O
The O
overall O
diagnostic O
yield O
with O
regard O
to O
a O
specific O
type O
of O
encephalitis B-NEG
was O
0.82 O
. O

Encephalitis B-NEG
was O
evident O
in O
an O
additional O
0.12 O
, O
but O
a O
specific O
disease B-NEG
could O
not O
be O
determined O
. O

There O
were O
no O
deaths O
caused O
by O
the O
biopsy O
procedure O
itself O
, O
but O
the O
indirect O
case O
fatality O
rate O
was O
0.06 O
. O

Morbidity O
was O
0.29 O
, O
including O
stupor B-NEG
, O
seizures B-NEG
, O
tetraparesis B-NEG
, O
hemiparesis B-NEG
, O
ataxia B-NEG
, O
and O
loss O
of O
conscious O
proprioception O
. O

All O
these O
signs O
resolved O
within O
0314 O
days O
. O

CONCLUSIONS O
AND O
CLINICAL O
IMPORTANCE O
: O
Minimally O
invasive O
brain O
biopsy O
in O
dogs O
with O
suspected O
encephalitis O
leads O
to O
a O
definite O
diagnosis O
in O
the O
majority O
of O
dogs O
, O
allowing O
for O
a O
specific O
treatment O
. O

The O
advantages O
of O
a O
definite O
diagnosis O
outweigh O
potential O
case O
fatality O
rate O
and O
temporary O
neurological B-NEG
deficits I-NEG
. O

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
distension B-NEG
of I-NEG
abdomen I-NEG
with O
a O
gas O
or O
fluid O

-DOCSTART- O

malignant O
furuncle B-NEG
due O
to O
scrofula B-NEG
. O

-DOCSTART- O

relieve O
fever B-NEG

-DOCSTART- O

injury B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins O
enhance O
glucose-dependent B-NEU
insulin I-NEU
secretion I-NEU
and O
exhibit O
other O
antihyperglycemic O
actions O
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 O
system O
increases O
insulin B-NEU
secretion I-NEU
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-NEG
insulin I-NEG
levels I-NEG
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-NEU
glucagon I-NEU
levels I-NEU
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-NEU
release I-NEU
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-NEU
of I-NEU
gastric I-NEU
emptying O
and O
decreases O
food B-NEU
intake I-NEU
, O
mitigating O
the O
potential O
severity O
of O
hyperglycemic O
events O
after O
meals O
. O

-DOCSTART- O

swelling B-NEG
of O
the O
foot O
; O
edema B-NEG
of O
foot O

-DOCSTART- O

Boils O
and O
carbuncles O
. O

-DOCSTART- O

incised B-NEG
wound I-NEG

-DOCSTART- O

Hypogonadotropic B-NEG
Hypogonadism I-NEG

-DOCSTART- O

boil B-NEG
in I-NEG
the I-NEG
throat I-NEG

-DOCSTART- O

Treatment O
of O
: O
1 O
Deficient O
yin O
of O
the O
lungs B-DNP
with O
heat B-NEU
manifested O
as O
dry B-NEG
cough I-NEG
or O
cough B-NEG
with O
scanty O
sputum B-NEG
, O
hoarse B-NEG
voice I-NEG
from O
a O
chronic B-NEG
cough I-NEG
, O
dry B-NEU
throat I-NEU
and O
thirst B-NEU
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
and O
Tendrilled O
fritillary O
bulb O
( O
Chuanbeimu O
) O
. O

2 O
Body O
fluids O
consumed O
by O
febrile B-NEG
diseases I-NEG
manifested O
as O
dry B-NEG
tongue I-NEG
and O
poor B-NEG
appetite I-NEG
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
, O
Fresh O
rehmannia O
root O
( O
Shengdihuang O
) O
and O
Fragrant O
solomonseal O
rhizome O
( O
Yuzhu O
) O
in O
the O
formula O
Yiwei O
Tang O
. O

-DOCSTART- O

dry O
phlegm B-DNP
; O
dry-phlegm B-NEG
( O
syndrome O
) O

-DOCSTART- O

infantile B-NEG
malnutrition I-NEG
an O
infantile B-NEG
disease I-NEG
due O
to O
digestive B-NEG
disturbance I-NEG
or O
intestinal B-NEG
parasites I-NEG
with O
symptoms O
of O
wasting O
, O
pallor B-NEG
or O
sallowness B-NEG
, O
potbelly B-NEG
, O
and O
chronic B-NEG
diarrhea I-NEG
. O

-DOCSTART- O

promote O
liquid O

-DOCSTART- O

hemoptysis B-NEG
; O
coughing O
up O
blood B-NEU

-DOCSTART- O

To O
eliminate O
toxic B-NEG
material I-NEG
, O
promote O
pus B-POS
drainage I-POS
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Eyebrow B-NEG
Hypotrichosis I-NEG

-DOCSTART- O

distribution O
) O
, O
absorption B-NEU
, O
Endurance B-NEU
, O
Body B-NEU
weight I-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU
, O
motility B-NEU
, O
Others O

-DOCSTART- O

spontaneous B-NEG
sweating(perspiration I-NEG
) O
frequent B-NEG
sweating I-NEG
due O
to O
lowered O
superficial O
resistance O
brought O
on O
by O
deficiency B-NEG
of O
Gi O
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
free O
network B-DNP
vessels I-DNP
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
, O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

secure O
the O
essence O

-DOCSTART- O

G4544 O
reduces O
bone B-NEG
loss I-NEG
by O
inhibiting O
calcium B-NEU
resorption I-NEU
from I-NEU
bone I-NEU
. O

Preclinical O
evidence O
suggests O
that O
the O
mechanism O
of O
G4544 O
action O
is O
multifactorial O
and O
different O
from O
other O
current O
therapies O
used O
to O
treat O
bone B-NEG
loss I-NEG
, O
such O
as O
estrogen B-DNP
or O
selective O
estrogen O
receptor O
modulators O
( O
SERMs O
) O
, O
calcitonin O
, O
or O
bisphosphonates O
( O
e.g O
. O
, O
Zometa O
or O
Fosamax O
) O
. O

G4544 O
preferentially O
accumulates O
in O
metabolically O
active O
regions O
of O
bone O
, O
inhibits O
osteoclast-mediated B-NEU
bone I-NEU
resorption I-NEU
, O
and O
favorably O
alters O
bone O
mineral O
composition O
and O
properties O
. O

-DOCSTART- O

menorrhagia B-NEG
; O
abnormally O
profuse B-NEG
menstruation I-NEG

-DOCSTART- O

Indacaterol O
works O
by O
stimulating O
adrenergic B-DNP
beta-2 I-DNP
receptors I-DNP
in O
the O
smooth O
muscle O
of O
the O
airways O
. O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O
emission O
; O
spermatorrhea B-NEG
; O
seminal B-NEU
emission I-NEU

-DOCSTART- O

epistaxis B-NEG

-DOCSTART- O

Sabarubicin O
blocking O
of O
DNA O
replication O
reduced O
the O
counteractive O
activity O
of O
mutagenic O
translesional O
bypass O
replication O
across O
cisplatin-DNA O
adducts O
. O

-DOCSTART- O

thirst B-NEG
with O
fever B-NEG

-DOCSTART- O

Cough B-NEG
and O
asthma B-NEG
, O
fright O
epilepsy B-NEG
, O
wind-cold-damp B-NEG
impediment O
, O
dysentery B-NEG
, O
prolapse B-NEG
of I-NEG
rectum I-NEG
, O
knocks O
and O
falls O
. O

-DOCSTART- O

To O
tonify O
the O
spleen B-DNP
, O
to O
relieve O
diarrhea B-NEG
, O
to O
replenish O
the O
kidney B-DNP
, O
to O
arrest O
seminal B-NEU
emission I-NEU
, O
and O
to O
nourish O
the O
heart B-DNP
, O
to O
induce O
tranquillization B-NEU
. O

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
wound O
swelling B-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
fracture B-NEG
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
. O

-DOCSTART- O

Glomerulonephritis B-NEG

-DOCSTART- O

Bofutsushosan O
( O
BOF O
) O
, O
a O
traditional O
Chinese O
formulation O
( O
Kampo O
formulation O
in O
Japanese O
) O
, O
is O
widely O
used O
for O
patients O
with O
obesity B-NEG
and O
hyperlipidemia B-NEG
resulting O
from O
long-term O
inappropriate O
lifestyles O
. O

Since O
atherosclerosis B-NEG
, O
a O
lifestyle-related B-NEG
disease I-NEG
, O
is O
accompanied O
by O
an O
abnormal O
accumulation O
of O
vascular B-DNP
smooth I-DNP
muscle I-DNP
cells I-DNP
( O
VSMCs B-DNP
) O
in O
the O
intimal O
area O
of O
the O
artery O
, O
we O
investigated O
the O
preventive O
effect O
of O
BOF O
on O
intimal O
thickening O
. O

Oral O
administration O
of O
BOF O
extracts O
3 O
d O
before O
and O
7 O
d O
after O
balloon O
endothelial O
denudation O
dose O
dependently O
suppressed O
the O
intimal O
thickening O
and O
proliferation O
of O
VSMCs B-DNP
in O
the O
intimal O
area O
in O
rat O
carotid O
arteries O
. O

This O
model O
has O
a O
similar O
pathologic O
process O
to O
atherosclerosis B-NEG
and O
is O
considered O
to O
be O
an O
accelerated O
atherosclerosis B-NEG
model O
. O

BOF O
extract O
also O
dose O
dependently O
inhibited O
the O
migration O
of O
cultured O
VSMCs B-DNP
. O

BOF O
extract O
suppressed O
serum B-DNP
lipid O
levels O
, O
which O
are O
a O
major O
risk O
factor O
for O
atherosclerosis B-NEG
. O

These O
findings O
clarified O
the O
usefulness O
of O
BOF O
in O
cardiovascular O
risk-reduction O
therapy O
. O

-DOCSTART- O

Menstrual B-NEG
disorder I-NEG
, O
postpartum B-NEG
abdominal I-NEG
pain I-NEG
due O
to O
stasis B-NEG
obstruction I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

To O
soothe O
the O
liver B-DNP
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
. O

-DOCSTART- O

warm O
the O
bladder O

-DOCSTART- O

neck B-NEG
stiffness I-NEG
; O
neck B-NEG
rigidity I-NEG
; O
rigidity B-NEG
of I-NEG
the I-NEG
neck I-NEG
; O
rigid B-NEG
neck I-NEG

-DOCSTART- O

BACKGROUND O
: O
Crohn's B-NEG
disease I-NEG
( O
CD B-NEG
) O
is O
a O
chronic B-NEG
inflammatory I-NEG
disease I-NEG
with O
increasing O
incidence O
in O
children O
. O

Current O
medications O
have O
potentially O
serious O
side O
effects O
, O
hence O
increasing O
interest O
in O
alternative O
therapies O
. O

We O
previously O
developed O
an O
herbal O
formula O
, O
FAHF-2 O
, O
based O
on O
a O
classical O
traditional O
Chinese O
herbal O
formula O
Wu O
Mei O
Wan O
that O
has O
long O
been O
used O
in O
China O
to O
treat O
colitis B-NEG
. O

We O
investigated O
FAHF-2's O
potential O
anti-inflammatory B-POS
effects O
. O

METHODS O
: O
FAHF-2 O
efficacy O
was O
tested O
in O
vivo O
in O
the O
CD45RbRAG1 O
transfer O
colitis O
model O
. O

Weight O
loss O
, O
colonic O
histology O
, O
and O
cytokine O
production O
from O
mesenteric O
lymph O
nodes O
were O
assessed O
. O

Human O
peripheral B-DNP
blood I-DNP
mononuclear I-DNP
cells I-DNP
( O
PBMCs B-DNP
) O
and O
colonic O
biopsies O
were O
obtained O
from O
children O
newly O
diagnosed O
with O
CD B-NEG
and O
controls O
and O
cultured O
with O
or O
without O
FAHF-2 O
. O

Cytokine B-NEU
levels I-NEU
were O
measured O
by O
multiplex O
immunoassay O
. O

The O
effect O
of O
FAHF-2 O
on O
TNF- B-NEU
- I-NEU
producing I-NEU
cells I-NEU
was O
determined O
by O
flow O
cytometry O
. O

NF-kB B-NEU
signaling I-NEU
was O
investigated O
in O
human O
lamina O
propria O
mononuclear O
cells O
upon O
FAHF-2 O
treatment O
by O
In-Cell O
Western O
. O

RESULTS O
: O
FAHF-2-treated O
mice O
had O
decreased O
weight O
loss O
, O
improved O
histology O
, O
and O
reduced O
TNF- B-DNP
, O
IL-17 B-DNP
, O
IL-6 B-DNP
, O
and O
IFN-y B-DNP
production O
. O

In O
vitro O
treated O
PBMCs B-DNP
produced O
less O
TNF- B-DNP
, O
IFN-y B-DNP
, O
and O
IL-12 B-DNP
. O

FAHF-2 O
reduced O
the O
TNF-a B-NEU
- I-NEU
producing I-NEU
monocytes O
and O
T B-DNP
cells I-DNP
. O

-DOCSTART- O

Ceftazidime O
inhibits O
the O
bacteria B-NEU
cell I-NEU
wall I-NEU
synthesis I-NEU
via O
affinity O
for O
penicillin-binding B-NEU
- I-NEU
binding I-NEU
proteins I-NEU
( O
PBPs B-NEU
) O
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial O
nucleic B-NEU
acid I-NEU
synthesis I-NEU
and O
resulting O
in O
bacterial O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
absorption B-NEU
, O
Lipid O
profile O
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Strength B-POS
and O
power B-POS
, O
Others O
, O
motility B-NEU

-DOCSTART- O

warm B-NEG
malaria I-NEG
; O

pyrexial B-NEG
malaria I-NEG

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
toothache B-NEG
, O
knee B-NEG
joint I-NEG
pain I-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
trichomoniasis B-NEG
, O
scalds B-NEG
, O
wound B-NEG
, O
enduring B-NEG
sores I-NEG
, O
bilharziosis B-NEG
, O
cough B-NEG
and O
asthma B-NEG
. O

-DOCSTART- O

Kidney B-NEG
Diseases I-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP
and O
send O
Gi(Qi O
) O
downward O

-DOCSTART- O

General O
woman O
, O
Woman O
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

Relaxing O
the O
smooth O
muscles O
of O
blood B-DNP
vessels I-DNP
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary O
bladderl B-DNP
bronchus O
and O
gastrointestines B-DNP
. O

-DOCSTART- O

retention O
of O
the O
dead O
fetus O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
throat B-NEG
pain I-NEG
due O
to O
Wind-Heat B-NEG
. O

It O
has O
red B-NEG
spots I-NEG
on O
all O
of O
the O
body O
, O
burning B-NEG
heat I-NEG
, O
difficulty O
in O
swallowing O
foods O
, O
headache B-NEG
, O
and O
aversion B-NEG
to O
cold O
. O

-DOCSTART- O

Purging B-POS

-DOCSTART- O

To O
nourish O
blood O
. O

-DOCSTART- O

Chinese O
herbal O
medicine O
( O
CHM O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-NEG
for O
more O
than O
2000 O
years O
. O

A O
systematic O
review O
including O
Chinese O
and O
English O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy O
, O
safety O
, O
and O
composition O
of O
CHM O
for O
insomnia B-NEG
. O

Among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
Jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

Meta-analyses O
of O
the O
studies O
with O
Jadad O
score O
>= O
3 O
found O
that O
CHM O
was O
similar O
to O
Western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-NEG
. O

Due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy O
of O
CHM O
for O
insomnia B-NEG
. O

The O
frequency O
of O
adverse O
events O
associated O
with O
CHM O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
Western O
medication O
. O

Gui O
Pi O
Tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
Suan O
Zao O
Ren O
( O
Ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

Further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
CHM O
for O
insomnia B-NEG
. O

-DOCSTART- O

Vaginitis B-NEG

-DOCSTART- O

asthma B-NEG
and O
cough B-NEG

-DOCSTART- O

1 O
Applicable O
to O
cases O
of O
hypovolumic B-NEG
and I-NEG
cardiogenic I-NEG
shock I-NEG
which O
are O
attributed O
to O
exhaustion B-NEG
of O
primordial O
energy O
and O
yang-energy O
. O
2 O
Also O
applicable O
to O
cases O
of O
hemorrhagic B-NEG
shock I-NEG
attributed O
to O
yang O
depletion O
. O

-DOCSTART- O

Macular B-NEG
Degeneration I-NEG

-DOCSTART- O

promote O
menstruation B-DNP

-DOCSTART- O

Pseudoephedrine B-DNP
relaxes O
bronchial O
smooth O
muscle O
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O

To O
benefit O
vital O
energy O
, O
lift O
yang O
and O
activate O
vital O
energy O
. O

-DOCSTART- O

Melphalan O
alkylates O
DNA O
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA O
inter-strand O
cross-linkages O
, O
resulting O
in O
the O
inhibition O
of O
DNA B-DNP
and I-DNP
RNA I-DNP
synthesis I-DNP
and O
cytotoxicity B-NEG
against O
both O
dividing O
and O
non-dividing O
tumor B-NEG
cells I-NEG
. O

-DOCSTART- O

Excessive O
Repair O

-DOCSTART- O

Drug B-NEG
Induced I-NEG
Hepatotoxicity I-NEG

-DOCSTART- O

To O
remove O
toxic B-NEG
heat I-NEG
, O
to O
soothe O
the O
sore B-NEG
throat I-NEG
, O
to O
resolve O
phlegm B-NEG
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

It O
contains O
about O
50% O
of O
fatty O
oil O
, O
exerting O
antitussive B-POS
effect I-POS
. O

-DOCSTART- O

To O
remove O
toxic B-NEG
heat I-NEG
, O
to O
promote O
the O
drainage B-POS
of I-POS
pus I-POS
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O

To O
nourish O
yin O
and O
moisterize O
lung B-DNP
; O

To O
suppress O
fire O
and O
desolve O
phlegm B-NEG

-DOCSTART- O

replenish O
Gi(Qi O
) O
and O
invigorate O
the O
spleen B-DNP

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Urinary B-DNP
systems I-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU
, O
Others O

-DOCSTART- O

phlegm B-NEG
; O
sputum B-NEG
pathologic O
mucoid O
substances O
collected O
in O
a O
diseased O
organ O
or O
tissue O
. O

-DOCSTART- O

amenorrhea B-NEG

-DOCSTART- O

vomiting B-NEG
of O
milk O

-DOCSTART- O

dizziness B-NEG
and O
palpitation B-NEG
due O
to O
congested B-NEG
fluids I-NEG

-DOCSTART- O

Liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
determination O
of O
arsenic B-DNP
species I-DNP
in O
dog O
plasma O
and O
its O
application O
to O
a O
pharmacokinetic O
study O
after O
oral O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
. O

-DOCSTART- O

Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-NEG
deficiency I-NEG
( O
TD B-NEG
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100-500 O
microg/ml O
) O
ameliorated O
the O
TD B-NEG
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-DNP
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta-glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-NEG
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration-dependent O
manner O
. O

These O
substances O
inhibited O
protein B-DNP
kinase I-DNP
C I-DNP
( O
PKC B-DNP
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta-glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-NEU
activity I-NEU
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O

Zidovudine O
inhibits O
the O
activity B-NEG
of I-NEG
HIV-1 I-NEG
reverse I-NEG
transcriptase I-NEG
( O
RT O
) O
via O
DNA O
chain O
termination O
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

Efavirenz O
inhibits O
the O
activity B-DNP
of I-DNP
viral I-DNP
RNA-directed I-DNP
DNA I-DNP
polymerase I-DNP
. O

Lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
DNA O
by O
HIV B-DNP
reverse I-DNP
transcriptase I-DNP
and O
HBV B-DNP
polymerase I-DNP
, O
resulting O
in O
DNA B-NEU
chain I-NEU
termination I-NEU
. O

-DOCSTART- O

Immune B-NEG
Thrombocytopenic I-NEG
Purpura I-NEG

-DOCSTART- O

To O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
, O
relieve O
cough B-NEG
and O
eliminate O
phlegm B-NEG
. O

-DOCSTART- O

syphilis B-NEG
; O
strawberry O
sores B-NEG
; O
syphilitic B-NEG
skin I-NEG
disease I-NEG

-DOCSTART- O

Fatigue B-NEG

-DOCSTART- O

prolapse B-NEG
of O
the O
rectum O

-DOCSTART- O

Hypertension B-NEG

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

cataract B-NEG
and O
nebula O

-DOCSTART- O

clear O
heat B-NEU
and O
calm O
the O
fetus O

-DOCSTART- O

Woman O
, O
Bone B-NEU
Health I-NEU
and O
Osteoporosis B-NEG
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

convulsive B-NEG
seizure I-NEG

-DOCSTART- O

Like O
other O
macrolides O
, O
it O
then O
penetrates O
bacteria O
cell O
wall O
and O
reversibly O
binds O
to O
domain O
V O
of O
the O
23S O
ribosomal O
RNA O
of O
the O
50S O
subunit O
of O
the O
bacterial O
ribosome O
, O
blocking O
translocation O
of O
aminoacyl B-NEU
transfer-RNA I-NEU
and I-NEU
polypeptide I-NEU
synthesis I-NEU
. O

-DOCSTART- O

Woman O
, O
Eldery O
, O
menopausal B-NEG
woman I-NEG
, O
Others O

-DOCSTART- O

To O
nourish O
yin O
and O
clear O
away O
heat B-NEU
, O
relieve O
restlessness B-NEG
and O
tranquilize O
the O
mind B-DNP
, O
regulate O
the O
equilibrium O
of O
the O
human B-DNP
body I-DNP
, O
improve O
health B-DNP
and O
prolong B-POS
life I-POS
. O

-DOCSTART- O

This O
is O
passing B-NEG
urine I-NEG
unconsciously I-NEG
. O

-DOCSTART- O

menstrual B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

Intelligence B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Others O

-DOCSTART- O

stop O
bleeding B-NEG
and O
stabilize O
pain B-NEG

-DOCSTART- O

Proteinuria B-NEG

-DOCSTART- O

distension B-NEG
and O
fullness B-NEG

-DOCSTART- O

disperse O
wart B-NEG

-DOCSTART- O

Treament O
of O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
premature B-NEG
greying I-NEG
of I-NEG
hair I-NEG
and I-NEG
beard I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
aching B-NEG
and I-NEG
weakness I-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
hematuria B-NEG
and O
diarrhea B-NEG
with O
bloody B-NEG
stools I-NEG
due O
to O
heat B-NEG
in I-NEG
the I-NEG
blood I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
. O

-DOCSTART- O

Nephrotic B-NEG
Syndrome I-NEG

-DOCSTART- O

relieve O
Clonorchiasis B-NEG
toxin B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
disinhibit O
damp B-NEU
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
stanch O
bleeding B-NEG
and O
disperse O
swelling B-NEG
, O
kill O
worms B-NEG
. O

-DOCSTART- O

dyspnea B-NEG
due O
to O
lung-heat O

-DOCSTART- O

( O
1 O
) O
pestilent B-NEG
lesions I-NEG
; O
leprosy B-NEG
( O
2 O
) O
malignant B-NEG
furuncle I-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
numbness B-NEG
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

Warfarin O
inhibits O
vitamin B-DNP
K I-DNP
reductase I-DNP
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-DNP
K I-DNP
which O
reduces O
the O
thrombogenicity B-NEG
of I-NEG
clots I-NEG
. O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-DNP
and O
other O
activated O
clotting B-DNP
factors I-DNP
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization B-NEU
of I-NEU
fibrinogen I-NEU
to O
fibrin O
and O
the O
subsequent O
formation B-NEU
of I-NEU
clots I-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
absorption B-NEU
, O
Digestion B-NEU
, O
motility B-NEU
, O
Others O
, O
General O
woman O

-DOCSTART- O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent O
RNA B-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression O
of O
RNA B-NEU
synthesis I-NEU
and O
cell O
death O
. O

-DOCSTART- O

dispel O
stasis B-NEG

-DOCSTART- O

Hypertrophy B-NEG
, I-NEG
Left I-NEG
Ventricular I-NEG

-DOCSTART- O

Inhibiting O
the O
growth O
of O
various O
kinds O
of O
dermatomyces B-DNP
. O

-DOCSTART- O

dispel O
cold B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

1 O
Its O
decoction O
in O
1:3000-1:200 O
concentration B-POS
inhibits O
the O
growth O
of O
influenzae B-NEG
virus I-NEG
and O
Bacillus B-NEG
dysenteriae I-NEG
in O
vitro.2 O
. O
Promoting O
the O
secretion O
of O
gastric B-DNP
juice I-DNP
and O
enhancing O
the O
digestive B-POS
function I-POS
, O
also O
as O
an O
astringent B-NEU
. O

-DOCSTART- O

infraumbilical B-NEG
cold I-NEG
pain I-NEG

-DOCSTART- O

cool O
the O
blood B-NEU
and O
move O
the O
blood B-NEU

-DOCSTART- O

Diagnostic O
yield O
and O
adverse O
effects O
of O
MRI-guided O
free-hand O
brain O
biopsies O
through O
a O
mini-burr O
hole O
in O
dogs O
with O
encephalitis O
. O

-DOCSTART- O

Sleep B-NEG
Disturbance I-NEG

-DOCSTART- O

To O
drain O
the O
pus O
and O
relieve O
swelling B-NEG
( O
external O
use O
for O
various O
kinds O
of O
severe O
skin B-NEG
lesions I-NEG
; O
oral O
use O
of O
Crotonis O
fried O
yellow O
wax O
for O
bone B-NEG
tuberculosis I-NEG
and O
osteomyelitis B-NEG
) O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD B-NEG
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
General O
skin B-DNP
health I-DNP
, O
Others O
, O
Reproductive B-DNP
systems I-DNP
, O
Protective O
immunity B-NEU

-DOCSTART- O

Methdilazine O
binds O
to O
the O
histamine O
H O
1 O
receptor O
. O

-DOCSTART- O

Gallbladder B-NEG
Neoplasms I-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

reinforce O
marrow B-DNP

-DOCSTART- O

Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O

For O
the O
treatment O
of O
Tuberculosis B-NEG
and O
Tuberculosis-related O
mycobacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP

-DOCSTART- O

To O
eliminate O
fluid O
and O
relieve O
edema B-NEG
( O
sthenia-syndrome B-NEG
with O
edema B-NEG
and O
ascites B-DNP
) O
. O

-DOCSTART- O

swelling B-NEG
and O
bearing-down O
pain B-NEG
of O
unilateral O
testis B-DNP
; O
unilateral O
swelling B-NEG
of O
the O
testis B-DNP

-DOCSTART- O

1 O
L-tetrahydropalmatine O
20-40mg/kg O
intraperitoneally O
in O
mice O
and O
15mg/kg O
intravenously O
in O
rabbits O
exert O
analgesic O
and O
sedative B-POS
effects I-POS
. O
2 O
Reducing O
the O
body B-NEG
temperature I-NEG
in O
healthy O
or O
thyroidectomized O
rats O
. O

-DOCSTART- O

( O
1 O
) O
hemorrhoids B-NEG
( O
2 O
) O
polyp B-NEG

-DOCSTART- O

regenerate O
blood B-NEU

-DOCSTART- O

painful O
urinary B-NEG
dysfunction I-NEG
; O
stranguria B-NEG
a O
syndrome O
characterized O
by O
frequent O
, O
painful O
and O
dripping O
urination B-DNP
. O

-DOCSTART- O

wind-heat O
; O
wind O
and O
heat O
; O
wind-heat O
pathogene O
wind O
and O
heat O
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O

Eye B-NEG
pain I-NEG
, O
eye B-NEG
swelling I-NEG
, O
red B-NEG
eyes I-NEG
and O
tearing B-NEU
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG

-DOCSTART- O

nausea B-NEG
without O
vomiting B-NEG
. O

-DOCSTART- O

Treatment O
of O
stagnancy B-NEG
of I-NEG
undigested I-NEG
food I-NEG
with O
abdominal B-NEG
distension I-NEG
and O
constipation B-NEG
, O
weakness B-NEG
and O
edema B-NEG
of O
the O
legs O
with O
oliguria B-NEG
. O

-DOCSTART- O

disperse O
goiter B-NEG
core O

-DOCSTART- O

Thoracic O
Surgery O

-DOCSTART- O

acute B-NEG
appendicitis I-NEG
; O
periappendicular B-NEG
abscess I-NEG
; O
intestinal B-NEG
carbuncle I-NEG
; O
intestinal B-NEG
abscess I-NEG

-DOCSTART- O

Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-DNP
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O

Treatment O
of O
menstrual B-NEG
disorders I-NEG
, O
anemia B-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
rheumatic B-NEG
arthralgia I-NEG
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
bladder B-NEG
cancer I-NEG
. O

-DOCSTART- O

swelling B-NEG
of O
the O
cheek O
; O
parotitis B-NEG

-DOCSTART- O

Chlorothiazide O
is O
indicated O
as O
adjunctive O
therapy O
in O
edema B-NEG
associated O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
hepatic B-NEG
cirrhosis I-NEG
, O
and O
corticosteroid O
and O
estrogen O
therapy O
. O

It O
is O
also O
indicated O
in O
the O
management O
of O
hypertension B-NEG
either O
as O
the O
sole O
therapeutic O
agent O
or O
to O
enhance O
the O
effectiveness O
of O
other O
antihypertensive O
drugs O
in O
the O
more O
severe O
forms O
of O
hypertension B-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
C I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

1 O
Applicable O
to O
cases O
of O
diarrhea B-NEG
in O
summer O
time O
, O
manifested O
as O
watery B-NEG
diarrhea I-NEG
, O
abdominal B-NEG
fullness I-NEG
, O
increased O
borborygmus B-NEG
, O
nausea B-NEG
, O
feeling O
of O
oppression B-NEG
over O
the O
chest O
, O
fatigue B-NEG
, O
white B-NEG
and I-NEG
smooth I-NEG
fur I-NEG
on I-NEG
the I-NEG
tongue I-NEG
, O
soft O
and O
floating O
, O
slow B-NEG
pulse I-NEG
, O
which O
are O
attribut O

-DOCSTART- O

cool O
the O
blood B-DNP

-DOCSTART- O

Treament O
of O
abdomen B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
worms I-NEG
, O
sores B-NEG
, O
uterine B-NEG
bleeding I-NEG
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O

an O
illness O
in O
which O
phlegm B-NEG
formed O
on O
chest O

-DOCSTART- O

1 O
Containing O
potassium O
acetate O
and O
chloride O
which O
exert O
diuretic O
effect O
. O
2 O
. O
Orall O
adminstration O
of O
its O
decoction O
or O
infusion O
( O
2g/kg O
) O
can O
reduce O
vaccine-induced O
fever B-NEG
in O
rabbits O
. O
3 O
. O
Cardiotonic O
on O
the O
heart O
of O
frog O
weakened O
by O
quinine O
. O
Also O
causing O
constriction B-NEU
of I-NEU
blood I-NEU
vessels I-NEU
and O
rising B-NEU
of I-NEU
blood I-NEU
pressure I-NEU
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
pain B-NEG
from O
arthritis B-NEG
, O
painful B-NEG
swelling I-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
amenorrhea B-NEG
, O
dysmenorrhea B-NEG
, O
swollen B-NEG
welling I-NEG
abscess I-NEG
, O
erysipelas B-NEG
, O
goose-foot B-NEG
wind I-NEG
, O
snake B-NEG
or I-NEG
insect I-NEG
bites I-NEG
. O

-DOCSTART- O

Cardiovascular B-NEG
Disorder I-NEG

-DOCSTART- O

Erlotinib O
inhibits O
the O
intracellular O
phosphorylation O
of O
tyrosine O
kinase O
associated O
with O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
which O
is O
expressed O
on O
the O
cell O
surface O
of O
normal O
cells O
and O
cancer B-NEG
cells O
. O

-DOCSTART- O

nocturnal B-NEG
emission I-NEG
; O
emission O
; O
spermatorrhea B-NEG
; O
seminal O
emission O

-DOCSTART- O

disperse O
glomus B-NEG

-DOCSTART- O

Rescinnamine O
Binds O
to O
and O
inhibits O
the O
angiotensin B-DNP
converting I-DNP
enzyme I-DNP
. O
Rescinnamine O
competes O
with O
angiotensin O
I O
for O
binding O
at O
the O
angiotensin-converting B-DNP
enzyme I-DNP
, O
blocking O
the O
conversion O
of O
angiotensin B-DNP
I I-DNP
to O
angiotensin B-DNP
II I-DNP
. O
Inhibition O
of O
ACE O
results O
in O
decreased O
plasma B-DNP
angiotensin I-DNP
II I-DNP
. O
As O
angiotensin B-DNP
II I-DNP
is I-DNP
a O
vasoconstrictor B-NEG
and O
a O
negative-feedback O
mediator O
for O
renin B-DNP
activity O
, O
lower O
concentrations O
result O
in O
a O
decrease O
in O
blood B-NEU
pressure I-NEU
and O
stimulation O
of O
baroreceptor O
reflex O
mechanisms O
, O
which O
leads O
to O
decreased O
vasopressor B-NEU
activity O
and O
to O
decreased O
aldosterone B-DNP
secretion O
. O

-DOCSTART- O

Bradycardia B-NEG
, O
sick B-NEG
sinus I-NEG
syndrome I-NEG
, O
angina B-NEG
and O
cardiac B-NEG
insufficiency I-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

insufficiency O
of O
heart B-DNP
Gi O

-DOCSTART- O

To O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-DNP
and O
the O
lung B-DNP
. O

-DOCSTART- O

Eldery O
, O
Others O

-DOCSTART- O

Treatment O
of O
carbuncle B-NEG
and O
boil B-NEG
at O
the O
early O
stage O
or O
formation B-NEG
of I-NEG
abscess I-NEG
difficult O
to O
burst B-NEU
, O
external O
use O
for O
scabies B-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

clear O
the O
lung B-DNP
and O
discharge O
fire O

-DOCSTART- O

consumption B-NEG
; O

deficiency B-NEG
syndrome I-NEG
; O

disease B-NEG
due O
to O
asthenia B-NEG
of O
the O
viscera O

-DOCSTART- O

Used O
to O
prolong O
the O
time O
to O
recurrence O
of O
paroxysmal B-NEG
atrial I-NEG
fibrillation/flutter I-NEG
( O
PAF B-NEG
) O
associated O
with O
disabling O
symptoms O
in O
patients O
without O
structural B-NEG
heart I-NEG
disease I-NEG
. O
Also O
used O
for O
the O
treatment O
of O
life-threatening O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained B-NEG
ventricular I-NEG
tachycardia I-NEG
. O

-DOCSTART- O

[Case O
of O
pneumonitis B-NEG
caused O
by O
Yokukansan] O
. O

-DOCSTART- O

sore B-NEG
throat I-NEG
; O

swollen B-NEG
and O
pailful B-NEG
throat I-NEG

-DOCSTART- O

restore O
depression B-NEG
and O
dissipate O
bind O

-DOCSTART- O

Woman O
, O
Mood O
, O
Menopausal B-DNP
woman I-DNP
, O
Dermatological B-DNP
systems I-DNP
health O
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

difficulty B-NEG
in I-NEG
feces I-NEG
and O
urine B-DNP

-DOCSTART- O

Wind-cold B-NEG
common O
cold B-NEG
, O
summerheat O
damage O
, O
vomiting B-NEG
diarrhea B-NEG
with O
abdominal O
pain B-NEG
, O
dribbling O
pain B-NEG
of O
urination O
, O
wind-damp B-NEG
impediment O
pain B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
bronchial O
asthma B-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP
and O
disperse O
food O

-DOCSTART- O

RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-NEG
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
breast B-NEG
cancer I-NEG
, O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
, O
and O
lung B-NEG
cancer I-NEG
. O

-DOCSTART- O

Prostate B-NEG
cancer I-NEG

-DOCSTART- O

Dental B-NEG
Plaque I-NEG

-DOCSTART- O

For O
the O
treatment O
of O
gastroesophageal B-NEG
reflux I-NEG
disease I-NEG
( O
GERD B-NEG
) O
. O

It O
is O
also O
used O
in O
treating O
nausea B-NEG
and O
vomiting B-NEG
, O
and O
to O
increase O
gastric B-NEU
emptying I-NEU
. O

Occasionally O
used O
in O
Cushing's B-NEG
syndrome I-NEG
. O

-DOCSTART- O

cold O
dysentery B-NEG

-DOCSTART- O

1 O
Broad-spectrum O
antibacteric O
. O
Its O
antibacterial O
components O
are O
para-hydroxyphenylacetic O
acid O
, O
salicylic O
acid O
, O
vanillic O
acid O
, O
pyromucic O
acid O
and O
hydroquinone O
. O
2 O
. O
Its O
1/1800-1/1600 O
decoction O
inhibits O
the O
growth B-NEU
of I-NEU
leptospira I-NEU
. O
3 O
. O
Anti-trichomonas B-POS
vaginalis I-POS
in O
vitro O
. O
4 O
. O
Its O
component O
, O
senecionine O
, O
is O
anticarcinogenic O
on O
Walker O
sarcoma256 O
. O

-DOCSTART- O

Decompensated B-NEG
Cirrhosis I-NEG

-DOCSTART- O

Reducing O
signs O
and O
symptoms O
of O
Crohn's B-NEG
disease I-NEG
and O
treatment O
of O
moderately O
to O
severely O
active O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
. O

-DOCSTART- O

For O
eliminating O
toxic B-NEG
materials I-NEG
, O
dissolving O
rottenness B-NEG
and O
growing O
new O
muscles B-NEG

-DOCSTART- O

1 O
Aloperine O
inhibits O
exudative B-NEG
inflammation I-NEG
and O
hemolysis B-NEG
of O
red O
blood O
cells O
2 O
. O
Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-NEG
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O
3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 O
in O
vitro O
. O

-DOCSTART- O

a O
disease O
like O
a O
cholera B-NEG
. O
That O
Has O
a O
abdominal O
pain B-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
caused O
by O
dirty O
and O
acute O
filthy O
Gi O

-DOCSTART- O

Endocrine B-DNP
system I-DNP
, O
insulin B-DNP
sensitivity I-DNP
and O
diabetes B-NEG
risk O
, O
Body O
weight O
regulation O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP

-DOCSTART- O

1 O
For O
cases O
of O
menorrhagia B-NEG
accompanied O
with O
listlessness B-NEG
and O
pale B-NEG
complexion I-NEG
due O
to O
deficiency B-NEG
of I-NEG
vital I-NEG
energy I-NEG
Radix O
Ginseng O
Jilin O
to O
invigorate O
vital B-POS
energy I-POS
and O
control O
blood B-DNP
of O
profuse B-NEG
uterine I-NEG
bleeding I-NEG
leading O
to O
deadly O
coldness B-NEG
of I-NEG
limbs I-NEG
and O

-DOCSTART- O

Heat B-NEU
bind O
and O
accumulation O
, O
constipation O
w O
ith O
abdominal B-NEG
pain I-NEG
, O
edema B-NEG
distention I-NEG
fullness I-NEG
. O

-DOCSTART- O

Treament O
of O
arthritis B-NEG
with O
ankylosis B-NEG
, O
aching B-NEG
and I-NEG
heaviness I-NEG
sensation I-NEG
of O
the O
loins O
and O
knees O
, O
systremma B-NEG
due O
to O
vomiting B-NEG
and O
diarrhea B-NEG
, O
edema B-NEG
and O
weakness B-NEG
of I-NEG
the I-NEG
legs I-NEG
. O

-DOCSTART- O

Rapamycin O
binds O
to O
the O
immunophilin O
FK O
Binding O
Protein-12 O
( O
FKBP-12 O
) O
to O
generate O
an O
immunosuppressive B-DNP
complex I-DNP
that O
binds O
to O
and O
inhibits O
the O
activation O
of O
the O
mammalian O
Target O
Of O
Rapamycin O
( O
mTOR O
) O
, O
a O
key O
regulatory O
kinase O
. O

This O
results O
in O
inhibition O
of O
T B-DNP
lymphocyte I-DNP
activation I-DNP
and I-DNP
proliferation I-DNP
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine O
( O
IL-2 O
, O
IL-4 O
, O
and O
IL-15 O
) O
stimulation O
and O
inhibition O
of O
antibody B-DNP
production I-DNP
. O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine O
kinases O
( O
TK O
) O
, O
thereby O
inhibiting O
ATP B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation B-NEU
of I-NEU
growth I-NEU
receptors I-NEU
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

This O
agent O
inhibits O
TK B-DNP
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor B-DNP
TKs I-DNP
encoded O
by O
the O
c-kit O
and O
platelet-derived B-DNP
growth I-DNP
factor I-DNP
receptor I-DNP
( O
PDGFR O
) O
oncogenes O
. O

Biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4I-BP1 O
phosphorylation B-NEU
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
PTK O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O

To O
dissipate O
stasis B-NEG
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEG
, O
to O
promote O
the O
production O
of O
body B-NEU
fluid I-NEU
, O
and O
to O
facilitate O
the O
drainage O
of O
pus B-NEG
and O
the O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG
of O
the O
back O
; O
carbuncle B-NEG
on O
the O
back O

-DOCSTART- O

thirst B-NEU

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
short B-NEG
, I-NEG
rapid I-NEG
and I-NEG
interrupted I-NEG
breathing I-NEG
. O

-DOCSTART- O

Treatment O
of O
fever B-NEG
with O
constipation B-NEG
, O
retention O
of O
the O
feces O
and O
abdominal B-NEG
pain I-NEG
, O
dysentery B-NEG
with O
inadequate O
discharge O
from O
the O
bowels B-DNP
, O
jaundice B-NEG
caused O
by O
damp-heat B-NEG
, O
haematemesis B-NEG
, O
epistaxis B-NEG
, O
inflammation B-NEG
of O
eye O
and O
swelling B-NEG
of O
the O
throat O
due O
to O
heat B-NEU
in O
the O
blood O
, O
appendicitis B-NEG
with O
abdominal B-NEG
pain I-NEG
, O
boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
hemorrhage B-NEG
from O
the O
upper B-DNP
gastrointestinal I-DNP
tract I-DNP
. O
External O
use O
for O
scalds B-NEG
and O
burns.Radixet O
Rhizoma O
Rhei O
( O
stir-fried O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
swelling B-NEG
of O
the O
throat O
and O
painful O
swelling B-NEG
of O
the O
gums O
. O
Radix O
et O
Rhizoma O
Rhei O
( O
prepared O
) O
Boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
. O
Radix O
et O
Rhizoma O
Rhei O
( O
carbonized O
) O
Hemorrhage B-NEG
with O
blood B-NEG
stasis I-NEG
due O
to O
heat B-NEU
in O
the O
blood O
. O

-DOCSTART- O

Bipolar B-NEG
Disorder I-NEG

-DOCSTART- O

sores B-NEG
with O
swelling B-NEG

-DOCSTART- O

1 O
nocturnal B-NEG
enuresis I-NEG
; O
bed-wetting B-NEG
2 O
incontinence B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

To O
strengthen O
the O
spleen B-DNP
. O

-DOCSTART- O

To O
invigo O
rate O
the O
function B-NEU
of I-NEU
the I-NEU
spleen I-NEU
, O
to O
regulate O
the O
function B-NEU
of I-NEU
the I-NEU
stomach I-NEU
, O
and O
to O
promote O
the O
flow B-NEU
of I-NEU
milk I-NEU
. O

-DOCSTART- O

The O
primary O
activity O
of O
insulin O
is O
the O
regulation O
of O
glucose B-NEU
metabolism I-NEU
. O

Insulin O
promotes O
glucose O
and O
amino O
acid O
uptake O
into O
muscle O
and O
adipose O
tissues O
, O
and O
other O
tissues O
except O
brain O
and O
liver O
. O

It O
also O
has O
an O
anabolic O
role O
in O
stimulating O
glycogen B-NEU
, I-NEU
fatty I-NEU
acid I-NEU
, I-NEU
and I-NEU
protein I-NEU
synthesis I-NEU
. O

Insulin O
inhibits O
gluconeogenesis B-DNP
in O
the O
liver O
. O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl O
, O
APS O
, O
Shc O
and O
Gab O

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
PI3 O
kinase O
and O
Akt O
. O

Akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
GLUT4 O
) O
and O
protein O
kinase O
C O
( O
PKC O
) O
which O
play O
a O
critical O
role O
in O
metabolism O
and O
catabolism O
. O

-DOCSTART- O

clear O
the O
head B-DNP
and O
eyes B-DNP

-DOCSTART- O

Pulmonary B-NEG
Disease I-NEG
, O
Chronic B-NEG
Obstructive I-NEG

-DOCSTART- O

Heavy O
flow O
in O
period O
due O
to O
blood B-NEG
stagnation I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
fibromyalgia B-NEG
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
benign B-NEG
prostatic I-NEG
hyperplasia I-NEG
. O

-DOCSTART- O

Dalfopristin O
inhibits O
the O
early O
phase B-NEU
of I-NEU
protein I-NEU
synthesis I-NEU
by O
acting O
on O
bacterial O
ribosome O
. O
Quinupristin O
binds O
to O
a O
nearby O
site O
on O
the O
50S O
ribosomal O
subunit O
and O
prevents O
elongation B-NEU
of I-NEU
the I-NEU
polypeptide I-NEU
as O
well O
as O
causing O
incomplete O
chains O
to O
be O
released O
. O

-DOCSTART- O

Amenorrhea B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
difficult O
labour O
, O
retention B-NEG
of I-NEG
placenta I-NEG
, O
postpartum B-NEG
abdominal I-NEG
pain I-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Cough B-NEG
in O
phthisis B-NEG
, O
dyspnea B-NEG
in O
the O
aged O
, O
depressed B-NEG
sensation I-NEG
and O
stuffiness B-NEG
in O
the O
chest O
. O

-DOCSTART- O

cooling O
throat B-DNP

-DOCSTART- O

frequent O
urination B-DNP

-DOCSTART- O

clear O
heat B-NEU
and O
dry O
dampness B-NEU

-DOCSTART- O

This O
disease O
has O
a O
characteristics O
of O
gradual O
onset O
, O
plat O
form O
of O
ulceration B-NEG
, O
mild O
or O
no O
pain B-NEG
, O
no O
change O
of O
skin O
color O
or O
dark O
reddish O
or O
blackened O
color O
change O
, O
mild O
or O
no O
fever B-NEG
, O
not O
well O
subsided O
or O
healed O
, O
occasional O
lump B-NEG
formation I-NEG
, O
no O
pus B-NEG
, O
long O
duration O
of O
treatment O
, O
thin O
colourful O
discharge O
, O
Chimse O
and O
weak O
Mac O
. O

-DOCSTART- O

Phlegm B-NEG
stagnation I-NEG
in O
chest O
and O
diaphragm O
, O
glomus O
in O
chest O
, O
distention O
in O
rib-side O
, O
food O
accumulation O
, O
retching O
counterflow O
. O

-DOCSTART- O

reddish B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

spasmodic B-NEG
contraction I-NEG
of O
tendons O
and O
meridian O

-DOCSTART- O

Dragon's O
blood B-DNP
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
in O
the O
formula O
Qili O
San O
. O

-DOCSTART- O

For O
prophylaxis O
of O
respiratory B-NEG
diseases I-NEG
casued O
by O
respiratory B-NEG
syncytial I-NEG
virus I-NEG
. O

-DOCSTART- O

heat B-NEG
in O
the O
stomach O
; O

stomach B-NEG
heat I-NEG
; O

stomach B-DNP
affected O
by O
heat B-NEG
impairment I-NEG
of O
the O
stomach O
by O
pathogenic B-NEG
heat I-NEG
or O
taking O
excessive O
heat-producing O
food O
, O
marked O
by O
thirst B-NEU
, O
halitosis B-NEG
, O
hyperorexia B-NEG
, O
oliguria B-NEG
with O
dark B-NEG
urine I-NEG
, O
constipation B-NEG
or O
even O
ulceration B-NEG
of O
the O
mouth O
, O
gingivitis B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained B-NEG
ventricular I-NEG
tachycardia I-NEG
, O
that O
, O
in O
the O
judgment O
of O
the O
physician O
, O
are O
life-threatening O
. O

-DOCSTART- O

chronic O
cough O
due B-NEG
to O
deficiency B-NEG
of O
the O
lung O

-DOCSTART- O

constipation B-NEG
and O
difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

Treament O
of O
heat B-NEU
in I-NEU
the I-NEU
lung I-NEU
with O
cough B-NEG
, O
sticky B-NEG
and I-NEG
bloody I-NEG
sputum I-NEG
, O
and O
distress B-NEG
in I-NEG
the I-NEG
chest I-NEG
. O

-DOCSTART- O

fullness B-NEU
of O
chest O
and O
abdomen O
. O
Indigestion B-NEG
caused O
by O
that O
cold O
pathogen O
of O
the O
middle-Cho O
disturb O
function O
of O
stomach B-DNP
and O
spleen B-DNP
. O
Feel O
tiring B-NEG
and O
heavy O
, O
pain B-NEG
in O
joint O
due O
to O
damp O
pathogen O

-DOCSTART- O

It O
causes O
blood B-DNP
vessels I-DNP
to O
narrow O
, O
resulting O
in O
an O
increase O
in O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

Pulmonary O
Aspiration O

-DOCSTART- O

settle O
fright O

-DOCSTART- O

Tardive B-NEG
Dyskinesia I-NEG
. O

-DOCSTART- O

Human B-NEG
Immunodeficiency I-NEG
Virus I-NEG
Infection I-NEG

-DOCSTART- O

major O
red O
and O
white O
dysentery B-NEG

-DOCSTART- O

Its O
biochemical O
mechanism O
of O
action O
is O
unknown O
, O
although O
data O
are O
available O
to O
suggest O
that O
the O
drug O
modifies O
the O
peripheral O
metabolism O
of O
steroids O
as O
well O
as O
directly O
suppressing O
the O
adrenal B-DNP
cortex I-DNP
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
quicken O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEG
, O
move O
qi O
and O
quicken O
blood B-DNP
. O

-DOCSTART- O

dyspnea B-NEG
and O
tachypnea B-NEG
; O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

fever B-NEG
with O
affection O
by O
cold B-NEG

-DOCSTART- O

Keishibukuryogan O
, O
one O
of O
the O
traditional O
herbal O
formulations O
, O
is O
used O
clinically O
to O
improve O
blood B-NEU
circulation I-NEU
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
keishibukuryogan O
on O
glucose B-NEU
and I-NEU
lipids I-NEU
metabolism I-NEU
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
, O
an O
animal O
model O
of O
type O
2 O
diabetes O
. O

Forty-five-week-old O
male O
OLETF O
rats O
were O
divided O
into O
three O
groups O
: O
diabetic O
control O
rats O
given O
a O
standard O
chow O
; O
diabetic O
rats O
given O
keishibukuryogan O
( O
0.03 O
, O
w/w O
in O
chow O
) O
; O
diabetic O
rats O
given O
pioglitazone O
( O
0.0001 O
, O
w/w O
in O
chow O
) O
. O

Oral O
administration O
of O
keishibukuryogan O
produced O
significant O
improvement O
against O
impaired O
glucose O
tolerance O
. O

On O
the O
other O
hand O
, O
fasting O
serum B-NEU
glucose I-NEU
and I-NEU
insulin I-NEU
levels I-NEU
, O
and O
the O
homeostasis O
index O
of O
insulin O
resistance O
did O
not O
change O
by O
keishibukuryogan O
treatment O
. O

Against O
lipid O
parameters O
, O
keishibukuryogan O
significantly O
lowered O
serum O
total O
cholesterol B-NEU
and I-NEU
triglyceride I-NEU
levels I-NEU
, O
and O
the O
hepatic O
total O
cholesterol B-NEU
level I-NEU
. O

Keishibukuryogan O
treatment O
also O
significantly O
reduced O
the O
serum O
leptin B-NEU
level I-NEU
, O
but O
it O
had O
no O
effect O
on O
the O
serum O
adiponectin B-NEU
level I-NEU
. O

Additionally O
, O
keishibukuryogan O
showed O
significant O
effects O
on O
epididymal O
adipose B-NEU
tissue I-NEU
by O
decreasing O
the O
size O
of O
fat B-DNP
cells I-DNP
and O
on O
skeletal O
muscle O
by O
reducing O
TNF-alpha B-DNP
protein O
content O
. O

From O
these O
results O
, O
it O
was O
suggested O
that O
keishibukuryogan O
exerts O
beneficial O
effects O
on O
the O
features O
associated O
with O
type B-NEG
2 I-NEG
diabetes I-NEG
. O

-DOCSTART- O

eliminate O
melasma B-NEG

-DOCSTART- O

pain B-NEG
and O
swelling B-NEG
of O
testis O

-DOCSTART- O

food B-NEG
damage I-NEG
; O

injury B-NEG
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-NEG
of O
spleen O
and O
stomach O

-DOCSTART- O

forceful O
pulse O

-DOCSTART- O

Treatment O
of O
endemic B-NEG
goiter I-NEG
, O
hyperthyroidism B-NEG
, O
whooping B-NEG
cough I-NEG
, O
cough B-NEG
of O
lung-heat O
type O
, O
thyroid B-NEG
adenoma I-NEG
, O
thyroid B-NEG
cancer I-NEG
, O
tumour B-NEG
of O
digestive O
tract O
, O
lung B-NEG
and I-NEG
mammary I-NEG
cancer I-NEG
, O
etc O
. O

-DOCSTART- O

stomachache B-NEG

-DOCSTART- O

Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O

wind B-NEG
syndrome I-NEG

-DOCSTART- O

acute O
infantile B-NEG
convulsion I-NEG

-DOCSTART- O

alleviate O
edema B-NEG
and O
toxin B-NEG

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
Reactivation I-NEG

-DOCSTART- O

Tourette B-NEG
Disorder I-NEG

-DOCSTART- O

thicken O
the O
intestine B-DNP
and O
stomach B-DNP

-DOCSTART- O

To O
relieve O
cough B-NEG
and O
promote O
expectoration B-NEG
, O
to O
promote O
digestion B-NEU
and O
remove O
stagnancy B-NEG
of I-NEG
food I-NEG
, O
and O
to O
promote O
blood B-NEU
circulation I-NEU
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

malaria B-NEG
; O

malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease B-NEG
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

Reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
ATP/Mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-DNP
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-DNP
neuron I-DNP
. O
Trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-DNP
of I-DNP
Henle I-DNP
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-DNP
tubule I-DNP
. O

-DOCSTART- O

deficiency B-NEG
and I-NEG
cold I-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG
; O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
with O
cold B-NEG
manifestations O

-DOCSTART- O

BACKGROUND O
_ O
AIMS O
: O
Chemotherapy O
with O
an O
anticancer O
agent O
generally O
causes O
gastrointestinal O
tract O
disorders B-NEG
such O
as O
vomiting B-NEG
and O
anorexia B-NEG
, O
but O
the O
mechanism O
remains O
unclear O
. O

Rikkunshito O
, O
a O
kampo O
preparation O
, O
is O
known O
to O
alleviate O
such O
adverse O
reactions O
. O

In O
this O
study O
, O
we O
attempted O
to O
clarify O
the O
mechanism O
. O

METHODS O
: O
We O
investigated O
the O
decreases O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
caused O
by O
cisplatin O
, O
serotonin B-DNP
( O
5-HT B-DNP
) O
, O
5-HT O
agonists O
, O
and O
vagotomy O
as O
well O
as O
the O
decrease-suppressing O
effects O
of O
rikkunshito O
and O
5-HT O
antagonists O
. O

In O
addition O
, O
binding O
affinities O
of O
rikkunshito O
components O
were O
determined O
in O
receptor-binding O
assays O
using O
5-HT2B O
and O
5-HT2C O
receptors O
. O

RESULTS O
: O
Cisplatin O
, O
5-HT B-DNP
, O
BW723C86 O
( O
5-HT2B-receptor O
agonist O
) O
, O
and O
m-chlorophenylpiperazine O
HCl O
( O
5-HT2C O
agonist O
) O
markedly O
decreased O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
levels I-NEU
, O
although O
5-HT3 O
and O
5-HT4 O
agonists O
had O
no O
effect O
. O

In O
contrast O
, O
5-HT2B O
and O
5-HT2C O
antagonists O
suppressed O
the O
cisplatin-induced O
decrease O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

Administration O
of O
rat O
ghrelin B-DNP
improved O
the O
cisplatin-induced O
decrease O
in O
food O
intake O
. O

Vagotomy O
decreased O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
which O
was O
decreased O
further O
by O
cisplatin O
. O

Rikkunshito O
suppressed O
such O
cisplatin-induced O
decreases O
of O
plasma B-NEU
acylated- I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

The O
suppressive O
effect O
of O
rikkunshito O
was O
blocked O
by O
a O
ghrelin O
antagonist O
. O

Components O
of O
rikkunshito O
, O
3,3',4',5,6,7,8-heptamethoxyflavone O
, O
hesperidin O
, O
and O
iso-liquiritigenin O
showed O
a O
5-HT2B-antagonistic O
effect O
in O
vitro O
, O
and O
oral O
administration O
of O
rikkunshito O
suppressed O
the O
cisplatin-induced O
decrease O
in O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
. O

CONCLUSIONS O
: O
The O
cisplatin-induced O
decreases O
of O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
are O
mediated O
by O
5-HT2B/2C B-DNP
receptors I-DNP
and O
suppressed O
by O
flavonoids O
in O
rikkunshito O
. O

-DOCSTART- O

Chronic B-NEG
hepatitis I-NEG

-DOCSTART- O

Eye B-DNP
health I-DNP
, O
Eye B-DNP

-DOCSTART- O

For O
clearing O
weakness B-NEG
and O
heat B-NEU

-DOCSTART- O

Secretin O
binds O
to O
the O
secretin O
receptor O
found O
on O
the O
lining O
of O
S O
cells O
in O
the O
duodenum B-DNP
and O
G O
cells O
in O
the O
stomach B-DNP
. O
Binding O
leads O
to O
the O
secrection O
of O
bicarbonate B-DNP
or O
the O
reduction O
of O
the O
secretion O
of O
gastrin B-DNP
. O
Properly O
functioning O
organs O
( O
duodenum O
, O
pancreas B-DNP
and O
stomach B-DNP
) O
should O
be O
responsive O
to O
this O
hormone O

-DOCSTART- O

To O
regulate O
menstruation B-NEU
, O
replenish O
blood B-DNP
and O
regulate O
qi O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

Measles B-NEG
papules O
with O
complicated O
pneumonia B-NEG
, O
throat B-NEG
erosion I-NEG
. O

-DOCSTART- O

Treament O
of O
unprocessed O
Fructus O
Hordei O
Germinatus O
: O

Anorexia B-NEG
due O
to O
diminished O
function O
of O
the O
spleen O
, O
galactostasis O
. O

Fructus O
Hordei O
Germinatus O
( O
stir-fried O
) O
: O

Indigestion B-NEG
, O
weaning O
a O
baby O
. O

Fructus O
Hordei O
Germinatus O
( O
charred O
) O
: O

Retention B-NEG
of O
undigested O
food O
with O
epigastric B-NEG
distension I-NEG
and O
pain B-NEG
. O

-DOCSTART- O

May O
be O
used O
to O
treat O
primary O
, O
secondary O
or O
tertiary O
hypothyroidism B-NEG
. O
May O
also O
be O
used O
to O
suppress O
thyroid B-DNP
stimulating I-DNP
hormone I-DNP
( O
TSH B-DNP
) O
secretion O
in O
patients O
with O
simple O
( O
nontoxic O
) O
goiter B-NEG
, O
subacute B-NEG
or I-NEG
chronic I-NEG
lymphocytic I-NEG
thyroiditis I-NEG
multinodular I-NEG
goiter I-NEG
, O
and O
in O
the O
management O
of O
thyroid B-NEG
cancer I-NEG
. O
May O
be O
used O
in O
conjunction O
with O
other O
antithyroid O
agents O
to O
treat O
thyrotoxicosis B-NEG
to O
prevent O
goitrogenesis B-NEG
and O
hypothyroidism B-NEG
. O
May O
also O
be O
used O
for O
differential O
diagnosis O
of O
suspected O
mild O
hyperthyroidism B-NEG
or O
thyroid B-DNP
gland I-DNP
autonomy O
. O

-DOCSTART- O

paralysis B-NEG
due O
to O
stroke B-NEG

-DOCSTART- O

irregular O
chills B-NEG
and I-NEG
fever I-NEG

-DOCSTART- O

Pi B-NEG
syndrome I-NEG
due O
to O
pathogenic B-NEG
wind I-NEG
, O
cold B-NEG
and O
damp B-NEU

-DOCSTART- O

nocturnal B-NEG
enuresis I-NEG
and O
frequency B-NEG
of I-NEG
micturition I-NEG

-DOCSTART- O

Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-NEG
cancer I-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

the O
stagnation B-NEG
of O
Gi O
a O
morbid B-NEG
condition I-NEG
due O
to O
impeded B-NEG
circulation I-NEG
of O
Gi O
that O
leads O
to O
a O
local B-NEG
obstruction I-NEG
, O
manifested O
by O
distension B-NEU
or O
pain B-NEG
in O
the O
affected O
part O
. O

-DOCSTART- O

nourish O
Eum(Yin O
) O
blood B-DNP

-DOCSTART- O

To O
strengthen O
spleen B-DNP
and O
benefit O
qi O
; O
To O
soothe O
liver B-DNP
and O
modulate O
qi O
; O
To O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

relax O
tension B-NEU

-DOCSTART- O

Temporomandibular B-NEG
Joint I-NEG
Dysfunction I-NEG

-DOCSTART- O

For O
clearing O
heat B-NEG
and O
removing O
toxic B-NEG
substances I-NEG

-DOCSTART- O

Its O
alcoholic O
extract O
relaxes O
the O
spasm B-NEG
of O
smooth O
muscles O
of O
gastrointestine O
, O
gallbladder O
and O
bronchus. O
. O

-DOCSTART- O

Inhibiting O
the O
excessive O
secretion O
of O
bronchi B-DNP
and O
uterus B-DNP
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

Pregnancy B-NEU

-DOCSTART- O

exogenous O
exogenous B-NEG
febrile I-NEG
disease I-NEG
; O

syndrome O
of O
T'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG

affection O
by O
cold B-NEG
; O

common B-NEG
cold I-NEG

-DOCSTART- O

protracted O
diarrhea B-NEG
; O
chronic O
diarrhea B-NEG
; O
prolonged O
diarrhea B-NEG

-DOCSTART- O

Diminshing O
the O
toxicity B-NEG
of I-NEG
kanamycin I-NEG
to O
guinea-pig's O
cochlea O
. O

the O
levels O
of O
serum B-DNP
cholesterol I-DNP
and O
triglyceride B-DNP
. O

Hindering O
the O
formation O
of O
arteriosclerotic B-NEG
deposits O
in O
the O
vessels O
. O

-DOCSTART- O

Infant B-NEG
, I-NEG
Diabetic I-NEG
Mother I-NEG

-DOCSTART- O

nourish O
Eum(Yin O
) O
and O
reinforce O
blood B-DNP

-DOCSTART- O

Hypertension B-NEG
, O
kidney B-NEG
vacuity I-NEG
lumbago I-NEG
, O
weakness B-NEG
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O

restlessness B-NEG
and O
thirst B-NEU
; O

polydipsia B-NEG

-DOCSTART- O

Liver O
Transplantation O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Hypersensitivity B-NEG
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

1 O
To O
dispel O
cold B-NEG
and O
stop O
pain B-NEG
; O
2 O
To O
regulate O
qi O
and O
harmonize O
the O
stomach B-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
Others O
, O
Hemostatic B-NEU
function I-NEU

-DOCSTART- O

1 O
Its O
decoction O
can O
lower O
blood B-NEU
pressure I-NEU

2 O
. O
Inhibiting O
the O
growth B-NEU
of I-NEU
(a)-streptococcus I-NEU

3 O
. O
Shortening O
the O
bleeding B-NEG
time O
. O

4 O
. O
Anti-inflammatory B-POS

5 O
. O
Diuretic O
. O

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
abscess B-NEG
of I-NEG
breast I-NEG
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

Red B-NEG
eyes I-NEG
with O
gall O
, O
pulmonary B-NEG
welling I-NEG
abscess I-NEG
, O
diarrhea B-NEG
, O
dysentery B-NEG
, O
leukorrhea B-NEG
, O
postpartum B-NEG
blood I-NEG
stasis I-NEG
abdominal I-NEG
pain I-NEG
, O
indigestion B-NEG
, O
nephritis B-NEG
with O
edema B-NEG
, O
cirrhosis B-NEG
with O
ascites B-NEG
, O
swelling B-NEG
toxin O
of O
welling B-NEG
abscess I-NEG
and O
sore B-NEG
. O

-DOCSTART- O

convulsive B-NEG
disease I-NEG
; O
epilepsy B-NEG
induced O
by O
frightening O

-DOCSTART- O

protracted O
dysentery B-NEG
; O
chronic O
dysentery B-NEG
; O
prolonged O
dysentery B-NEG

-DOCSTART- O

epilepsy B-NEG
induced O
by O
frightening O
and O
mania-withdrawal O

-DOCSTART- O

cool O
blood B-DNP

-DOCSTART- O

white-haired O

-DOCSTART- O

Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-NEU
circulation. I-NEU
. O

-DOCSTART- O

Treatment O
of O
mass O
in O
the O
abdomen B-DNP
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
abdominal B-NEG
distension I-NEG
and O
pain B-NEG
caused O
by O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
. O

-DOCSTART- O

To O
relieve O
rheumatic B-NEU
conditions I-NEU
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
( O
SBB O
) O
. O

So O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
. O

METHODS O
: O
Between O
1998 O
and O
2003 O
, O
155 O
SBBs O
were O
performed O
in O
153 O
patients O
with O
micro-Doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

All O
operations O
were O
performed O
using O
a O
ZD-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
Leibinger O
SPP O
) O
. O

A O
16 O
MHz O
micro-Doppler O
probe O
( O
diameter O
1 O
mm O
, O
DWL O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

Serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
Sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

We O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-Doppler O
, O
intraoperative O
bleedings O
as O
well O
as O
bleedings O
detected O
by O
postoperative O
CT O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

We O
compared O
our O
results O
according O
to O
bleeding O
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

RESULTS O
: O
A O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

A O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

In O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-Doppler O
. O

In O
the O
remainder O
, O
a O
signal O
of O
arterial O
vessels O
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous O
vessels O
in O
35 O
cases O
( O
23 O
% O
) O
. O

Detection O
of O
a O
vessel O
in O
the O
micro-Doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

Biopsy-related O
bleedings O
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

Among O
these O
, O
the O
only O
bleeding B-NEG
which O
occurred O
without O
any O
signs O
of O
vessels B-DNP
in O
the O
micro-Doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-NEG
. O

The O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

The O
biopsy-related O
mortality O
was O
0 O

CONCLUSIONS O
: O
Despite O
the O
overall O
high O
security O
of O
SBB O
, O
the O
use O
of O
intraoperative O
micro-Doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding O
without O
enormous O
expense O
. O

-DOCSTART- O

Hip B-NEG
Fracture I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
heat O
; O

heat-type B-NEG
stranguria I-NEG

-DOCSTART- O

deficiency O
of O
the O
Yang O
of O
the O
spleen O
and O
the O
kidney O

-DOCSTART- O

arthralgia B-NEG
and O
myalgia B-NEG
; O
pain B-NEG
in O
the O
muscles O
and O
bones O

-DOCSTART- O

dispel O
wind B-NEG

-DOCSTART- O

Neuropathic B-NEG
pain I-NEG

-DOCSTART- O

Pneumonia B-NEG
, O
pyothorax B-NEG
, O
sore B-NEG
pharynx I-NEG
, O
oral B-NEG
ulcer I-NEG
, O
vesical B-NEG
calculus I-NEG
, O
swollen O
welling O
abscess B-NEG
. O

-DOCSTART- O

Urinary B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Liver B-DNP
health I-DNP
, O
Liver B-DNP

-DOCSTART- O

clear O
the O
lung B-DNP

-DOCSTART- O

Tuberculosis B-NEG
, O
weak O
yin O
and O
agitated O
fire O
, O
thin B-NEU
and I-NEU
hot I-NEU
body I-NEU
, O
cough B-NEG
, O
phlegm B-NEG
, O
spitting B-NEG
blood I-NEG
, O
chest B-NEG
pain I-NEG
, O
dry B-NEG
mouth I-NEG
, O
frequent B-NEG
pulse I-NEG

-DOCSTART- O

Propranolol O
competes O
with O
sympathomimetic O
neurotransmitters O
such O
as O
catecholamines O
for O
binding O
at O
beta(1)-adrenergic O
receptors O
in O
the O
heart O
, O
inhibiting O
sympathetic B-NEU
stimulation I-NEU
. O

Hydrochlorothiazide O
, O
a O
thiazide O
diuretic O
, O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
5% O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

-DOCSTART- O

resolve O
phlegm B-NEG
and O
relieve O
cough B-NEG

-DOCSTART- O

To O
purge O
pathogenic O
fire O
and O
lessen O
virulence B-NEG
of O
any O
pathogenic O
organism O
. O

-DOCSTART- O

Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 B-NEU
relaxation I-NEU
time O
, O
thus O
producing O
an O
increase O
in O
signal B-NEU
intensity I-NEU
. O

Gadodiamide O
does O
not O
cross O
the O
intact B-DNP
blood-brain I-DNP
barrier I-DNP
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-DNP
nervous I-DNP
system I-DNP
( O
CNS B-DNP
) O
lesions O
that O
have O
not O
caused O
an O
abnormal B-DNP
blood-brain I-DNP
barrier I-DNP
( O
e.g O
. O
, O
cysts O
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-NEG
vascularity I-NEG
or O
disruption B-NEG
of I-NEG
the I-NEG
blood-brain I-NEG
barrier I-NEG
allows O
accumulation O
of O
gadodiamide B-DNP
in I-DNP
lesions I-DNP
such O
as O
neoplasms B-DNP
, O
abscesses B-NEG
, O
and O
subacute B-NEG
infarcts I-NEG
. O

-DOCSTART- O

a O
disease O
that O
difficult O
to O
sleep O
, O
beating O
fast O
in O
the O
chest O
, O
feel O
anxiety B-NEG
, O
sometimes O
frightening B-NEG
well O
due O
to O
cold B-NEG
of O
gallbladder B-DNP
meridian I-DNP

-DOCSTART- O

Used O
mainly O
in O
female O
infertility O
due O
to O
anovulation B-NEG
( O
e.g O
. O
due O
to O
polycystic B-NEG
ovary I-NEG
syndrome I-NEG
) O
to O
induce O
ovulation B-NEU
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
suppress O
cough B-NEG
and O
calm O
asthma B-NEG
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Mycophenolate O
stops O
T-cell B-DNP
and I-DNP
B-cell I-DNP
proliferation I-DNP
through O
selective O
inhibition O
of O
the O
de O
novo O
pathway O
of O
purine B-DNP
biosynthesis I-DNP
. O

-DOCSTART- O

prolonged O
chronic B-NEG
headache I-NEG

dead B-NEG
coldness I-NEG
of O
the O
extremities O

morbid B-NEG
condition I-NEG
of O
intense O
pain B-NEG
in O
the O
chest O
and O
abdomen O
, O
sudden O
coldness B-NEG
of O
the O
two O
feet O
, O
restlessness B-NEG
with O
disinclination B-NEG
ti O
eat O
and O
unsmooth O
pulse B-DNP

-DOCSTART- O

hematuria B-NEG
; O
bloody B-NEG
urine I-NEG
without O
pain B-NEG

-DOCSTART- O

Its O
decoction O
promotes O
the O
secretion O
of O
pepsin O
and O
gastric O
juice O
. O

-DOCSTART- O

Used O
for O
the O
treatment O
of O
individual O
patients O
with O
certain O
filarial B-NEG
diseases I-NEG
including O
tropical B-NEG
pulmonary I-NEG
eosinophilia I-NEG
, O
loiasis B-NEG
, O
and O
lymphatic B-NEG
filariasis I-NEG
caused O
by O
infection B-NEG
with I-NEG
Wuchereria I-NEG
bancrofti I-NEG
, I-NEG
Brugia I-NEG
malayi I-NEG
, I-NEG
or I-NEG
Brugia I-NEG
timori I-NEG
. O

-DOCSTART- O

damp-warm B-NEG
disease I-NEG
febrile B-NEG
disease I-NEG
often O
occurring O
around O
mid-summer O
, O
July O
, O
caused O
by O
damp-heat B-NEG
pathogene I-NEG
, O
which O
mainly O
involves O
the O
gastro-intestinal B-DNP
tract I-DNP
often O
in O
a O
protracted O
course O
. O

It O
may O
sometimes O
be O
seen O
in O
diseases O
such O
as O
typhoid B-NEG
fever I-NEG
. O

-DOCSTART- O

Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA O
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
initiating O
cell B-NEG
death I-NEG
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
hemiplegia B-NEG
, O
gan B-NEG
accumulation I-NEG
, O
dysentery B-NEG
. O

-DOCSTART- O

pectoral B-NEG
pain I-NEG
with O
stuffiness B-NEG
; O
chest B-NEG
impediment I-NEG
; O
chest B-NEG
blockage I-NEG
; O
obstruction O
of O
Gi O
in O
the O
chest O
( O
1 O
) O
a O
morbid B-NEG
condition I-NEG
due O
to O
stagnation O
of O
dampness O
and O
phlegm O
, O
marked O
by O
choking B-NEG
pain I-NEG
in O
the O
chest O
, O
sometimes O
referring O
to O
the O
back B-DNP
, O
usually O
accompanied O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
. O
( O

2 O
) O
obstruction O
of O
Gi O
in O
the O
stomach O
, O
chest B-NEG
pain I-NEG
that O
occurs O
immediately O
after O
eating O
, O
accompanied O
by O
difficulty B-NEG
in I-NEG
swallowing I-NEG
and O
frequent O
vomiting B-NEG
. O

-DOCSTART- O

To O
clear O
damp B-NEG
heat I-NEG
, O
resolve O
sore O
toxin B-NEG
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Pain B-NEG
Due O
to O
Certain O
Specified O
Procedures O

-DOCSTART- O

Menopausal B-NEG
syndrome I-NEG
marked O
by O
afternoon O
fever B-NEG
, O
excessive B-NEG
sweating I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
insomnia B-NEG
and O
unsteady B-NEG
blood I-NEG
pressure I-NEG
. O

-DOCSTART- O

Relief O
of O
mild O
to O
moderate O
pain B-NEG
of O
acte B-NEG
musculoskeletal I-NEG
disorders I-NEG
. O

-DOCSTART- O

Healthy O

-DOCSTART- O

distribution O
) O
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Strength B-POS
and O
power B-POS
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

The O
role O
of O
crude O
polysaccharide O
fractions O
on O
the O
mitogenic B-NEU
activity I-NEU
by O
Shosaikoto O
. O

-DOCSTART- O

disperse O
accumulation O
and O
relieve O
pain B-NEG

-DOCSTART- O

Blood B-NEG
vaculty I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
amenorrhea B-NEG
, O
postpartum B-NEG
vacuity I-NEG
weakness I-NEG
, O
aching B-NEG
in I-NEG
lumbus I-NEG
and I-NEG
legs I-NEG
, O
fracture B-NEG
due O
to O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Anti-inflammatory O
activity O
of O
Gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-NEU
factor-kappa I-NEU
B I-NEU
activation I-NEU
in O
peritoneal O
macrophages O
. O

-DOCSTART- O

vomiting B-NEG
due O
to O
dysphagia B-NEG

-DOCSTART- O

For O
breaking O
blood B-DNP
and O
desolving O
stasis B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Inflammation B-NEG
, O
Other O
system O
health O
, O
Others O

-DOCSTART- O

anal B-NEG
fistula I-NEG
hemorrhoids I-NEG
complicated O
by O
anal B-NEG
fistula I-NEG
. O

-DOCSTART- O

sores B-NEG
of O
the O
mouth O
or O
tongue O
; O
aphthae B-NEG
and O
boil B-NEG
of O
mouth O
and O
tongue O

-DOCSTART- O

abortion B-NEG

-DOCSTART- O

dry B-NEG
mouth I-NEG
; O

xerostomia B-NEG
; O

dryness B-NEG
of I-NEG
mouth I-NEG

-DOCSTART- O

1 O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
2 O
leg O
Gi O
; O
beriberi O

-DOCSTART- O

postpartum B-NEG
anemic I-NEG
faintness I-NEG
; O
faint B-NEG
after O
childbirth O

-DOCSTART- O

latent O
summer B-NEG
heat I-NEG
syndrome I-NEG

-DOCSTART- O

This O
is O
an O
external B-NEG
wound I-NEG
in O
muscle O
of O
waist O
. O

-DOCSTART- O

distention O
and O
pain B-NEG
in O
chest O
and O
abdomen O
with O
driving O
up O
Qi O

-DOCSTART- O

stiffness B-NEG
of O
four O
ends O

-DOCSTART- O

Both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O
This O
antagonism O
results O
in O
inhibition O
of O
bladder B-NEG
contraction I-NEG
, O
decrease O
in O
detrusor B-NEG
pressure I-NEG
, O
and O
an O
incomplete B-NEG
emptying I-NEG
of I-NEG
the I-NEG
bladder I-NEG
. O

-DOCSTART- O

Insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

Insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
B3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
B29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
poor B-NEG
appetite I-NEG
, O
vomiting B-NEG
, O
and O
diarrhea B-NEG
due O
to O
various O
reasons O
. O

-DOCSTART- O

Tourette B-DNP
Syndrome I-DNP

-DOCSTART- O

promote O
blood B-DNP
vessel I-DNP

-DOCSTART- O

Taxation B-NEG
damage I-NEG
and O
sinew B-NEG
bone I-NEG
pain I-NEG
, O
impotence B-NEG
, O
stomachache B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
knife B-NEG
wound I-NEG
. O

-DOCSTART- O

Intercritical O
Gout B-NEG

-DOCSTART- O

refers O
to O
the O
heavy O
coughing B-NEG
and O
shortness B-NEG
of I-NEG
breath I-NEG
due O
to O
the O
heat B-NEU
In O
the O
lung B-DNP

-DOCSTART- O

To O
benefit O
qi O
and O
revitalize B-POS
blood I-POS
; O
To O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O

Parasite O
worms B-NEG

-DOCSTART- O

The O
antiinflammatory O
effects O
of O
tenoxicam O
may O
result O
from O
the O
inhibition O
of O
the O
enzyme B-DNP
cycooxygenase I-DNP
and O
the O
subsequent O
peripheral O
inhibition O
of O
prostaglandin B-DNP
synthesis I-DNP
. O
As O
prostaglandins O
sensitize O
pain O
receptors O
, O
their O
inhibition O
accounts O
for O
the O
peripheral O
analgesic O
effects O
of O
tenoxicam O
. O
Antipyresis O
may O
occur O
by O
central O
action O
on O
the O
hypothalamus B-DNP
, O
resulting O
in O
peripheral B-NEU
dilation I-NEU
, O
increased O
cutaneous B-NEU
blood I-NEU
flow I-NEU
, O
and O
subsequent O
heat O
loss O
. O

-DOCSTART- O

For O
the O
treatment O
of O
essential B-NEG
hypertension I-NEG
, O
alone O
or O
as O
an O
adjunct O
. O

Also O
for O
the O
management O
of O
severe B-NEG
hypertension I-NEG
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-NEU
pressure I-NEU
must O
be O
lowered O
immediately O
, O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-NEG
secondary I-NEG
to O
pre-eclampsia B-NEG
/ O
eclampsia B-NEG
. O

-DOCSTART- O

plum-stone B-NEG
syndrome I-NEG
; O
globus B-NEG
hystericus I-NEG
a O
subjective O
sensation O
as O
if O
a O
plum O
pit O
is O
stuck O
in O
the O
throat O
is O
compressed O
. O

-DOCSTART- O

strengthen O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

Treatment O
of O
rheumatic B-NEG
arthritis I-NEG
with O
muscular B-NEG
contracture I-NEG
, O
aching B-NEG
of O
the O
loins O
and O
knees O
, O
inflammation B-NEG
of O
the O
throat O
, O
carbuncle B-NEG
and O
boils B-NEG
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

Chlorambucil O
alkylates O
and O
cross-links O
DNA O
during O
all O
phases O
of O
the O
cell O
cycle O
, O
resulting O
in O
disruption B-NEG
of I-NEG
DNA I-NEG
function I-NEG
, O
cell B-POS
cycle I-POS
arrest I-POS
, O
and O
apoptosis B-POS
. O

-DOCSTART- O

desire B-NEG
for I-NEG
vomiting I-NEG
; O
feel O
nauseated B-NEG
; O
nausea B-NEG

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
Infection I-NEG

-DOCSTART- O

For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-NEG
associated O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
( O
CRF B-NEG
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-NEG
and O
reduction B-NEG
of I-NEG
transfusion I-NEG
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-NEG
tumours I-NEG
, O
malignant B-NEG
lymphoma I-NEG
or O
multiple B-NEG
myeloma I-NEG
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia O
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-DNP
blood I-DNP
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O

Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O

-DOCSTART- O

dispel O
wind B-NEG
and O
drain O
dampness B-NEU

-DOCSTART- O

The O
functional O
group O
of O
the O
anion O
exchange O
resin O
is O
a O
quaternary O
ammonium O
group O
attached O
to O
an O
inert O
styrene-divinylbenzene O
copolymer O
. O

-DOCSTART- O

rhIGFBP-3 O
is O
a O
protein O
that O
is O
normally O
found O
in O
our O
bloodstream O
that O
has O
been O
shown O
to O
induce O
cancer O
cell O
death O
in O
a O
variety O
of O
experimental O
systems O
. O
Several O
studies O
have O
demonstrated O
that O
cancer B-NEG
risk O
increases O
with O
decreasing O
levels O
of O
circulating O
IGFBP-3 B-DNP
. O
IGFBP-3 B-DNP
can O
induce O
cell O
cycle O
arrest O
and O
enhance O
the O
efficacy O
of O
chemotherapeutic O
agents O
. O

-DOCSTART- O

normalize O
Gi(Qi O
) O
and O
relieve O
pain B-NEG

-DOCSTART- O

1 O
Hypotensive B-NEG
2 O
Promoting O
phagocytosis B-NEU
of I-NEU
mononuclear I-NEU
phagocytes I-NEU
. O

Sedative O
and O
diuretic O
. O

-DOCSTART- O

Kidney B-NEG
disease I-NEG
of O
diabetes O
type O

-DOCSTART- O

Gastric B-NEG
Cancer I-NEG

-DOCSTART- O

Native O
Americans O
residing O
in O
a O
broad O
region O
downwind O
from O
the O
Nevada O
Test O
Site O
during O
the O
1950s O
and O
1960s O
received O
significant O
radiation O
exposures O
from O
nuclear O
weapons O
testing O
. O

Because O
of O
differences O
in O
diet O
, O
activities O
, O
and O
housing O
, O
their O
radiation O
exposures O
are O
only O
very O
imperfectly O
represented O
in O
the O
Department O
of O
Energy O
dose O
reconstructions O
. O

There O
are O
important O
missing O
pathways O
, O
including O
exposures O
to O
radioactive O
iodine O
from O
eating O
small O
game O
. O

The O
dose O
reconstruction O
model O
assumptions O
about O
cattle O
feeding O
practices O
across O
a O
year O
are O
unlikely O
to O
apply O
to O
the O
native O
communities O
as O
are O
other O
model O
assumptions O
about O
diet O
. O

Thus O
exposures O
from O
drinking O
milk O
and O
eating O
vegetables O
have O
not O
yet O
been O
properly O
estimated O
for O
these O
communities O
. O

Through O
consultations O
with O
members O
of O
the O
affected O
communities O
, O
these O
deficiencies O
could O
be O
corrected O
and O
the O
dose O
reconstruction O
extended O
to O
Native O
Americans O
. O

An O
illustration O
of O
the O
feasibility O
of O
extending O
the O
dose O
reconstruction O
is O
provided O
by O
a O
sample O
calculation O
to O
estimate O
radiation O
exposures O
to O
the O
thyroid B-DNP
from O
eating O
radio-iodine-contaminated O
rabbit O
thyroids B-DNP
after O
the O
Sedan O
test O
. O

The O
illustration O
is O
continued O
with O
a O
discussion O
of O
how O
the O
calculation O
results O
may O
be O
used O
to O
make O
estimates O
for O
other O
tests O
and O
other O
locations O
. O

-DOCSTART- O

sore B-NEG
of I-NEG
scrotum I-NEG

-DOCSTART- O

dirty B-NEG
face I-NEG
; O

dirty B-NEG
complexion I-NEG
; O

grimy B-NEG
facial I-NEG
complexion I-NEG
a O
face O
appearing O
as O
if O
covered O
with O
dirt B-NEG
, O
as O
often O
seen O
in O
hepatic B-NEG
disease I-NEG
, O
disease B-NEG
due O
to O
damp-heat B-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Motivation O
, O
Mood O
, O
Endocrine B-DNP
system I-DNP
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

cool O
blood B-DNP
and O
stop O
dysentery B-NEG

-DOCSTART- O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation O
of O
clots O
. O

-DOCSTART- O

scrofula B-NEG
; O
tuberculosis B-NEG
of O
the O
cervical O
lymphic O
node O

-DOCSTART- O

function O

-DOCSTART- O

NRP409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid O
hormone O
thyroxine O
( O
T O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

In O
the O
liver B-DNP
and O
kidney B-DNP
, O
T O
4 O
is O
converted O
to O
T O
3, O
the O
active O
metabolite O
. O

In O
order O
to O
increase O
solubility O
, O
the O
thyroid O
hormones O
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding O
globulin O
, O
and O
thyroxin-binding O
prealbumin O
( O
transthyretin O
) O
. O

Transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

Thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine O
, O
symptoms O
of O
thyroxine O
deficiency O
are O
relieved O
. O

-DOCSTART- O

To O
resolve O
phlegm B-NEG
and O
benefit O
throat B-DNP

-DOCSTART- O

Bone B-NEG
Marrow I-NEG
Suppression I-NEG

-DOCSTART- O

Motivation O
, O
Mood O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Others O
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

Chai O
Hu O
( O
Radix O
Burpleuri O
) O
, O
a O
major O
ingredient O
in O
many O
traditional O
Chinese O
medicine O
formulas O
, O
such O
as O
Xiao O
Yan O
Wan O
, O
is O
used O
in O
the O
treatment O
of O
liver B-DNP
stagnation O
and O
spleen B-DNP
deficiency O
syndrome O
( O
LSSDS O
) O
. O

The O
objectives O
of O
this O
study O
were O
to O
examine O
the O
effects O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
changes B-NEU
of I-NEU
plasma I-NEU
indices I-NEU
in O
patients O
with O
LSSDS O
. O

Fifty-eight O
cases O
of O
LSSDS O
were O
randomly O
divided O
into O
two O
groups O
: O
41 O
cases O
in O
the O
experimental O
group O
were O
treated O
with O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
and O
17 O
cases O
in O
the O
control O
group O
were O
treated O
with O
Zhi O
Bai O
Di O
Huang O
Wan O
for O
one O
consecutive O
month O
in O
a O
single O
blind O
design O
. O

Before O
and O
after O
treatment O
, O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
applied O
to O
determine O
the O
changes B-NEU
of I-NEU
plasma I-NEU
norepinephrine I-NEU
( I-NEU
NE I-NEU
) I-NEU
, I-NEU
epinephrine I-NEU
( I-NEU
E I-NEU
) I-NEU
and I-NEU
dopamine I-NEU
( I-NEU
DA I-NEU
) I-NEU
. O

Radioimmunoassay O
was O
performed O
to O
measure O
the O
amount O
of O
plasma O
beta-endorphin O
( O
beta-EP O
) O
, O
adrenocorticotropin O
hormone O
( O
ACTH O
) O
, O
estradiol O
( O
E2 O
) O
and O
testosterone O
( O
T O
) O
, O
and O
laser O
nephelometry O
was O
also O
conducted O
to O
measure O
plasma O
immunoglobulin O
A O
( O
Ig O
A) O
and O
G O
( O
Ig O
G O
) O
. O

Compared O
to O
baseline O
levels O
, O
plasma B-DNP
beta-EP I-DNP
was O
significantly O
increased O
(p O
< O
0.01 O
) O
, O
while O
E B-DNP
and O
DA B-DNP
were O
markedly O
decreased O
(p O
< O
0.01 O
) O
after O
the O
administration O
of O
Xiao O
Yao O
Wan O
in O
the O
experimental O
group O
. O

The O
other O
indices O
did O
not O
change O
. O

This O
is O
the O
first O
evidence O
showing O
that O
the O
effect O
of O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
on O
the O
treatment O
of O
patients O
with O
LSSDS O
may O
be O
through O
enhancing O
plasma B-DNP
beta-EP I-DNP
and O
decreasing O
E B-DNP
and O
DA B-DNP
release O
. O

We O
conclude O
that O
Xiao O
Yao O
Wan O
containing O
Chai O
Hu O
regulates O
nervous B-DNP
and I-DNP
endocrine I-DNP
systems I-DNP
and O
contributes O
to O
the O
improvement O
of O
the O
clinical O
status O
of O
patients O
with O
LSSDS O
. O

-DOCSTART- O

Diabetes B-NEG
Mellitus I-NEG
, I-NEG
Type I-NEG
2 I-NEG

-DOCSTART- O

Promethazine O
hydrochloride O
selectively O
blocks O
peripheral O
H1 O
receptors O
thereby O
diminishing O
the O
effects O
of O
histamine B-DNP
on O
effector O
cells O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
liver B-NEG
cancer I-NEG
. O

-DOCSTART- O

sores B-NEG
due O
to O
swelling B-NEG
of O
carbuncle B-NEG
. O

-DOCSTART- O

Melanoma B-NEG

-DOCSTART- O

asthma B-NEG
; O

dyspnea B-NEG
; O

abnormal O
rising O
of O
Gi O
; O

upward O
Gi O
dyspnea O
due O
to O
upward O
adverse O
flow O
of O
the O
lung-Gi O

-DOCSTART- O

the O
steaming O
of O
bone O
and O
tidal O
fever B-NEG

-DOCSTART- O

AIDS B-NEG
With O
Tuberculosis B-NEG

-DOCSTART- O

abdominal B-NEG
fullness I-NEG
; O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

fever B-NEG
with O
affection B-NEG
by O
cold B-NEG

-DOCSTART- O

Lopinavir O
inhibits O
the O
HIV B-DNP
viral I-DNP
protease I-DNP
enzyme I-DNP
. O

-DOCSTART- O

Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O

Treatment O
of O
aching B-NEG
and I-NEG
weakness I-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
asthma B-NEG
and O
cough B-NEG
of O
deficiency-cold O
type O
, O
seminal B-NEU
emission I-NEU
, O
impotence B-NEG
. O

-DOCSTART- O

The O
bactericidal O
action O
of O
dalbavancin O
results O
primarily O
from O
inhibition O
of O
cell-wall O
biosynthesis O
. O

-DOCSTART- O

epilepsy B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Others O
, O
Overall O
CVD O
, O
Diet related O
cardiovascular B-NEG
disease I-NEG
, O
Body B-NEU
weight I-NEU
, O
Evacuation B-NEU
, O
Hemostatic O
function O
. O

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP

-DOCSTART- O

spinal B-NEG
cord I-NEG
problems I-NEG
, O
pain B-NEG
etc O
. O

-DOCSTART- O

Breech B-NEU
Presentation I-NEU
in O
Pregnancy O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU

-DOCSTART- O

profuse B-NEG
metrorrhagia I-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
effuse O
sweat B-NEU
, O
dissipate O
cold B-NEG
and O
dry O
damp B-NEU
. O

-DOCSTART- O

Colonic B-NEG
Cancer I-NEG
. O

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
of O
the O
anus O

-DOCSTART- O

sudden O
turmoil B-NEG
; O
cholera B-NEG
disease I-NEG
; O
acute B-NEG
gastroenteritis I-NEG
; O
acute O
vomiting B-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases O
including O
cholera B-NEG
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU

-DOCSTART- O

Simultaneous O
quantitative O
analyses O
of O
indole O
and O
oxindole O
alkaloids O
of O
Uncaria O
Hook O
in O
rat O
plasma O
and O
brain O
after O
oral O
administration O
of O
the O
traditional O
Japanese O
medicine O
Yokukansan O
using O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
. O

-DOCSTART- O

Woman O
, O
Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Menopausal B-NEG
woman I-NEG
, O
Eye B-DNP
health I-DNP
, O
Lipid B-NEU
profile I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
sleep B-NEU
, O
Inflammation B-NEG
, O
Other B-DNP
system I-DNP
health I-DNP
, O
Memory B-POS
, O
Reproductive B-DNP
systems I-DNP
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
post B-NEU
delivery I-NEU
, O
Hypersensitivity B-NEG
, O
Protective B-NEU
immunity I-NEU
, O
Quality O
of O
life O
, O
Eye B-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Blood B-NEU
pressure I-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Diet B-NEG
cardiovascular I-NEG
disease I-NEG
, O
Endocrine B-DNP
system I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Liver B-DNP
, O
Others O
, O
vigilance B-NEG
, O
Bone B-DNP
Health I-DNP
and O
Osteoporosis B-NEG
, O
Homocysteine B-NEU
metabolism I-NEU
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
activation B-POS
, O
attention B-POS
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Liver B-DNP
health I-DNP
, O
Eldery O
, O
Strength B-POS
and O
power B-POS
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Hemostatic B-NEU
function I-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Overall O
CVD B-NEG
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
Strength B-POS
and O
power B-DNP
Reproductive I-DNP
systems I-DNP
, O
Arousal B-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Man O
, O
sleep B-NEU

-DOCSTART- O

clear O
the O
liver B-DNP

-DOCSTART- O

Strength B-POS
and O
power B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Mood O

-DOCSTART- O

wind B-NEG
rash I-NEG
; O
German B-NEG
measles I-NEG
; O
rubella B-NEG
; O
urticaria B-NEG

-DOCSTART- O

Rikkunshito O
( O
RKT O
) O
, O
a O
Japanese O
traditional O
medicine O
, O
has O
been O
shown O
to O
stimulate O
food O
intake O
in O
rats O
with O
cisplatin-induced O
anorexia B-NEG
; O
however O
, O
the O
underlying O
mechanisms O
remain O
unknown O
. O

In O
this O
study O
, O
we O
investigated O
whether O
RKT O
is O
involved O
in O
the O
degradation O
of O
peripheral O
ghrelin B-DNP
. O

RKT O
inhibited O
decreases O
in O
plasma B-NEU
ghrelin I-NEU
level I-NEU
and O
enhanced O
acyl- O
to O
desacyl-ghrelin O
( O
A/D O
) O
ratio O
in O
cisplatin-treated O
rats O
. O

Several O
components O
of O
RKT O
demonstrated O
inhibitory O
activity O
against O
ghrelin B-DNP
deacylating I-DNP
enzymes I-DNP
. O

In O
addition O
, O
10-gingerol O
, O
a O
component O
of O
RKT O
, O
inhibited O
exogenous O
ghrelin B-DNP
deacylation I-DNP
. O

Therefore O
, O
RKT O
may O
enhance O
plasma B-NEU
acyl I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
at O
least O
in O
part O
, O
by O
inhibiting O
the O
circulating O
ghrelin B-DNP
degrading I-DNP
enzyme I-DNP
. O

-DOCSTART- O

dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O

stop O
diarrhea B-NEG

-DOCSTART- O

This O
is O
carbuncle B-NEG
and O
cellulites B-NEU
occurred O
on O
the O
back O
. O

-DOCSTART- O

In O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
NF-kB B-NEU
activation I-NEU
and O
apoptotic O
pathways O
. O

-DOCSTART- O

aversion B-NEG
to O
cold O
; O

severe B-NEG
chillness I-NEG
; O

creeping B-NEG
chills I-NEG

-DOCSTART- O

malaria B-NEG
; O
malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

For O
the O
treatment O
of O
cancer B-NEG
patients O
with O
severe O
pain B-NEG
that O
breaks O
through O
their O
regular O
narcotic O
therapy O
. O

-DOCSTART- O

To O
transform O
water O
and O
reduce O
edema B-NEG

-DOCSTART- O

dissipate O
depression B-NEG

-DOCSTART- O

warm O
the O
lumbus B-DNP
and O
knees B-DNP

-DOCSTART- O

Ritonavir O
inhibits O
the O
HIV B-DNP
viral I-DNP
proteinase I-DNP
enzyme I-DNP
which O
prevents O
cleavage O
of O
the O
gag-pol O
polyprotein O
, O
resulting O
in O
noninfectious O
, O
immature O
viral O
particles O
. O

-DOCSTART- O

dry B-NEG
heat I-NEG
and O
cough B-NEG
with O
much O
expectoration B-NEG

-DOCSTART- O

Organic O
iodine O
compounds O
attenuate O
x-rays O
as O
they O
pass O
through O
the O
body O
, O
thereby O
allowing O
the O
body O
structures O
containing O
iodine O
to O
be O
delineated O
in O
contrast O
to O
those O
structures O
that O
do O
not O
contain O
iodine O
. O

The O
degree O
of O
opacity O
produced O
by O
these O
compounds O
is O
directly O
proportional O
to O
the O
total O
amount O
( O
concentration O
and O
volume O
) O
of O
the O
iodinated O
contrast O
agent O
in O
the O
path O
of O
the O
x-rays O
. O

After O
intravascular O
administration O
, O
iodixanol O
makes O
opaque O
those O
internal O
structures O
in O
its O
path O
of O
flow O
, O
allowing O
their O
visualization O
until O
significant O
hemodilution B-NEU
and O
elimination O
occur O
. O

-DOCSTART- O

bloodshot B-NEG
eyes I-NEG
; O
congestion B-NEG
of I-NEG
the I-NEG
eye I-NEG
; O
red B-NEG
eyes I-NEG
; O
redness B-NEG
of I-NEG
the I-NEG
eye I-NEG

-DOCSTART- O

lumbago B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

wind B-NEG
invaded O
Chang O
organ O

-DOCSTART- O

Serious O
heat B-NEG
in O
lung O
and O
stomach O
, O
epidemic B-NEG
infectious I-NEG
diseases I-NEG
, O
fever B-NEG
, O
dizziness B-NEG
, O
aching B-NEG
of O
limbs O
, O
cough B-NEG
with O
copious B-NEG
phlegm I-NEG
, O
sore B-NEG
throat I-NEG
, O
epistaxis B-NEG
, O
haemoptysis B-NEG
, O
dryness B-NEG
of I-NEG
mouth I-NEG
and I-NEG
tongue I-NEG
. O

-DOCSTART- O

Lidocaine O
alters O
signal O
conduction O
in O
neurons O
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
Na+ O
) O
channels O
in O
the O
neuronal O
cell O
membrane O
that O
are O
responsible O
for O
signal O
propagation O
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
move O
stasis B-NEG

-DOCSTART- O

impotence B-NEG

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
in O
the O
chest O
, O
to O
eliminate O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
, O
relieve O
vomiting B-NEG
. O

-DOCSTART- O

Treatment O
of O
cough B-NEG
with O
profuse B-NEG
expectoration I-NEG
, O
indigestion B-NEG
, O
stagnancy B-NEG
of I-NEG
food I-NEG
with O
abdominal B-NEG
pain I-NEG
, O
traumatic B-NEG
swelling I-NEG
and O
ecchymoses B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl O
, O
APS O
, O
Shc O
and O
Gab O

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
PI3 O
kinase O
and O
Akt O
. O

Akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
GLUT4 B-DNP
) O
and O
protein B-DNP
kinase I-DNP
C I-DNP
( O
PKC B-DNP
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O

lubricate O
the O
intestines B-DNP

-DOCSTART- O

Infant B-NEG
, I-NEG
Large I-NEG
for I-NEG
Gestational I-NEG
Age I-NEG

-DOCSTART- O

Treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-DNP
and O
stomach B-DNP
manifested O
by O
distending O
pain B-NEG
in O
the O
chest O
and O
hypochodria B-NEG
, O
fullness B-NEG
and O
stuffiness B-NEG
sensation O
in O
the O
epigastrium O
, O
vomiting B-NEG
and O
belching B-NEG
, O
cough B-NEG
with O
copious O
expectoration B-NEG
. O

-DOCSTART- O

sore B-NEG
; O
pain B-NEG
; O
to O
ache B-NEG

-DOCSTART- O

Heat B-NEG
vexation I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
vomiting B-NEG
nausea I-NEG
, O
vacuity B-NEG
heat I-NEG
cough I-NEG
, O
dry O
stool B-NEG
, O
swelling B-NEG
of O
welling B-NEG
abscess I-NEG
, O
welling B-NEG
abscess I-NEG
and O
flat B-NEG
abscess I-NEG
with O
swelling B-NEG
sore I-NEG
. O

-DOCSTART- O

sparrow O
vision O
; O
night B-NEG
blindness I-NEG

-DOCSTART- O

anhidrosis B-NEG
and O
aversion B-NEG
to O
cold O

-DOCSTART- O

Used O
to O
numb O
the O
skin O
, O
or O
surfaces O
of O
the O
penis O
or O
vagina O
, O
in O
preparation O
for O
a O
medical O
procedure O
or O
to O
lessen O
the O
pain B-NEG
of O
inserting O
a O
medical O
instrument O
such O
as O
a O
tube O
or O
speculum O
. O

-DOCSTART- O

Treatment O
of O
jaundice B-NEG
caused O
by O
damp-heat O
, O
heat B-NEG
stroke I-NEG
with O
diarrhea B-NEG
, O
urolithiasis B-NEG
and O
hematuria B-NEG
, O
carbuncles B-NEG
and O
boils B-NEG
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material O
, O
deprive O
dampness B-NEU
and O
kill B-POS
parasites I-POS
. O
For O
sorethroat B-NEG
, O
dysentery B-NEG
, O
trichomonas B-NEG
enteritis I-NEG
, O
toothache B-NEG
, O
stomachache B-NEG
and O
leucorrhagia B-NEG
, O
external O
use O
for O
tinea B-NEG
and O
eczema B-NEG
. O
2 O
To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
. O
3 O
Anticarcinogenic B-POS
. O
For O
malignant B-NEG
hydatidiform I-NEG
mole I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
and O
leukemia B-NEG
. O

-DOCSTART- O

1 O
An O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-DNP
on O
experimental O
tuberculosis B-NEG
in O
mice O
. O
Accelerating O
gastrointestinal B-NEU
peristalsis I-NEU
, O
and O
promoting O
eliminating B-NEU
of I-NEU
flatus I-NEU
. O
Eliminating O
phlegm B-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEU
from I-NEU
the I-NEU
lung I-NEU
, O
relieve O
cough B-NEG
and O
resolve O
phlegm B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
the O
following O
mild-to-moderate O
infections B-NEG
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-NEG
bacterial I-NEG
exacerbations I-NEG
of I-NEG
chronic I-NEG
bronchitis I-NEG
, O
secondary B-NEG
bacterial I-NEG
infection I-NEG
of O
acute B-NEG
bronchitis I-NEG
, O
community B-NEG
- I-NEG
acquired I-NEG
pneumonia I-NEG
, O
pharyngitis B-NEG
/ I-NEG
tonsilitis I-NEG
, O
and O
uncomplicated O
skin B-NEG
and I-NEG
skin I-NEG
structure I-NEG
infections I-NEG
. O

-DOCSTART- O

Atrophic B-NEG
Vaginitis I-NEG

-DOCSTART- O

Its O
chief O
component O
is O
berberine O
. O
1 O
Possessing O
broad-spectrum O
antibacterial B-POS
and O
antiprotozoal B-POS
effects O
. O
2 O
Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEG
effect O
on O
experimental O
animals O
. O
3 O
Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-DNP
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O
4 O
Relaxing O
the O
smooth B-DNP
muscles I-DNP
of O
blood O
vessels O
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary B-DNP
bladderl I-DNP
bronchus I-DNP
and O
gastrointestines B-DNP
. O
5 O
Promoting O
bile B-NEU
secretion I-NEU
. O
6 O
Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic O
cancer B-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

Adult B-NEG
Acute I-NEG
Megakaryoblastic I-NEG
Leukemia I-NEG
( O
M7 B-NEG
) O

-DOCSTART- O

cool O
blood B-NEU

-DOCSTART- O

dysenteric B-NEG
disorder I-NEG
; O

dysentery B-NEG

-DOCSTART- O

absorption O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
motility O

-DOCSTART- O

Dimethindene O
is O
also O
indicated O
for O
pruritus B-NEG
in O
eruptive B-NEG
skin I-NEG
diseases I-NEG
such O
as O
chicken-pox B-NEG
. O

-DOCSTART- O

Asthma B-NEG

-DOCSTART- O

anticancer O

-DOCSTART- O

To O
tonify O
the O
kidney B-DNP

-DOCSTART- O

1 O
To O
relieve O
carbuncle B-NEG
and O
drain B-NEG
pus I-NEG
. O

For O
the O
early O
stage O
of O
carbuncle B-NEG
or O
carbuncle B-NEG
with O
unruptured O
abscess B-NEG
. O

2 O
To O
expel O
wind B-NEG
and O
kill O
parasites B-NEG
. O

For O
tinea B-NEG
infection I-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Mood O
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Endocrine B-DNP
system I-DNP
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Inflammation B-NEG
, O
Others O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

Treatment O
of O
impotence O
, O
seminal O
emission O
, O
enuresis O
, O
frequent O
urination B-NEU
, O
aching B-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
with O
cold B-NEG
sensation O
, O
asthma B-NEG
in O
deficiency B-NEG
syndromes I-NEG
of O
the O
kidney O
, O
diarrhea B-NEG
occurring O
before O
dawn O
daily O
. O

-DOCSTART- O

Endocrine B-DNP
system I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP

-DOCSTART- O

hemicrania B-NEG
; O
migraine B-NEG
; O
megrim B-NEG

-DOCSTART- O

severe O
palpitation B-NEG
; O

continuous O
violent O
palpitation B-NEG

-DOCSTART- O

a O
stomachache B-NEG
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O

Tsumura O
Hachimijiogan O
, O
7.5 O
g O
a O
day O
, O
was O
administered O
to O
30 O
patients O
with O
benign B-NEG
prostatic I-NEG
hypertrophy I-NEG
( O
BPH B-NEG
) O
. O
Clinical O
effects O
were O
estimated O
based O
on O
subjective O
symptoms O
and O
objective O
findings O
obtained O
by O
uroflowmetry O
. O

Twenty O
patients O
( O
0.667 O
) O
showed O
improvement O
of O
subjective O
symptoms O
and O
14 O
patients O
( O
0.467 O
) O
showed O
good O
response O
in O
uroflowmetry O
. O

An O
improvement O
of O
overall O
clinical O
efficacy O
was O
observed O
in O
21 O
patients O
( O
0.7 O
) O

. O
These O
results O
were O
better O
than O
those O
obtained O
with O
5 O
g O
a O
day O
doses O
of O
Tsumura O
Hachimijiogan O
. O

No O
significant O
relation O
between O
the O
Sho O
in O
Chinese O
medicine O
and O
the O
clinical O
effects O
of O
Hachimijiogan O
was O
detected O
. O

No O
side O
effects O
or O
abnormal O
laboratory O
data O
were O
found O
in O
any O
of O
these O
30 O
patients O
. O

-DOCSTART- O

Kampo O
( O
traditional O
Japanese O
herbal O
) O
medicines O
are O
taken O
orally O
due O
to O
which O
the O
gastric O
mucosal O
immune O
system O
may O
act O
as O
one O
of O
the O
major O
targets O
for O
the O
expression O
of O
pharmacological O
activity O
. O

The O
inner O
surface O
of O
the O
intestinal O
tract O
possesses O
a O
large O
area O
of O
mucosal O
membranes O
, O
and O
the O
intestinal O
epithelial O
cells O
sit O
at O
the O
interface O
between O
a O
lumen O
and O
a O
lymphocyte-rich O
lamina O
propria O
. O

The O
cross B-DNP
talk I-DNP
that O
occurs O
between O
these O
compartments O
serves O
to O
maintain O
intestinal O
homeostasis O
, O
and O
the O
cytokine B-DNP
network I-DNP
plays O
an O
important O
role O
in O
the O
cross B-DNP
talk I-DNP
. O

In O
this O
study O
, O
the O
effect O
of O
Hochuekkito O
( O
HET O
) O
, O
one O
of O
Kampo O
medicines O
, O
on O
cytokine B-NEU
secretion I-NEU
of O
intestinal O
epithelial O
cells O
was O
investigated O
. O

When O
murine O
normal O
colonic O
epithelial O
cell-line O
MCE301 B-DNP
cells I-DNP
were O
stimulated O
with O
HET O
, O
the O
contents O
of O
granulocyte B-DNP
colony-stimulating I-DNP
factor I-DNP
( O
G-CSF B-DNP
) O
in O
the O
conditioned O
medium O
were O
significantly O
increased O
in O
dose- O
and O
time-dependent O
manners O
. O

The O
enhanced O
G-CSF B-NEU
gene I-NEU
transcription I-NEU
in O
MCE301 O
cells O
by O
the O
stimulation O
of O
HET O
was O
observed O
by O
RT-PCR O
. O

The O
enhanced O
G-CSF B-NEU
secretion I-NEU
by O
HET O
was O
also O
observed O
in O
C3H/HeJ O
mice-derived O
primary O
cultured O
colonic O
epithelial O
cells O
. O

When O
the O
HET O
was O
fractionated O
, O
only O
the O
polysaccharide O
fraction O
( O
F-5 O
) O
enhanced O
the O
G-CSF B-NEU
secretion I-NEU
of O
MCE301 O
cells O
, O
and O
the O
activity O
of O
F-5 O
lost O
after O
the O
treatment O
of O
periodate O
that O
can O
degrade O
the O
carbohydrate O
moiety O
. O

These O
results O
suggest O
that O
HET O
enhances O
secretion B-NEU
of I-NEU
G-CSF I-NEU
from O
colonic O
epithelial O
cells O
and O
the O
polysaccharide O
is O
one O
of O
the O
active O
ingredients O
of O
HET O
. O

The O
enhanced O
G-CSF B-NEU
secretion I-NEU
by O
HET O
may O
partly O
contribute O
to O
the O
clinically O
observed O
various O
pharmacological O
activities O
of O
HET O
including O
immunomodulating B-NEU
activity I-NEU
. O

-DOCSTART- O

a O
disease O
of O
periumbilical O
sharp O
pain B-NEG
and O
cold B-NEG
hand O
and O
foot O

-DOCSTART- O

Perennial B-NEG
Allergic I-NEG
Rhinitis I-NEG

-DOCSTART- O

Nevirapine O
binds O
directly O
to O
reverse O
transcriptase O
and O
blocks O
the O
RNA-dependent O
and O
DNA-dependent O
DNA O
polymerase O
activities O
by O
causing O
a O
disruption O
of O
the O
enzyme's O
catalytic O
site O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
diabetes B-NEG
mellitus I-NEG
( O
type O
2 O
) O
. O

-DOCSTART- O

Emtricitabine O
is O
an O
analogue O
of O
cytidine O
. O

The O
drug O
works O
by O
inhibiting O
reverse B-DNP
transcriptase I-DNP
, O
the O
enzyme O
that O
copies O
HIV O
RNA O
into O
new O
viral O
DNA O
. O

By O
interfering O
with O
this O
process O
, O
which O
is O
central O
to O
the O
replication B-NEG
of I-NEG
HIV I-NEG
, O
emtricitabine O
can O
help O
to O
lower O
the O
amount O
of O
HIV B-NEG
, O
or O
viral B-NEG
load I-NEG
. O

Efavirenz O
falls O
in O
the O
NNRTI O
class O
of O
antiretrovirals O
. O

Both O
nucleoside O
and O
non-nucleoside O
RTIs O
inhibit O
the O
same O
target O
, O
the O
reverse B-DNP
transcriptase I-DNP
enzyme I-DNP
, O
an O
essential O
viral B-DNP
enzyme I-DNP
which O
transcribes O
viral O
RNA O
into O
DNA O
. O

-DOCSTART- O

Cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-NEU
production I-NEU
and O
interleukin B-NEU
release I-NEU
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O

pain B-NEG
and O
swelling B-NEG
of I-NEG
testis I-NEG

-DOCSTART- O

acute B-NEG
arthritis I-NEG
; O
gout B-NEG

-DOCSTART- O

stop O
itching B-NEG

-DOCSTART- O

Metformin O
acts O
by O
the O
initial O
activation O
of O
AMP-activated B-DNP
protein I-DNP
kinase I-DNP
( O
AMPK B-DNP
) O
, O
a O
liver B-DNP
enzyme I-DNP
that O
plays O
an O
important O
role O
in O
insulin O
signaling O
, O
whole O
body B-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and O
fats B-NEG
. O

Sulfonylureas O
such O
as O
glyburide O
bind O
to O
ATP-sensitive B-DNP
potassium I-DNP
channels I-DNP
on O
the O
pancreatic O
cell O
surface O
, O
raising O
intracellular B-NEU
concentrations I-NEU
of I-NEU
calcium I-NEU
ions O
, O
which O
induces O
the O
secretion B-NEU
, O
or O
exocytosis B-NEU
, O
of O
insulin O
. O

-DOCSTART- O

cool O
blood B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

Liver B-NEG
Cirrhosis I-NEG

-DOCSTART- O

To O
supplement O
blood B-DNP
and O
quicken O
blood B-DNP
, O
free O
channels B-DNP
and O
quicken O
network B-DNP
vessels I-DNP
. O

-DOCSTART- O

Intelligence B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Memory B-POS

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

Reproductive B-DNP
systems I-DNP
, O
Mood O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Endocrine B-DNP
system I-DNP
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Memory B-POS
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Quality O
of O
life O
, O
UV B-POS
protection I-POS
, O
Others O
, O
Man O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Motivation O
, O
Strength B-POS
and O
power B-POS
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
, O
Hemostatic B-DNP
function I-DNP
, O
effort O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Intelligence B-POS
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Overall O
CVD B-NEG
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

( O
1 O
) O
precordial B-NEG
pain I-NEG
; O
intermittent O
cardiac B-NEG
pain I-NEG
( O
2 O
) O
epigastric B-NEG
pain I-NEG

-DOCSTART- O

This O
is O
a O
symptom O
with O
yellow B-DNP
body I-DNP
due O
to O
blood B-NEG
deficiency I-NEG
. O

-DOCSTART- O

Acute B-NEG
otitis I-NEG
media I-NEG
in O
children O
that O
is O
caused O
by O
susceptible O
strains O
of O
Haemophilus B-NEG
influenzae I-NEG
. O

-DOCSTART- O

To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention O
of O
undigested O
food O
. O

-DOCSTART- O

anti-inflammatory B-POS
effects O
of O
the O
Chinese O
herbal O
formula O
FAHF-2 O
in O
experimental O
and O
human O
IBD O
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
swelling B-NEG
pain I-NEG
in I-NEG
throat I-NEG
, O
scrofula B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
eczema B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

nourish O
blood B-DNP

-DOCSTART- O

fever B-NEG
and O
aversion B-NEG
to O
cold O

-DOCSTART- O

In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-NEG
, O
bruises B-NEG
and O
arthritis B-NEG
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery B-POS
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' O
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone O
injury O
and O
regulates O
bone B-NEU
metabolism I-NEU
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
spinal B-NEG
compression I-NEG
fracture I-NEG
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain B-NEG
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-POS
began O
promptly O
after O
administration O
and O
the O
pain B-NEG
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-POS
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-NEG
of O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
one O
spinal B-NEG
compression I-NEG
fracture I-NEG
. O

-DOCSTART- O

Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
has O
been O
used O
to O
cure O
neuropsychological B-NEG
disorders I-NEG
. O

In O
the O
present O
study O
, O
the O
effect O
of O
Yokukansan O
on O
social B-NEG
isolation-induced I-NEG
- I-NEG
induced I-NEG
aggressive I-NEG
behavior I-NEG
was O
examined O
in O
zinc-deficient O
mice O
, O
which O
were O
fed O
a O
zinc-deficient O
diet O
and O
a O
drinking O
water O
containing O
Yokukansan O
for O
2 O
weeks O
. O

In O
the O
resident-intruder O
test O
, O
the O
rate O
of O
mice O
that O
exhibited O
aggressive B-NEG
behavior I-NEG
in O
zinc-deficient O
mice O
, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
mice O
, O
was O
significantly O
decreased O
by O
administration O
of O
Yokukansan O
. O

The O
basal O
level O
of O
serum B-DNP
glucocorticoid I-DNP
, O
which O
was O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
was O
lowered O
by O
administration O
of O
Yokukansan O
. O

On O
the O
other O
hand O
, O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
after O
the O
resident-intruder O
test O
were O
almost O
the O
same O
between O
the O
control O
and O
zinc-deficient O
mice O
. O

However O
, O
administration O
of O
Yokukansan O
to O
zinc-deficient O
mice O
significantly O
increased O
serum B-NEU
glucocorticoid I-NEU
level I-NEU
after O
the O
resident-intruder O
test O
and O
the O
significant O
difference O
in O
the O
rate O
of O
serum B-DNP
corticosterone I-DNP
level I-DNP
after O
the O
test O
to O
the O
basal O
level O
between O
the O
control O
and O
zinc-deficient O
mice O
was O
abolished O
. O

Dietary O
zinc O
deficiency O
increases O
the O
basal O
levels B-NEU
of I-NEU
serum I-NEU
glucocorticoid I-NEU
, O
while O
may O
insufficiently O
increase O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
in O
the O
resident-intruder O
test O
. O

The O
concentrations O
of O
glutamate B-DNP
and O
GABA B-DNP
( O
y-aminobutyric B-DNP
acid I-DNP
) O
in O
the O
brain O
were O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
while O
Yokukansan O
ameliorated O
the O
significant O
increases O
. O

These O
results O
indicate O
that O
Yokukansan O
ameliorates O
social O
isolation-induced O
aggressive B-NEG
behavior I-NEG
of O
zinc-deficient O
mice O
, O
probably O
via O
amelioration O
of O
abnormal O
glucocorticoid B-DNP
secretion O
. O

The O
ameliorative O
effect O
seems O
to O
be O
linked O
to O
the O
modification O
of O
glutamatergic O
neuron B-NEU
activity I-NEU
after O
administration O
of O
Yokukansan O
. O

-DOCSTART- O

To O
dispel O
wind-heat B-NEU
, O
to O
subdue O
hyperactivity B-NEG
of I-NEG
the I-NEG
liver I-NEG
, O
and O
improve O
eyesight B-POS
. O

-DOCSTART- O

This O
is O
insanity B-NEG
caused O
by O
hurt O
of O
mind O
due O
to O
vexation B-NEG
and O
stuffiness B-NEG
. O

-DOCSTART- O

vomiting B-NEG
and O
diarrhea B-NEG

-DOCSTART- O

Bone B-NEU
Health I-NEU
and O
Osteoporosis B-NEG
, O
Woman O
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

Asthma B-NEG
, O
chronic B-NEG
bronchitis I-NEG
, O
stomachache B-NEG
, O
wind-damp B-NEG
pain I-NEG
, O
scrofula B-NEG
, O
cold B-NEG
suppurative I-NEG
sore I-NEG
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Ephedrine O
is O
a O
sympathomimetic O
amine O
- O
that O
is O
, O
its O
principal O
mechanism O
of O
action O
relies O
on O
its O
direct O
and O
indirect O
actions O
on O
the O
adrenergic O
receptor O
system O
, O
which O
is O
part O
of O
the O
sympathetic O
nervous O
system O
. O

Ephedrine O
increases O
post-synaptic B-NEU
noradrenergic I-NEU
receptor I-NEU
activity I-NEU
by O
( O
weakly O
) O
directly O
activating O
post-synaptic B-DNP
receptors I-DNP
and O
receptors O
, O
but O
the O
bulk O
of O
its O
effect O
comes O
from O
the O
pre-synaptic O
neuron O
being O
unable O
to O
distinguish O
between O
real O
adrenaline O
or O
noradrenaline O
from O
ephedrine O
. O

The O
ephedrine O
, O
mixed O
with O
noradrenaline O
, O
is O
transported O
through O
the O
noradrenaline O
reuptake O
complex O
and O
packaged O
( O
along O
with O
real O
noradrenaline O
) O
into O
vesicles O
that O
reside O
at O
the O
terminal O
button O
of O
a O
nerve O
cell O
. O

Ephedrine's O
action O
as O
an O
agonist O
at O
most O
major O
noradrenaline O
receptors O
and O
its O
ability O
to O
increase O
the O
release O
of O
both O
dopamine O
and O
to O
a O
lesser O
extent O
, O
serotonin O
by O
the O
same O
mechanism O
is O
presumed O
to O
have O
a O
major O
role O
in O
its O
mechanism O
of O
action O
. O

-DOCSTART- O

settle O
the O
pain B-NEG
and O
tranquilize O

-DOCSTART- O

Ureteral B-NEG
Stent I-NEG
Occlusion I-NEG

-DOCSTART- O

Pulmonary B-NEG
Disease I-NEG
, I-NEG
Chronic I-NEG
Obstructive I-NEG

-DOCSTART- O

expel O
worm B-NEG

-DOCSTART- O

vomiting B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
engender O
liquid O
, O
moisten O
dryness B-NEG
and O
harmonize O
center O
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

uncomfortable O
of O
the O
heart B-DNP
and O
gallbladder B-DNP

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
C I-NEG

-DOCSTART- O

urinary B-NEG
incontinence I-NEG
; O
galacturia B-NEG
; O
stranguria B-NEG
with I-NEG
chyluria I-NEG
; O
stranguria B-NEG
marked O
by O
chyluria B-NEG

-DOCSTART- O

Non B-NEG
Small I-NEG
Cell I-NEG
Lung I-NEG
Carcinoma I-NEG

-DOCSTART- O

HIV B-NEG
Infections I-NEG

-DOCSTART- O

pulmonary B-NEG
asthenia I-NEG
; O
lung B-NEG
atropy I-NEG
; O
pulmonary B-NEG
flaccidity I-NEG
syndrome I-NEG

-DOCSTART- O

Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-NEU
of I-NEU
neutrophils I-NEU
in O
the O
bone O
marrow O
. O

-DOCSTART- O

a O
mass O
amount O
of O
phlegm B-NEG
, O
and O
dyspnea B-NEG
and O
cough B-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
quicken O
blood B-DNP
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
drain O
accumulated O
cold B-NEG
downward O

-DOCSTART- O

Otitis B-NEG
Media I-NEG

-DOCSTART- O

cosolidate O
bones B-DNP

-DOCSTART- O

Metformin O
acts O
by O
the O
initial O
activation B-DNP
of I-DNP
AMP-activated I-DNP
protein I-DNP
kinase I-DNP
( O
AMPK O
) O
, O
a O
liver O
enzyme O
that O
plays O
an O
important O
role O
in O
insulin B-NEU
signaling I-NEU
, O
whole B-NEU
body I-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and I-NEU
fats I-NEU
. O

Pioglitazone O
activates O
peroxisome B-DNP
proliferator-activated I-DNP
receptor I-DNP
gamma I-DNP
( O
PPAR-gamma B-DNP
) O
, O
a O
ligand-activated B-DNP
transcription I-DNP
factor I-DNP
, O
thereby O
inducing O
cell B-NEU
differentiation I-NEU
and O
inhibiting O
cell B-NEU
growth I-NEU
and O
angiogenesis B-NEU
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
powerlessness B-NEG
in O
a O
waist O
and O
knee O
. O

-DOCSTART- O

dyspnea B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

Adult B-NEG
Acute I-NEG
Lymphocytic I-NEG
Leukemia I-NEG

-DOCSTART- O

refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
motility B-NEU
, O
Others O

-DOCSTART- O

Since O
it O
is O
not O
degraded O
in O
the O
neuromuscular O
junction O
, O
the O
depolarized O
membrance O
remains O
depolarized O
and O
unresponsive O
to O
any O
other O
impulse O
, O
causing O
muscle B-NEG
paralysis I-NEG
. O

-DOCSTART- O

clear O
the O
heart B-DNP
and O
relieve O
vexation B-NEG

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver B-DNP

-DOCSTART- O

( O
1 O
) O
/ O
/ O
morbid O
leukorrhea B-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

HIV-1 B-NEG
Infections I-NEG

-DOCSTART- O

sore B-NEG
throat I-NEG
; O
swollen B-NEG
and O
pailful B-NEG
throat O

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
taxation O
damage O
in O
lumbar B-DNP
muscle I-DNP
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
pricking B-NEG
pain I-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

metrorrhagia B-NEG
and O
bloody B-NEG
stool I-NEG

-DOCSTART- O

For O
tonifying O
weakness O

-DOCSTART- O

Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEU
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

Treament O
of O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
amenorrhea B-NEG
with O
blood O
stasis O
, O
arthralgia B-NEG
, O
traumatic O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

To O
dissipate O
binds B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Body B-NEG
fat I-NEG
deposition I-NEG
( O
total O
amount O

-DOCSTART- O

To O
eliminate O
phlegm B-NEG
( O
Powder O
insufflation O
for O
pharyngitis B-NEG
and O
diphtheria B-NEG
) O
. O

-DOCSTART- O

Phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa O
of O
the O
respiratory O
tract O
. O

-DOCSTART- O

insomnia B-NEG

-DOCSTART- O

Treatment O
of O
deficiency B-NEG
syndrome I-NEG
of O
the O
kidney O
marked O
by O
back B-NEG
pain I-NEG
, O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
and O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
traumatic B-NEG
injury I-NEG
, O
bone B-NEG
fracture I-NEG
, O
external O
use O
for O
alopecia B-NEG
areata I-NEG
, O
vitiligo B-NEG
. O

-DOCSTART- O

Pancreatic B-NEG
cancer I-NEG

-DOCSTART- O

Gout B-NEG

-DOCSTART- O

Hochuekkito O
, O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
and O
its O
Polysaccharide O
Portion O
Stimulate O
G-CSF O
Secretion O
from O
Intestinal O
Epithelial O
Cells O
. O

-DOCSTART- O

the O
symptom O
caused O
by O
stagnation O
of O
phlegm-heat B-NEG

-DOCSTART- O

For O
malaria B-NEG
, O
applying O
crushed O
product O
on O
Neiguan O
( O
P.6 O
) O
and O
Dazhui O
( O
Du' O
14 O
) O
2 O
hours O
before O
the O
episode O
; O
alos O
used O
for O
dyspnea B-NEG
due O
to O
the O
retention O
of O
phlegm B-NEG
. O

-DOCSTART- O

mania-withdrawal B-NEG
; O

mania B-NEG
; O

manic-depressive B-NEG
psychosis I-NEG

-DOCSTART- O

1 O
For O
cases O
with O
paralysis B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
and O
feverish B-NEG
sensation I-NEG
of O
joints,which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin,omit O
menthae,Ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic O
heat O
. O

-DOCSTART- O

all O
kinds O
of O
disease O
due O
to O
wind B-NEG

-DOCSTART- O

End B-NEG
Stage I-NEG
Renal I-NEG
Disease I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Fat B-NEU
storage I-NEU
and O
oxidation O

-DOCSTART- O

Promoting O
bile B-NEU
secretion I-NEU
. O

-DOCSTART- O

Lenalidomide O
inhibits O
TNF-alpha B-NEU
production I-NEU
, O
stimulates O
T B-DNP
cells I-DNP
, O
reduces O
serum B-NEU
levels I-NEU
of I-NEU
the I-NEU
cytokines I-NEU
vascular I-NEU
endothelial I-NEU
growth I-NEU
factor I-NEU
( O
VEGF B-NEU
) O
and O
basic O
fibroblast B-DNP
growth I-DNP
factor I-DNP
( O
bFGF O
) O
, O
and O
inhibits O
angiogenesis B-NEU
. O

-DOCSTART- O

thirst B-NEG

-DOCSTART- O

To O
relax O
the O
bowels B-NEG
, O
and O
to O
cause O
diuresis B-NEG
. O

-DOCSTART- O

redness B-NEG
, O
swelling B-NEG
and O
pain B-NEG
of O
the O
eyes O

-DOCSTART- O

excessive O
drinking O
of O
water O
due O
to O
thirst B-NEU

-DOCSTART- O

Leukemia B-NEG

-DOCSTART- O

severe O
palpitation B-NEG
; O
continuous O
violent O
palpitation B-NEG

-DOCSTART- O

unblock O
blood B-DNP

-DOCSTART- O

five O
colored O
dysentery B-NEG
; O
dysentery B-NEG
with O
multi-colored O
stools B-NEG

-DOCSTART- O

Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O

aversion B-NEG
to I-NEG
heat I-NEG
during O
fever B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
, O
dry O
damp B-NEU
and O
kill O
worms B-NEG
. O

-DOCSTART- O

acute B-NEG
appendicitis I-NEG
; O
periappendicular O
abscess B-NEG
; O
intestinal O
carbuncle B-NEG
; O
intestinal O
abscess B-NEG

-DOCSTART- O

Not O
discarded O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

chest O
and O
hypochondriac O
pain O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
HIV B-NEG
infection I-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
. O

-DOCSTART- O

Lymphoma B-NEG
, I-NEG
Non-Hodgkin I-NEG

-DOCSTART- O

Quality O
of O
life O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Mood O

-DOCSTART- O

fever B-NEG
with O
dysphoria B-NEG
; O
dysphoria B-NEG
with O
smothery O
sensation B-NEG
; O
smothery O
fever B-NEG

-DOCSTART- O

Circulating O
Tumor B-DNP
Cells I-DNP
in O
Pancreatic O
Cancer O
Surgery O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
colorectal B-NEG
cancer I-NEG
. O

-DOCSTART- O

night B-NEU
sweat I-NEU
; O

night B-NEU
sweating I-NEU
spontaneous O
sweating B-NEU
during O
asleep O
and O
no B-NEU
sweating I-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency O
of O
vital O
essence O
and O
presence O
of O
internal B-NEU
heat I-NEU
. O

-DOCSTART- O

morbid B-NEG
leukorrhea I-NEG
; O

gynecological B-NEG
diseases I-NEG
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O

The O
hormones O
, O
T O
4 O
and O
T O
3, O
are O
tyrosine-based O
hormones O
produced O
by O
the O
thyroid O
gland O
. O

Iodine O
is O
an O
important O
component O
in O
their O
synthesis O
. O

The O
major O
secreted O
form O
of O
thyroid O
hormone O
is O
T4 O
. O

T4 O
is O
converted O
T3 O
, O
the O
more O
active O
thyroid O
hormone O
, O
by O
deiodinases O
in O
peripheral O
tissues O
. O

T3 O
acts O
in O
the O
body O
to O
increase O
basal B-NEU
metabolic I-NEU
rate I-NEU
, O
alter O
protein B-NEU
synthesis I-NEU
and O
increase O
the O
body's B-NEU
sensitivity I-NEU
to O
catecholamines O
( O
such O
as O
adrenaline O
) O
. O

Thyroid O
hormones O
are O
essential O
for O
proper O
development O
and O
differentiation O
of O
all O
cells O
of O
the O
human O
body O
. O

T O
4 O
and O
T O
3 O
regulate O
protein O
, O
fat O
and O
carbohydrate O
metabolism O
to O
varying O
extents O
. O

The O
most O
pronounced O
effect O
of O
the O
hormones O
is O
in O
altering O
how O
human O
cells O
use O
energetic O
compounds O
. O

The O
thyroid O
hormone O
derivatives O
bind O
to O
the O
thyroid O
hormone O
receptors O
initially O
to O
initiate O
their O
downstream B-NEU
effects I-NEU
. O

-DOCSTART- O

( O
1 O
) O
/ O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Treatment O
of O
dry B-NEG
cough I-NEG
caused O
by O
heat B-NEU
in I-NEU
the I-NEU
lung I-NEU
, O
bloody B-NEG
sputum I-NEG
in O
phthisis B-NEG
, O
thirst B-NEU
in O
febrile B-NEG
diseases I-NEG
. O

-DOCSTART- O

terminate O
delivery O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Memory B-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Hemostatic B-DNP
function I-DNP
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

( O
1 O
) O
tangling O
up O
of O
intestine O
; O
accumulation O
of O
pathogenic O
factor O
in O
viscera O
( O
2 O
) O
Accumulation O
of O
Eum O
Cold B-NEG
in O
Viscera O
one O
of O
the O
symptoms O
in O
Soeumin O
( O
marked O
by O
hard O
mass O
on O
the O
right O
side O
of O
the O
epigastrium O
. O
The O
prognosis O
is O
not O
hopeful O
. O

-DOCSTART- O

Its O
solution O
may O
kill O
the O
oncomelania O
. O

-DOCSTART- O

ascites B-NEG
; O
abdominal B-NEG
distention I-NEG
due O
to O
accumulation O
of O
liquid B-NEU

-DOCSTART- O

menstrual B-NEG
irregularities I-NEG
; O
menstrual B-NEG
disorders I-NEG
; O
abnormal B-NEG
menstruation I-NEG

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Others O

-DOCSTART- O

SR O
58611 O
has O
positive B-NEU
chronotropic I-NEU
effect I-NEU
which O
is O
mainly O
of O
peripheral O
origin O
and O
can O
be O
attributed O
to O
a O
baroreceptor-mediated B-NEU
reflex I-NEU
due O
to O
the O
beta3-adrenoceptor B-NEU
mediated I-NEU
vasodilation I-NEU
with O
an O
increase O
in O
sympathetic B-NEU
tone I-NEU
and O
a O
reduction O
in O
vagal B-NEU
tone I-NEU
to O
the O
heart O
. O

-DOCSTART- O

Deficiency O
of O
both O
qi O
and O
blood B-NEU
marked O
by O
pallor B-NEG
, O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cardiac B-NEG
palpitation I-NEG
, O
dizziness B-NEG
, O
spontaneous B-NEU
sweating I-NEU
, O
lassitude B-NEG
and O
cold B-NEG
extremities O
, O
or O
excessive B-NEG
menstrual I-NEG
discharge I-NEG
. O

-DOCSTART- O

stop O
dysentery B-NEG

-DOCSTART- O

Diarrhea B-NEG
, O
Malnutrition B-NEG

-DOCSTART- O

pain B-NEG
from O
cramped O
tendons O
and O
bones O

-DOCSTART- O

Treatment O
of O
taeniasis B-NEG
, O
ancylostomiasis B-NEG
, O
ascariasis B-NEG
, O
intestinal B-NEG
parasitosis I-NEG
with O
abdominal B-NEG
pain I-NEG
or O
with O
infantile B-NEG
malnutrition I-NEG
. O

-DOCSTART- O

lack O
of O
essence O
and O
blood B-DNP

-DOCSTART- O

damp B-NEU
Pi O
arthritis B-NEG
due O
to O
dampness B-NEU
. O

damp B-NEG
stroke I-NEG
; O

attack O
of O
dampness B-NEU
syndrome O
due O
to O
attack O
of O
pathogenic B-NEG
factors I-NEG
. O

-DOCSTART- O

Trachoma B-NEG

-DOCSTART- O

wind B-NEG
stroke I-NEG

apoplexy B-NEG

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG

wind-stroke B-NEG
syndrome I-NEG
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-NEG
wind I-NEG
, O
manifested O
by O
fever B-NEG
, O
headache B-NEG
, O
perspiration B-NEG
, O
slow O
and O
floating O
pulse B-DNP
. O

-DOCSTART- O

After O
binding O
to O
HER2 O
on O
the O
tumor O
cell O
surface O
, O
trastuzumab O
induces O
an O
antibody-dependent B-NEG
cell-mediated I-NEG
cytotoxicity I-NEG
against O
tumor B-DNP
cells I-DNP
that O
overexpress O
HER2 O
. O

Epirubicin O
intercalates O
into O
DNA O
and O
interacts O
with O
topoisomerase B-DNP
II I-DNP
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
repair O
and O
RNA O
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

Infection B-NEG
of O
upper O
respiratory O
tract O
, O
pneumonia B-NEG
, O
acute B-NEG
gastroenteritis I-NEG
, O
dysentery B-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
burns B-NEG
and O
scalds B-NEG
, O
infection B-NEG
of O
biliary O
tract O
, O
poisonous B-NEG
insect I-NEG
stings I-NEG
. O

-DOCSTART- O

Glaucoma B-NEG
, O
Open-angle O

-DOCSTART- O

furuncle B-NEG
and O
swelling B-NEG
of O
carbuncle B-NEG

-DOCSTART- O

A O
symptom O
that O
the O
chest O
and O
a O
middle O
part O
of O
the O
stomach O
are O
full O
and O
uncomfortable O
. O

-DOCSTART- O

Good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
DNA O
, O
interfering O
with O
synthesis B-DNP
of I-DNP
RNA I-DNP
( O
prevention O
of O
RNA B-DNP
polymerase I-DNP
elongation O
) O
and O
, O
consequently O
, O
with O
protein B-DNP
synthesis I-DNP
. O

-DOCSTART- O

Seasonal O
Allergic B-NEG
Rhinitis I-NEG

-DOCSTART- O

